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Summary
SUMMARY
The aims of the work described in this thesis were to generate well 
characterised stable cymelarsan (melCy)-resistant and suramin-resistant lines of 
Trypanosoma brucei, and to use these lines to investigate the biochemical and 
genetic basis of drug-resistance. During these studies, different methods were 
used to assay drug-resistance in the cloned lines and these methods were 
critically compared to develop a rapid method for determining drug-resistance. 
MelCy-resistance was investigated by analysing the pattern of cross-resistance to 
other melaminophenyl arsenicals and two diamidines, and the role of altered drug 
uptake in the mechanism of melCy-resistance. Genetic exchange between drug- 
resistant lines provided information on the genetic basis of melCy-resistance and 
suramin-resistance.
Four drug-resistant lines were generated from two cloned stocks of 
Trypanosoma brucei (STIB 247 and STIB 386) by passaging trypanosomes in 
immunosuppressed mice in the presence of gradually increasing sub-curative 
drug doses. Drug-resistant populations were recloned, producing two melCy- 
resistant lines (247MelCyR and 386MelCyR) and two suramin-resistant lines 
(247SurR and 386SurR). In vivo assays in mice indicated that the levels of 
melCy-resistance had increased to greater than 40mg/Kg in both 247MelCyR 
(130-fold increase) and 386MelCyR (20-fold increase). Similarly, suramin- 
resistance was measured at 70mg/Kg for both 247SurR (47-fold increase) and 
386SurR (35-fold increase). No cross-resistance between the two drugs was 
observed. The drug-resistant phenotypes in all four lines were stable upon 
passaging in mice for a number of weeks in the absence of drug pressure. Three 
lines (247MelCyR, 247SurR and 386MelCyR) were transmitted through tsetse 
flies, without attenuation of their levels of drug-resistance.
Summary
The levels of sensitivity/resistance to each drug were determined in the 
two unselected stocks (247 and 386) in vitro in procyclic culture forms and in 
short-term axenic bloodstream form cultures. Results were expressed in terms of 
the effective concentration that inhibited growth by 50% over twenty-four hours 
(EC50). MelCy-resistance was expressed in procyclic and bloodstream culture 
forms. Suramin-resistance was not expressed in procyclic culture forms, with 
EC50 values of approximately 0.1 mM for both the unselected and suramin- 
resistant lines, although suramin-resistance was expressed in bloodstream culture 
forms. There was no convincing evidence for the existence of cross-resistance 
between melCy and suramin in any of the drug-resistant lines in vitro. It was 
concluded that the short-term bloodstream culture was a suitable method for the 
rapid assessment of drug-resistance.
Both melCy-resistant lines expressed cross-resistance to melarsoprol 
(melB) and trimelarsen (melW) in vivo at the maximum doses tolerated in mice 
of 40mg/Kg. Procyclic culture forms of 247MelCyR expressed resistance to 
melW and melarsen oxide (melOx), with increases in drug-resistance in vitro of 
770-fold and 290-fold respectively. However, cross-resistance with melB was 
considerably lower in procyclic culture forms, with an increase in resistance from 
247 to 247MelCyR of only 2.3-fold. A similar pattern was seen with 386 and 
386MelCyR, with the melCy-resistant line expressing resistance to both melW 
(79-fold increase) and melOx (310-fold increase) but not to melB (1.3-fold 
increase) in procyclic culture forms. Furthermore, the melCy-resistant lines did 
not express melB-resistance in short-term bloodstream culture forms. It was 
concluded that melCy-resistance and melB-resistance may be brought about 
through different mechanisms.
The 247MelCyR line was characterised with respect to its mechanism(s) 
of arsenical uptake, the relationship between arsenical transport and purine and
Summary
diamidine transport, and the alterations in uptake associated with melCy- 
resistance. Cross-resistance was observed in the 247MelCyR line to the two 
diamidines, berenil and pentamidine, in vivo. The possibility that melCy, melB 
and melOx, together with berenil and pentamidine, shared a common adenosine 
transporter for entry into the trypanosome was investigated in vitro. Berenil and 
pentamidine were able to inhibit lysis by all three melaminophenyl arsenicals in a 
concentration-dependent manner. MelOx and melCy-induced lysis of 247 were 
inhibited in a concentration-dependent manner by adenosine and adenine, in 
agreement with the proposal that these arsenical drugs compete with these 
purines for transport (Carter and Fairlamb 1993). However, melB-induced lysis 
could not be blocked by adenosine or adenine, suggesting that melB did not 
share this adenosine transporter. Furthermore, the melCy-resistant line, 
247MelCyR, showed a marked decrease in susceptibility to melOx and melCy- 
induced lysis and only a very slight decrease in susceptibility to melB-induced 
lysis, suggesting that the mechanism(s) of melCy-resistance may differ from 
those of melB-resistance. Procyclic culture forms of 247 could not be lysed by 
maximal concentrations of the arsenical drugs over one hour. The adenosine 
transport system in 247 and 247MelCyR were further characterised by 
conducting tritiated adenosine uptake studies. It was proposed that at least four 
distinct adenosine transporters existed, one of which (termed P2) was 
responsible for the uptake of melCy and melOx, and that the uptake of lipid 
soluble melB was either by diffusion or by an as yet unidentified route.
MelCy-resistant and suramin-resistant lines were used in co-transmission 
experiments to generate hybrid progeny that expressed resistance to both melCy 
and suramin. Double drug-resistant (putative hybrid) trypanosomes were 
identified in vivo in five metacyclic populations by allowing flies producing 
mature infections to feed on mice, although no clones were isolated. A single 
three-way co-transmission experiment was also conducted with 247SurR,
Summary
247MelCyR and 386MelCyR Twenty-three trypanosome clones were generated 
from flies producing double drug-resistant infections in mice. Eight of these 
clones expressed resistance to both melCy and suramin in vivo. Four of these 
clones also expressed melCy-resistance and (partial) suramin-resistance in vitro. 
No evidence of genetic exchange (including self-fertilisation) could be found 
from isoenzyme and karyotype analysis of these cloned progeny. It was 
concluded that the double drug-resistant clones were likely to be the products of 
selfing although the limited number of markers available to detect self­
fertilisation were unable to provide supporting evidence for this conjecture.
In conclusion, cloned drug-resistant lines of trypano somes from well 
characterised genetic backgrounds can be successfully employed as tools to 
investigate the inheritance of drug-resistance and genetic exchange. Furthermore, 
the possibility that melCy does not share a common transport system with melB 
suggests a potential role for melCy in the treatment of some melB-resistant cases 
of sleeping sickness.
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General Introduction
CHAPTER 1
GENERAL INTRODUCTION
1.1 TRYPANOSOMES
1.1.1 Introduction
The genus Trypanosoma covers a large range of parasitic protozoa found 
throughout the world in a variety of both vertebrate and invertebrate hosts. Most 
species live in the body fluids and tissues of their host without any apparent 
pathological consequences, but there are a few species that are responsible for a 
range of diseases collectively known as the trypanosomiases. Of these 
pathogenic species, it is the tsetse-transmitted trypanosomes of sub-Saharan 
Africa and the reduviid-transmitted trypanosomes of South America that cause 
most concern to mankind. In terms of the total number of humans infected, 
Trypanosoma cruzi, the causative agent of Chagas' disease, is by far the most 
important species with at least 20 million people infected in Central and South 
America each year. In Africa the annual rate of human infection by trypanosomes 
is much lower. An estimated 25 000 new cases of sleeping sickness, caused 
either by Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense, 
are reported each year (WHO 1986a), all of which are invariably fatal unless 
treated. However, the African problem can not be so easily quantified (see 
review by Kuzoe 1993), since it is not only the direct effect on humans that 
causes concern, but also the indirect effect trypanosomiasis can have on humans, 
such as on the domestic livestock, upon which so much depends. Domestic 
animals become diseased when infected with T. congolense and T. vivax, which 
like T. b. brucei, T. b. gambiense and T. b. rhodesiense, are transmitted by the 
tsetse fly. Animal trypanosomiasis, "nagana", is one of the biggest economic 
problems of African livestock farming, with an immeasurable cost in terms of 
loss of production, wasting and infertility. The effect upon rural farming is 
confounded with the fact that the most fertile and well vegetated areas are often
l
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the most ideal habitats for the tsetse, and are therefore avoided by humans and 
their domestic animals (Jordan 1986a).
The different species of mammalian trypanosomes that have just been 
mentioned do not all share a common life cycle. Of the species that are 
pathogenic to mankind and its livestock, most are transmitted by an insect 
vector, although in some cases, transmission can also occur through other 
means, such as the venereal transmission between horses of T. equiperdum. The 
insect transmitted trypanosomes can be divided into two groups depending on 
the method by which transmission from the vector to the new host occurs. These 
two groups are the Salivctria and the Stercoraria, with trypanosomes of the 
former group being transmitted through the insect's saliva as opposed to the 
latter group in which transmission occurs through the insect's faeces. T. cruzi 
belongs to the Stercoraria which is distinguished by having its mammalian- 
infective forms (metacyclics) in the faeces and urine of the insect vector, the 
reduviid bug. Transmission is via contamination of a wound, often the insect 
bite. With the salivarian trypanosomes such as T. b. brucei, T. b. gambiense, T. 
b. rhodesiense, T. congolense, and T. vivax, transmission occurs through the 
mouthparts of the insect vector with the metacyclic trypanosomes being present 
in the saliva. However, there are substantial differences in the development of 
these trypanosome species in the tsetse fly (see Vickerman et al. 1991). For 
example, whereas both 71 brucei and 71 congolense develop in the tsetse midgut 
before migration to the insect's mouthparts, 71 vivax development is totally in the 
mouthparts. 71 evansi is also a salivarian trypanosome, although transmission 
differs from that of the tsetse-transmitted trypanosomes in that cyclical 
development does not occur at all in the insect, and syringe-like, or mechanical 
transmission occurs from the insect's saliva without the existence of metacyclics.
2
General Introduction
This study is concerned solely with the tsetse-transmitted trypanosomes 
of sub-Saharan Africa, and in particular those of the T. brucei species. The 
brucei group of trypanosomes consists of three subspecies, T. b. brucei, T. b. 
rhodesiense and T. b. gambiense. They are morphologically indistinguishable 
from each other but can be distinguished in a number of other ways, not least by 
the nature of the diseases they bring about. T. b. brucei is non-infective to 
humans, and can be distinguished from the other two by its sensitivity to human 
serum (Rickman and Robson 1970). The two human-infective subspecies, T. b. 
rhodesiense and T. b. gambiense, can be distinguished from each other by the 
course of human infection, with T. b. rhodesiense bringing about an acute 
infection compared to the more chronic infection of T. b. gambiense. 
Furthermore, T. b. rhodesiense and T. b. brucei are transmitted by Glossina 
morsitans morsitans, G. m. centralis and G. pallidipes whereas T. b. gambiense 
is transmitted principally by G. palpalis, G. fuscipes and G. tachinoides (Jordan 
1986b). Biochemical and molecular analysis of the three different subspecies 
have shown that T. b. rhodesiense and T. b. brucei are also closely related with 
respect to isoenzymes (Tait et al. 1985). However this close relationship does 
not extend to T. b. gambiense (Gibson et al. 1980; Tait et al. 1984). Studies on 
DNA polymorphisms in ribosomal RNA genes further indicated the close 
relationship between T. b. brucei and T. b. rhodesiense and the relative distance 
of these from T. b. gambiense (Hide et al. 1990). Despite the fact that on this 
evidence it is possible to consider T. b. gambiense as a separate species, for the 
purpose of the present study, it will be regarded, together with T. b. brucei and 
T. b. rhodesiense, as subspecies of T. brucei. References to individual subspecies 
will therefore be made as T. b. brucei, T. b. rhodesiense and T. b. gambiense, 
and general comments for the species as a whole will be made as T. brucei.
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1.1.2 Life Cycle of T. brucei
Trypanosomes of the T. brucei species share a common life cycle, with 
development in the mammalian host being followed by transmission in an insect 
vector to a new host. These salivarian trypanosomes have a life cycle that 
consists of at least six distinct stages that differ not only in morphology, but also 
in their biochemistry, particularly their energy metabolism (Opperdoes 1985). 
The life cycle of T. brucei has been well studied (reviewed in Vickerman 1985; 
Vickerman et al. 1991) and is of direct relevance to this study, which involves T. 
b. brucei and T. b. rhodesiense. Figure 1 shows the life cycle divided into three 
different environments (mammalian host, tsetse midgut and tsetse salivary 
gland). Each environment has two life cycle stages: a dividing form to establish 
the infection in the current environment, and a non-dividing form that acts as a 
link from one environment to the next. For simplicity, this life cycle does not 
include the many intermediate forms previously described (Vickerman 1985), 
nor does it make any reference to the occurrence of any sexual stage, which will 
be dealt with later (section 1.3.2).
Briefly, a mammalian host initially becomes infected by non-dividing 
metacyclic trypanosomes when an infected tsetse fly takes a blood meal. The 
mature metacyclics in the fly's saliva pass into the mammalian tissues and drain 
into the blood via the lymphatics. The metacyclics transform to long-slender 
bloodstream forms which divide rapidly and establish the infection in the host 
(Figure 1). Long-slender forms also transform to short-stumpy bloodstream 
forms. These cannot divide and have a finite lifespan, but unlike long-slender 
forms they are pre-adapted to be able to establish a new infection in a tsetse fly's 
gut, when a fly takes a blood meal from the infected mammal (Vickerman 1965). 
The short-stumpy trypanosomes are ingested with the blood meal into the tsetse 
gut where they transform to procyclics. Procyclics divide and establish a very
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dense midgut infection. A salivary gland infection becomes established some 
weeks after the midgut has been infected. Procyclics transform to the non­
dividing proventricular forms that travel up the fly's alimentary canal to the 
proboscis and then into the salivary gland (Evans and Ellis 1983). The salivary 
gland infection then becomes established when the proventricular forms 
transform to dividing epimastigotes that attach themselves to the gland's 
epithelium. Finally the cycle is completed with the epimastigotes, which can not 
survive in the mammalian host, transforming to the non-dividing metacyclics 
(Tetley and Vickerman 1985), which are free in the saliva and can withstand the 
mammalian host's defences, thereby completing the life cycle upon their entry 
into a new mammalian host.
1.1.3 Pathology of Human Sleeping Sickness
Humans are susceptible to infection by T. b. rhodesiense and T. b. 
gambiense. Infection by either will ultimately bring about death if the disease is 
left untreated. The pathology associated with early-stage and late-stage sleeping 
sickness (CNS involvement) is reviewed in Poltera (1985). Briefly, infections of 
both species begin in the same way, with metacyclic trypanosomes entering the 
dermis, causing a local inflammatory response at the site of infection and 
resulting in a noticeable swelling on the skin - the trypanosome-containing 
chancre (Barry and Emery 1984). From this chancre, the trypanosomes drain 
into the bloodstream via the lymphatics. Upon establishment of a bloodstream 
infection, the characteristic fluctuations in parasitaemia can be observed. These 
parasitaemic waves are brought about by the interaction of the host's immune 
response with the ability of the long-slender forms to change their surface 
antigen approximately once every 100 cell divisions (Turner and Barry 1989). 
Trypanosomes are coated with more than 107 copies of a single molecular 
species of variant surface glycoprotein (VSG) which is present only on
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metacyclics and bloodstream forms (Cross 1990). This protective coat not only 
protects the trypanosome against non-specific immune responses, but also the 
structure of these VSGs determine the variable antigen type (VAT) of the 
trypanosome. The long-slender forms have both the ability to divide rapidly and 
switch their VSG, and consequently their surface antigen, thereby evading the 
host's specific antibody response, which can only eliminate parasites possessing 
the VAT against which the antibodies were produced (Vickerman 1969). It is 
therefore the long-slender forms, able to evade the host's immune response, that 
are responsible for the gross pathology and ultimate death of infected 
individuals.
Bloodstream infections have an adverse effect on the blood and vascular 
system of infected individuals and they are frequently associated with anaemia 
(Poltera 1985; Jenkins and Facer 1985). Although some damage must 
undoubtedly be due to the direct invasion of the tissue by the parasite, much of 
the damage has been attributed to adverse immune reactions. A large increase in 
B-cell proliferation invariably accompanies infection and is usually accompanied 
with a reduction in the T-cell response, although the significance of these with 
respect to their pathological consequences remain unclear (Vickerman et al. 
1991). It has been proposed that the large-scale destruction of trypanosomes 
results in the release of a vast number of trypanosome antigens that form 
immune complexes with circulating antibodies. These immune complexes could 
play an important role in the pathology of the disease (Galvao-Castro et al. 
1978; Boreham 1985) and have been found in the blood and CSF of human 
patients (Lambert et al. 1981). Complement activation by the immune 
complexes, and the subsequent cellular response has been shown to cause 
damage to host tissues, such as heart and skeletal muscle and the brain 
(Morrison et al. 1983). The migration of the long-slender bloodstream forms 
from the blood into other body fluids and host tissue (such as the lymph, the
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CSF and particularly the brain) not only causes the disease to spread into various 
host organs but it also causes problems with drug therapy, as some of these 
areas are partially, if not totally, inaccessible to a number of drugs (Gutteridge 
1985). The migration and spread of the dividing forms from the blood is 
important in both the acute infections of T. b. rhodesiense and the chronic 
infections of T. b. gambiense, although the protracted nature of the Gambian 
form of the disease lends itself to a more extensive spread of the trypanosome 
infection in the host. There are reports, using experimental models, of 
trypanosome infiltration into a wide variety of organs and tissues with 
trypanosomes having been observed in the tissues of the heart, lungs, liver, 
spleen, kidneys, pancreas, stomach, small intestine and numerous endocrine 
tissues (reviewed in Poltera 1985).
The effect of trypanosomiasis on extra-vascular sites is arguably most 
significant in the CNS. Late-stage sleeping sickness is defined when parasites 
have entered the CNS with the resulting symptoms varying from a slight 
headache to coma (Giordano et al. 1977). As with the infections outside the 
CNS, trypanosomes have been found in a number of locations in and around the 
brain (Poltera 1985). It would appear that CNS involvement can occur fairly 
early in the infection and that it gradually worsens and spreads through the CNS 
as the infection develops. This may account for some of the relapse infections 
that occur after melarsoprol treatment, which can pass the blood-brain barrier, 
but may not be able to reach high enough levels at all the sites of infection in the 
brain, with a number of drug barriers existing within the brain rather than a 
single one at the blood-brain barrier (Raseroka and Ormerod 1986). This may be 
extremely important during arsenical treatment of late-stage infections. The rapid 
destruction of trypanosomes by melarsoprol will free a huge quantity of 
trypanosome antigens, and it has been proposed that the adverse effects of the 
host's immune reactions in response to this release of antigens actually leads to
7
General Introduction
arsenical encephalopathy (Poltera et al. 1984).
1.1.4 Metabolic Differences Between Life Cycle Intermediates
and the Mammalian Host
The change in the trypanosome's surface coat to protect it against the 
host's immune response has already been dealt with. There are a number of 
equally important adaptations made by T. brucei in order to survive in the 
different environments encountered in the life cycle. Particularly important are 
the changes in energy metabolism between the insect-stages and the mammalian- 
stages of the parasite's life cycle (Bowman and Flynn 1976). The mitochondrion 
of long-slender forms is repressed (Vickerman 1965) and they do not possess a 
functioning electron-transport chain to generate ATP. They use glucose as their 
sole source of energy, absorbing glucose from the blood and generating energy 
through glycolysis carried out in the spherical glycosome, after which pyruvate is 
then excreted. The glycosome is an organelle unique to Trypanosomatids and it 
contains all the trypanosome's glycolytic enzymes, the opposite of the situation 
found in all other eukaryotes in which the glycolytic machinery is present in the 
cytosol (Opperdoes and Borst 1977). Glycolysis in T. brucei also differs from 
mammalian glycolysis in the way NAD is regenerated. Under anaerobic 
conditions in mammalian cells, NADH produced during glycolysis is oxidised 
during the production of lactate from pyruvate. However, in T. brucei, NADH 
from glycolysis is oxidised to NAD indirectly by a unique glycerol-3-phosphate 
oxidase located in the mitochondrion (Grant and Sargent 1960). These marked 
differences, together with the fact that a number of the trypanosomal glycolytic 
enzymes have different kinetic properties to their mammalian equivalents, make 
glycolysis an ideal target for chemotherapy (Opperdoes 1983).
Due to the relative lack of glucose and abundance of proline in the tsetse
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midgut, procyclic trypanosomes utilise this amino acid as their primary energy 
source. Their ability to oxidise proline coincides with a well developed 
mitochondrion (Bowman and Flynn 1976) and a complete cytochrome electron- 
transport chain appears for the production of ATP from oxidative 
phosphorylation (Njogu et al. 1980). Furthermore, the limited amount of oxygen 
in the tsetse gut, together with the rapid disappearance of glucose from an 
ingested blood meal in an uninfected fly, is catered for by the reduction of the 
glycosome from a spherical organelle to an ovoid one, and the decrease in 
activity of some key glycolytic enzymes (Hart et al 1984). Short-stumpy forms, 
the link between long-slender forms and procyclics, are bloodstream forms that 
possess some of the biochemical peculiarities of procyclics, in preparation for life 
in the fly's midgut. Short-stumpy forms have an enlarged mitochondrion when 
compared to long-slender forms and proline oxidase activity appears in 
preparation for an amino acid based energy source (Vickerman 1965).
Relatively little is known about the metabolism of proventricular forms 
and epimastigotes, although it appears that the mitochondrion remains enlarged 
and the glycosomes are suppressed throughout the life cycle in the fly until a 
short time before the metacyclics detach from the salivary gland epithelium and 
become mature metacyclics in the gland's lumen (Vickerman 1985). While still 
attached to the gland, immature metacyclics acquire a VSG coat, the 
mitochondria regress and the glycosomes become spherical once more (Tetley 
and Vickerman 1984). Thus upon detachment, the mature metacyclics possess a 
protective coat and a metabolism which once again is adapted for life in a 
glucose rich environment.
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1.2 CHEMOTHERAPY
1.2.1 Introduction
A concerted effort has been made to control the problem of African 
trypanosomiasis, and the problem has been tackled in four ways, each with 
varying degrees of success. Firstly, avoiding tsetse-infested areas, although an 
obvious solution, is of little help to the rural African, since the high risk areas are 
often the best grazing land, with the tsetse fly inhabiting the less arid, more 
vegetated areas (Jordan 1986a). Secondly, a solution to the problem of animal 
trypanosomiasis could come from the increased use of stock resistant to 
trypanosome infection (Murray et al. 1979). However, such a solution does 
nothing to alleviate the human disease of sleeping sickness as such animals 
would still provide a reservoir host for the human-infective trypanosomes. A 
third method of control is by controlling the tsetse fly vector. A large amount of 
effort has been put into this approach with a degree of success, particularly with 
the use of insecticides and fly traps (Jordan 1986c). Finally, the last and most 
widely used method of controlling the human disease still lies with the use of 
trypanocidal drugs, used either to treat infected individuals or to prevent 
infection by prophylaxis. Although almost a century of research has been carried 
out into the development of drugs for the treatment of human sleeping sickness, 
only four (suramin, melarsoprol, pentamidine and DFMO) are routinely used in 
Africa. The development, mode of action and treatment regimes of each will be 
dealt with separately, together with the various drawbacks associated with their 
use.
1.2.2 The History of Trypanocide Evolution
Suramin
The turn of the century saw the first real beginnings of experimental
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chemotherapy for the treatment of parasitic diseases, particularly for the 
protozoal infections of plasmodia and trypanosomes (reviewed in Williamson 
1970). Work was pioneered by Paul Ehrlich, following on from his initial 
research into the selective uptake by cells of certain synthetic cotton-dyes, and 
the use of these for studies on histology and, in particular, haematology. The 
cytotoxic effect of some of these dyes, together with the fact they were taken up 
at different rates by different cells, brought Ehrlich to the logical conclusion that 
they could be used as the basis for selective chemotherapy, and this soon led to 
the subsequent discovery, in 1891, of the antimalarial property of Methylene 
Blue (Hawking 1963a). By the turn of the century, Ehrlich had focused his 
attention on trypanosomes, as they provided a convenient laboratory model with 
which he could standardise his findings. In his search for trypanocidal 
compounds, and with the help of his chemist colleagues, he screened hundreds of 
synthetic cotton-dyes based on Congo Red, using his standard mouse model 
infected with T. equinum. In 1904, he found the first trypanocidal signs in 
Nagana Red, from which a more water soluble form called Trypan Red was 
synthesised (Hawking 1963b).
The subsequent years saw the application of a large amount of effort into 
the gradual improvement of Trypan Red into a less toxic and more active 
compound. By 1907, Mesnil and Nicolle from the Institut Pasteur had taken 
Ehrlich's earlier work a step further, and produced Trypan Blue (Trefouel 1962). 
This was then improved further to a colourless analogue by a German firm, 
Bayer, with whom Mesnil and Nicolle had previously been collaborating. 
Ultimately, Bayer refined their product and in 1916 produced suramin (Bayer 
205, Germanin). Suramin has since proved to be invaluable and is still the first 
drug of choice used to treat early-stage sleeping sickness, especially in East and 
Central Africa, and is very occasionally used for prophylaxis (Gutteridge 1985).
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Arsenicals
At the same time that suramin was being developed, the potential of 
arsenical drugs was also being investigated. It had already been shown some 
decades previously by Livingstone, that "two grains of arsenic in a little barley" 
had a beneficial effect on a tsetse-bitten mare (Livingstone 1858), although the 
parasitic nature of nagana was not then known. It was almost another forty years 
until Bruce, in 1896, showed the susceptibility of trypanosome infections to 
sodium arsenite and arsenious oxide. In 1902, Lavaren and Mesnil, demonstrated 
the action of sodium arsenite in their mouse model infected with T. brucei, but it 
was universally accepted that although inorganic arsenic was effective, it was too 
toxic for the treatment of human sleeping sickness (Hawking 1963a). A 
revolutionary breakthrough came in 1905, when Wolferston Thomas, working in 
Liverpool, used an organic rather than an inorganic arsenical to treat 
trypanosomiasis. This organic arsenical, atoxyl, was forty times less toxic than 
sodium arsenite, while still retaining the latter's activity against trypanosomes 
(Hawking 1963a). Atoxyl had been produced a few years earlier as a by-product 
of parafuchsin synthesis, which was itself a highly active trypanocide although 
being quite unrelated to atoxyl. The trypanocidal action of atoxyl had at first 
been overlooked by Ehrlich, who in 1903, had discarded it as having no 
trypanocidal activity in the "test tube". However, by 1908, Ehrlich and others 
had independently shown that atoxyl and other pentavalent arsenicals, must first 
be converted to their trivalent form to become active against trypanosomes, and 
that this reduction occurred in vivo (Himmelweit 1960).
The next major development came in 1919, with the introduction of 
tryparsamide by Jacobs and Heidelberger from the Rockefeller Institute, New 
York. Curiously, tryparsamide seemed to have limited success against the early- 
stages of the disease, but it was the first drug to be able to pass into the CSF and
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thus cure late-stage Gambian sleeping sickness (Williamson 1970). It also had 
the further advantage of being less toxic than atoxyl, which had been shown to 
have undesirable side effects, especially on the optic nerve. Unfortunately, 
tryparsamide was of no use against the still incurable late-stage Rhodesian 
sleeping sickness. Furthermore, its extensive use as the only late-stage cure for 
the Gambian disease, resulted in widespread tryparsamide-resistance, to the 
extent that in some areas of West Africa, 100% of all cases were reported 
tryparsamide-resistant. This occurred at a time when 60% of the 50 000 newly 
reported cases were already late-stage sleeping sickness (Van Hoof 1947).
The introduction of Friedheim's melaminophenyl arsenicals was therefore 
a very welcome development in the treatment of trypanosomiasis. Melarsen and 
its reduced equivalent, melarsen oxide, introduced by Friedheim in 1940, proved 
to be successful in curing tryparsamide-resistant cases (Friedheim 1948). 
However, late-stage Rhodesian sleeping sickness was still incurable, and like 
other arsenicals, melarsen and melarsen oxide were still fairly toxic. This toxicity 
was reduced in 1949 by Friedheim and Vogel with the addition of British Anti- 
Lewisite (BAL) to melarsen oxide to produce melarsoprol (melB, arsobal) 
(Friedheim 1949). BAL, which was originally produced as an antidote to an 
arsenical warfare agent, allowed a much greater dose of arsenical to be given and 
consequently, for the first time even late-stage Rhodesian sleeping sickness could 
be treated. Ten years after the introduction of melarsoprol, Friedheim produced 
a water soluble alternative in trimelarsen (melW) (De Jongh and Friedheim 
1959), and in the last decade, cymelarsan (melCy, RM 110) has also been 
introduced by Rhone Merieux (Zweygarth and Kaminsky 1990). However, 
extensive field trials of these last two compounds have not been carried out and 
they initially appear to have no clear advantage over the established cure of 
melarsoprol. Consequently, melarsoprol remains the only arsenical in use today 
for the routine treatment of the late stages of both Rhodesian and Gambian
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forms of the disease.
Pentamidine
The only drug that has been proven to be successful as a large scale 
prophylactic is pentamidine (Demarchi 1958). In the mid 1930s, investigations 
were carried out into the effect of lowering blood sugar to combat trypanosome 
infections. Compounds were developed from synthetic insulin analogues, 
resulting in 1942 with the introduction of pentamidine, which, curiously, does 
not owe its trypanocidal activity to any hypoglycaemic action (Williamson 
1970). In fact, hypoglycaemia resulting from pentamidine treatment is regarded 
as an unfortunate side-effect. Following its introduction, large scale use of 
pentamidine as a prophylactic was carried out in West Africa with a large 
amount of success, although the end of European influence in Africa led to a 
disintegration of an organised system of routine prophylaxis (Jordan 1986d). The 
main drawback with pentamidine is that it can not pass the blood-brain barrier 
and consequently is useless in cases with CNS involvement. However, it still 
remains highly effective in prevention and cure of early stage sleeping sickness.
DFMO
In recent years many experimental compounds have been screened for 
their potential as anti-trypanosomal agents. Of these, with the possible exception 
of nifurtimox (Pepin et al. 1989) only the anti-cancer drug, a - 
difluoromethylomithine (DFMO) has proved to be of any major significance. 
The last 20 years has seen a large amount of interest in the mechanisms of 
polyamine metabolism of eukaryotic cells. Polyamines are present in all living 
cells and are vital for cell differentiation and division. A key enzyme in the 
biosynthesis of polyamines was found to be ornithine decarboxylase (ODC),
14
General Introduction
which could be irreversibly inhibited by a-difluoromethylomithine (DFMO), a 
synthetic analogue of its true substrate, ornithine (Metcalf et al. 1978). Since 
trypanosomes rapidly divide, investigations were begun into the potential of 
DFMO as a trypanocidal drug, with the initial findings that mice infected with T. 
b. brucei or T. b. rhodesiense could be cured by DFMO treatment (Bacchi et al. 
1980; McCann et al. 1981a). Further studies showed that DFMO was able to 
cure late-stage infections of T. b. gambiense in human patients that had relapse 
infections after melarsoprol treatment (Sjoerdsma et al. 1984). However, in 
clinical trials, DFMO has had limited success against T. b. rhodesiense (Van 
Nieuwenhove 1992). Although the expense of DFMO treatment and the large 
quantities required for a full course of treatment have put some question marks 
over its future, it is arguably the most important drug to have emerged since 
Friedheim's melaminophenyl arsenicals.
1.2.3 Administration, Uptake and Mode of Action of Trypanocides
Suramin
Suramin has been used as a trypanocide for almost eight decades, and is 
still a first choice drug in the treatment of early cases with no CNS involvement. 
It is effective against both T. b. rhodesiense and T. b. gambiense as well as T. b. 
brucei, T. evansi and T. equiperdum, although relatively ineffective against T. 
vivax and T. congolense (Hawking 1963b). Furthermore, it has had some 
success as an anti-cancer drug (Allolio et al. 1989), in the treatment of HIV 
infections (Mitsuya et al. 1984) and also onchocerciasis (Hawking 1978).
The actual treatment regime for human trypanosomiasis with suramin 
may vary depending on the health of the patient. Generally, a number of doses of 
up to 20mg/Kg are given intravenously over a 3 week period, with a possible 
further weekly dose for the next 5 weeks. Suramin binds tightly to serum
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proteins (Gutteridge 1985) and it has been recently found that 15% of this bound 
suramin is in fact attached to the apoprotein of LDL (Vansterkenberg et al. 
1993). Although about 80% of the suramin administered is cleared by the 
kidneys, this renal clearance is fairly slow, with suramin having a serum half-life 
of between 44 and 54 days (Collins et al. 1986). As a result of this, a single dose 
of suramin can give protection against trypanosomes for up to 3 months. 
Suramin becomes distributed around the body in most tissues at concentrations 
similar to those in the plasma, with the most important exception being the low 
absorption into the brain (Voogd et al. 1993). It is generally assumed that the 
high negative charge of the suramin molecule blocks its transport across the 
blood-brain barrier. However a small amount of the drug can pass into the CSF 
giving rise to concentrations of less than 1% of the levels in the plasma (Stein et 
al. 1989). Furthermore it has also been reported that these low levels of suramin 
in the brain may in fact be sufficient to effect a cure if the parasites have only 
recently entered the CNS (Raseroka and Ormerod 1985).
Although it is not entirely clear how suramin enters the trypanosome, it is 
assumed that the drug is mainly taken up by receptor-mediated endocytosis 
bound to protein, possibly on LDLs (Vansterkenberg et al. 1993), as it is most 
certainly too highly charged to diffuse across biological membranes and it 
accumulates in trypanosomes too rapidly for non-specific fluid endocytosis 
(Fairlamb and Bowman 1980b). Once inside the parasite, suramin has been 
shown to interact with a number of enzymes. Particularly significant may be its 
strong inhibition of almost all the glycolytic enzymes (Misset and Opperdoes
1987). Although the interaction of suramin with these glycolytic enzymes is 
complex and suggestive of multiple sites at which suramin can bind, it is 
significant that the inhibition is specific for the trypanosomal and not the 
mammalian forms of these enzymes. It has already been mentioned (section 
1.1.4) that bloodstream trypanosomes have no electron transport chain. As a
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consequence, the parasite is reliant on a glycerol-3-phosphate 
dehydrogenase/glycerol-3-phosphate oxidase system to oxidise the NADH 
formed during glycolysis and it is during this process that the long-slender 
bloodstream form consumes oxygen (Opperdoes 1985). Suramin was found to 
inhibit the utilisation of oxygen in a concentration-dependant manner and this 
inhibition of respiration has been attributed to the inhibition of the glycerol-3- 
phosphate dehydrogenase/glycerol-3-phosphate oxidase system along with the 
inhibition of the other glycolytic enzymes (Fairlamb and Bowman 1980a).
Suramin can act synergistically to cure late-stage infections with drugs 
that are totally ineffective when used singly, such as the permanent cures 
obtained with a combination of suramin and substituted 5-nitroimidazoles 
(Jennings et al. 1983). Furthermore, it has also been shown that DFMO and 
suramin act synergistically (Clarkson et al. 1984), and this may indicate that the 
mode of action of suramin may also be involved with polyamine metabolism. A 
recent development has come with the finding that suramin strongly binds to 
LDL and thereby inhibits receptor-mediated endocytosis of LDL by 50%. It has 
been proposed that the trypanosome is reliant on the cholesterol and 
phospholipids present in LDL for the maintenance of its membranes, and that the 
action of suramin in inhibiting LDL uptake may be sufficient to cause death 
(Vansterkenberg et al. 1993). In conclusion therefore, the primary target of 
suramin still remains unclear, and its wide range of uses on a range of cell types 
may indeed indicate no one target is singly responsible for its trypanocidal nature 
(Voogd et al. 1993).
Arsenicals
The arsenical drugs differ markedly from suramin in pharmacokinetics, 
mode of action and effectiveness against sleeping sickness. Whereas suramin has
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an effective clearance rate of 0.3ml/min (with a measured volume of distribution 
of 40 litres) and a half-life of approximately 50 days (Collins et al. 1986), 
melarsoprol has a total clearance of 50ml/min (volume of distribution was 100 
litres) and a serum half-life of 35 hours (Burri et al. 1993). A typical full course 
of treatment for melarsoprol consists of two or three sets of intravenous 
injections, with each set of injections being separated by 2 weeks, and consisting 
of 4 daily injections at gradually increasing doses between 1.2 and 3.6mg/Kg 
(WHO 1986b). This treatment regime results in serum concentrations of 
approximately 5pg/ml (lOpM) 30 minutes after drug injection which gradually 
drops to approximately 0.2pg/ml (0.4pM) 120 hours post-treatment (Burri et al. 
1993). In the same study, the levels of melarsoprol in the CSF averaged 
approximately 50-fold lower than those in the serum.
It is generally thought that the trypanocidal activity of melarsoprol is 
largely due to its interaction with trypanothione (Fairlamb et al. 1989) and 
possibly also with its inhibition of pyruvate kinase, due to the trypanosome's sole 
dependence on continuous glucose catabolism to generate ATP in the long- 
slender bloodstream forms (Flynn and Bowman 1974). At melarsoprol 
concentrations equivalent to those found in the serum, it was found that 
trypanosomes were lysed rapidly in vitro, and that this lysis was not a result of 
the inhibition of pyruvate kinase (Van Schaftingen et al. 1987). The active form 
of melarsoprol is thought to be the trivalent moiety of melarsen oxide, which 
forms a stable adduct with trypanothione (melT) in vivo and it is for this reason 
that trypanothione has been proposed as the primary target of arsenical 
compounds (Fairlamb et al. 1989). Trypanothione in conjunction with 
trypanothione reductase carries out a vital role in trypanosomes in maintaining 
the intracellular redox balance and detoxifying H20 2, in a similar way to 
glutathione and glutathione reductase in mammalian cells. Therefore, it is 
possible to account for the extremely toxic nature of melarsoprol (and
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presumably the other melaminophenyl arsenicals such as melCy) through the 
interaction of melarsen oxide with trypanothione. This mechanism also provides 
an explanation for the specificity of melarsoprol for trypanosomes, as 
mammalian cells do not possess trypanothione. Furthermore, the synergistic 
effect of DFMO with melarsoprol (Jennings 1988) further lends itself to the 
proposal of trypanothione being the primary target, since the proposed pathway 
for trypanothione biosynthesis is blocked by DFMO at ornithine decarboxylase 
(reviewed in Henderson and Fairlamb 1987). During the early development of 
melaminophenyl arsenicals by Friedheim and others, it was known that they had 
a high affinity for sulphydryl groups. Consequently, melarsoprol may in fact have 
many more important targets, such as lipoic acid. This has been found to have an 
affinity for melarsen oxide 500 times greater than the affinity of trypanothione 
for melarsen oxide and may be involved in arsenical uptake (Fairlamb et al. 
1992a). There is however, stronger evidence to suggest that arsenicals are taken 
up via an adenosine transporter at the cell surface (Carter and Fairlamb 1993). 
The rapid lysis of trypanosomes in the presence of arsenicals was found to be 
blocked by adenosine and adenine, and radiolabelled adenosine uptake was 
found to be inhibited by melarsoprol (Kj = 0.28jliM). Furthermore, this study 
also found that a particular type of adenosine transporter (termed P2) may be 
involved in melarsen oxide uptake (chapter 6).
In light of the recent data on the pharmacokinetic properties of 
melarsoprol (Burri et al. 1993), it would appear that concentrations in the serum 
are sufficiently high to bring about the rapid lysis in vivo that is seen in vitro. 
However, the levels in the CSF were estimated at being around 30ng/ml 
(0.06pM) and these may be insufficient to cause this rapid lysis in some strains 
(chapters 3 and 6). Furthermore, the investigations carried out on the 
interaction of arsenicals and trypanothione (Fairlamb et al. 1989) were carried 
out at much higher concentrations of arsenical (lOpM melarsen oxide and 50pM
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melB) than that found in the CSF. This difference may indicate that the 
trypanosomes in the CSF are killed by arsenicals at a lower rate than in the 
bloodstream, and it is also possible that these lower concentrations of arsenicals 
in the CSF are insufficient to interact with trypanothione to the same extent as in 
the bloodstream.
Pentamidine
Pentamidine is the only drug in current use that has been used for large- 
scale prophylaxis (see Dukes 1984). A typical treatment regime consists of a 
series of intramuscular injections once every 3-6 months. In this respect it is 
much easier to administer than the other trypanocides in current use. Each series 
of injections comprises of daily doses of 3-4mg/Kg for 7-10 days. Similar 
regimes are adopted for the treatment of individuals already infected that do not 
have trypanosomes present in the CNS, since pentamidine cannot pass the 
blood-brain barrier. Not only is pentamidine easier to administer, but the adverse 
side-effects associated with treatment are also relatively mild compared to other 
drugs, with hypertension due to histamine release being one of the most common 
(Gutteridge 1985).
There has been very little work carried out on the mode of action of 
pentamidine in recent years. Earlier studies showed that pentamidine inhibits 
biosynthetic processes, particularly nucleic acid synthesis (Gutteridge 1969) 
although the effect of this binding of pentamidine to DNA has not been 
evaluated and may in fact have little or no physiological significance. 
Pentamidine was also found to inhibit S-adenosyl-L-methionine decarboxylase in 
T. brucei (Bitonti et al. 1986a), although more recent work suggested that this 
interference with polyamine metabolism was not the primary mode of action of 
the drug (Berger et a l 1993). Most work carried out on the mode of action of
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pentamidine has been carried out on drug uptake. A number of studies showed 
pentamidine to be accumulated within the trypanosome at levels higher than 
those found in the serum. Furthermore, a temperature- and pH-dependant 
transporter has been identified with a for pentamidine of 158|iM for 
bloodstream forms of 71 b. brucei (Damper and Patton 1976). It was interesting 
to note that this same study, using a pleomorphic line, showed pentamidine 
uptake to be much reduced in short-stumpy forms and even more so in cultured 
procyclic forms. More recently it has been proposed that the P2 type adenosine 
transporter, responsible for the uptake of the melaminophenyl arsenicals, is also 
responsible for the uptake of pentamidine thereby accounting for the patterns of 
cross-resistance observed between diamidines, like pentamidine, and 
melaminophenyl arsenicals (Fromell et al. 1987; Fairlamb et al. 1992b).
DFMO
In comparison to the other trypanocides in current use, the mode of 
action of DFMO is extremely well characterised, and indeed, it is the only drug 
that has been developed with a specific target in mind. DFMO is activated by its 
target (ornithine decarboxylase) which it irreversibly inhibits, thereby blocking 
polyamine biosynthesis (Metcalf et al. 1978). Studies in vivo on the morphology 
of T. b. brucei after treatment with DFMO indicated that the drug caused a 
predominantly monomorphic line to become mainly short-stumpy in 
morphology, and that this alteration in morphology was preceded by a depletion 
in polyamine levels (Bacchi et al. 1983). It has since been shown that a T-cell 
independent antibody response was necessary to fully cure infections after 
DFMO treatment (Bitonti et a l 1986b). The overall mode of action of DFMO 
would therefore appear to be a block in replication, by inhibiting polyamine 
metabolism, with a resultant block in the cell's ability to switch its antigenic coat 
(Turner and Barry 1989). Trypanosome specific antibodies then enable the
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immune system to clear the infection.
It is now firmly established that DFMO is the most important drug to be 
introduced for treating human sleeping sickness, particularly arsenical-resistant 
cases, since Friedheim's arsenicals in the 1940s. Some of the more recent studies 
have investigated the use of combination therapy with other trypanocides such as 
suramin (Zweygarth and Kaminsky 1991), melarsoprol (Jennings 1988) and 
berenil (Onyeyili and Anika 1989) each with some degree of success. Therapy 
with DFMO alone is expensive and requires up to lKg per patient for a full 
course, with the drug being administered either orally or intravenously at doses 
of up to 400mg/Kg/day for about 6 weeks (Van Nieuwenhove et al. 1985). 
These large amounts of DFMO can be difficult to administer due simply to the 
solubility of the drug and the physical limitations of the patient. Despite these 
problems, the side effects are remarkably mild, with the most common being 
diarrhoea, which can be avoided with either lower oral doses or intravenous 
administration.
1.2.4 Drug-Resistance in Parasites
Definition o f Drug-Resistance
Drug-resistance has been studied in a wide range of organisms with most 
work having been concerned with drug-resistance in bacteria, tumour cells and 
insects. With respect to drug-resistance in parasites, a large amount of attention 
has been focused on chloroquine-resistant (and multiple drug-resistant) 
Plasmodium falciparum and on the drug-resistant nematodes of ruminants.
Stable drug-resistance that can be inherited from one trypanosome 
generation to the next is brought about through one or more genetic mutations. 
The results of these mutations are expressed through an increased ability for the
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parasite to survive in the presence of drug pressure. In 1963, the World Health 
Organisation defined resistance as the "ability of a parasite strain to multiply or 
to survive in the presence of concentrations of a drug that normally destroy 
parasites of the same species or prevent their multiplication. Such resistance may 
be relative (yielding to increased doses of the drug tolerated by the host) or 
complete (withstanding maximum doses tolerated by the host)." However, an 
important distinction was made between this and "drug failure", which is defined 
as the "absence or insufficiency of drug action after administration of a normally 
effective dose." That there is a difference between the two is of fundamental 
importance in that although it is true that drug-resistance will bring about drug 
failure, it may not necessarily be true that drug failure is a result of drug- 
resistance since resistance is only one of many factors affecting drug failure. 
Throughout this study, the meanings of both drug-resistance and drug failure 
will be consistent with the above definitions.
Resistance to Trypanocides
Resistance to the various trypanocidal compounds can be rapidly 
achieved in the laboratory either in vitro or in vivo, and much of the work 
carried out investigating mechanisms of drug action has centred on the 
comparison of drug-sensitive and laboratory-derived drug-resistant lines. In the 
field there have been many reports of natural and developed resistance to the 
drugs used (Bacchi 1993).
Definite reports of resistance to suramin in T. brucei are relatively scarce, 
and there appears to be more evidence of suramin-resistance in T. evansi than in 
I  brucei. The lack of definite reports of suramin-resistance in T. brucei is 
probably due to the fact that relapses after suramin treatment are often 
designated as having resulted from trypanosomes being present in the central
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nervous system. These relapses are thus ascribed to drug failure and not the 
presence of suramin-resistant trypanosomes. Of the reported cases using mouse 
models, levels of suramin-resistance of greater than 40mg/Kg have been recently 
shown for field isolates of T. brucei and greater than lOOmg/kg in T. evansi 
(Zweygarth and Kaminsky 1990). Of particular interest was the finding that out 
of 29 stocks of T. evansi isolated from Egypt, Sudan and Indonesia, all o f the 
stocks that expressed levels of suramin-resistance greater than 64mg/Kg also had 
a type VII isoenzyme banding pattern for malic enzyme. The other more 
sensitive stocks had a type II banding pattern (Boid et al. 1989). Whether this 
can be used as a genuine indication of suramin-resistance and/or has some 
significance for the mechanism of suramin-resistance remains to be seen.
Relapses after melarsoprol treatment are arguably the most serious of all 
the problems associated with trypanosomiasis chemotherapy. Arsenical 
chemotherapy fails in an estimated 10% of field cases (Kazyumba et al. 1988), 
with this failure being attributed to melarsoprol-resistance. The position is 
worsened with an equal number of people suffering from arsenical 
encephalopathy after treatment, which is frequently fatal (Pepin et al. 1989). 
Experimental studies have been carried out both on field isolates and laboratory 
generated resistant lines using a variety of in vivo and in vitro methods to 
measure the levels of arsenical-resistance (discussed in more detail in chapter 3). 
Field isolates from patients with relapse infections after one or more courses of 
melarsoprol treatment have levels of resistance of greater than 25mg/Kg in 
experimental mouse models (Yarlett et al. 1991). However, resistant field 
isolates do not always express resistance in vitro, with 24 hour growth inhibition 
assays showing no difference between some resistant and sensitive clones (Brun 
et al. 1989), whereas melarsoprol levels required to induce rapid lysis do show 
differences between resistant and sensitive clones and therefore appears to be a 
more reliable method for assessing drug-resistance (Yarlett et al. 1991). A
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number of studies have been carried out to identify the mechanisms of arsenical- 
resistance. Although the role of trypanothione and the formation of melT upon 
exposure to melarsoprol and melarsen oxide has been established (Fairlamb et al.
1989), alterations in trypanothione and polyamine metabolism have not been 
shown in trypanosomes which express arsenical-resistance. In one well 
characterised line and its resistant derivative, the levels of trypanothione and 
glutathione were not significantly different, and although significant differences 
were found in the levels of trypanothione reductase (Fairlamb et al. 1992b), the 
mechanism of arsenical resistance was attributed to an altered purine transporter 
(Carter and Fairlamb 1993). Similar findings were made independently in a study 
of a number of T. b. rhodesiense isolates expressing different levels of arsenical- 
resistance. It was found that different levels of trypanothione did not correlate 
with levels of arsenical-resistance, and that uptake of melarsen oxide was found 
to be reduced in resistant isolates (Yarlett et al. 1991). It has been proposed that 
the cross-resistance patterns seen between the different melaminophenyl 
arsenicals (melOx, melB, melCy and melW) and the diamidines (berenil and 
pentamidine) can be accounted for by alterations in the P2-type adenosine 
transporter which is thought to be responsible for arsenical uptake as well as 
berenil and pentamidine uptake (Frommel and Balber 1987; Zweygarth and 
Kaminsky 1990; Fairlamb et al. 1992b; Carter and Fairlamb 1993).
Current evidence not only suggests that pentamidine uptake is via a 
transporter but also that pentamidine-resistance, like arsenical-resistance is 
brought about through an alteration in drug uptake. A recent study investigating 
pentamidine-resistance failed to find alterations in polyamine levels (thought to 
be a drug target) or differences in the rate of metabolic conversion of 
pentamidine between sensitive and resistant trypanosomes (Berger et al. 1993). 
Furthermore, a comparison of a number of isolates with different levels of 
resistance to pentamidine showed a correlation between drug accumulation and
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pentamidine-sensitivity (Damper and Patton 1976).
Altered uptake also appears to be involved in some cases of laboratory 
generated DFMO-resistance. A study with a DFMO-resistant line of T. brucei 
selected in procyclic culture showed decreased uptake of DFMO in the resistant 
line after the removal of drug pressure (Phillips and Wang 1987). A separate 
study also using an in vitro generated DFMO-resistant line of procyclic T. brucei 
showed a 2.5-fold decrease in DFMO accumulation in the resistant line after 
DFMO had been removed for one week. However, in this study, DFMO induced 
an increase in the levels of ornithine decarboxylase (4-fold) and a marked 
increase in ornithine (24-fold) in the resistant line. It was proposed that these 
changes in ornithine metabolism negated the inhibition of ornithine 
decarboxylase by DFMO and accounted for DFMO-resistance in this line 
(Bellofatto et al. 1987). A similar study carried out on Leishmania donovani 
promastigotes also found DFMO-resistance to be brought about through 
increased ornithine decarboxylase activity (Coons et al. 1990).
1.3 GENETIC EXCHANGE
1.3.1 The Role of Non-Obligatory Mating in Natural Populations
Trypanosomes reproduce by binary fission. Evidence for a sexual process 
also occurring during the life cycle was first observed in a study of cloned 
trypanosome stocks isolated from a single focus in Uganda over a 2 year period. 
Extensive isoenzyme analysis of these stocks showed the population to be in 
Hardy-Weinberg equilibrium, which, by analogy to similar studies on other 
organisms, indicated that trypanosomes are diploid and undergo random mating 
(Tait 1980). Following this finding, mating has been demonstrated in the 
laboratory, and it has been shown by a number of independent studies that 
mating is a non-obligatory event in the trypanosome life cycle (section 1.3.2).
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However, in the last few years, opinions are divided as to the relevance of a 
sexual stage in natural populations of trypanosomes (Tibayrenc et al. 1990; 
Maynard Smith et al. 1993). It has been proposed that although genetic 
exchange can take place, it has little or no consequence to natural populations 
(Tibayrenc and Ayala 1991).
The role of mating in trypanosome populations has mainly been studied 
by analysing isoenzyme electrophoretic variability within trypanosome 
populations. Seventeen T. b. brucei isolates from Lugala, Uganda, were found to 
have variations in their isoenzymes that indicated that the population had 
undergone random mating and was in Hardy-Weinberg equilibrium (Tait 1980). 
A more extensive study was conducted on a population of T. brucei using 220 
isolates, taken over a period of years up to and including a time of marked 
increase in cases of sleeping sickness. These stocks were isolated in the Lambwe 
Valley, Western Kenya, from tsetse flies and a variety of mammalian hosts, 
including humans. Isoenzyme analysis of trypanosomes taken from humans 
during the epidemic, revealed new zymodemes (trypanosome strains) that had 
not been observed previously. Since these were also different from those 
observed in neighbouring sleeping sickness foci, it was concluded that genetic 
exchange provided the most plausible explanation for the emergence of these 
new zymodemes (Gibson and Wellde 1985). The possibility that mutations alone 
could account for the observed isoenzyme variability was discounted since, in 
both the Lugala study and the Lambwe Valley study, a relatively high number of 
recurrent mutations would be needed to explain the patterns observed (Cibulskis
1988). However, a further analysis on the isoenzyme data from the Lambwe 
Valley suggested that, although genetic exchange played an important long-term 
role in the evolution of the parasite, this was unlikely to be the cause for the 
emergence of the previously unobserved zymodemes during the epidemic 
(Mihok et al. 1990). Rather, it was proposed that these new zymodemes had in
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fact been present in animal hosts, and the increase in tsetse fly numbers prior to 
the epidemic allowed the transmission of these strains from the animal reservoirs 
to new human hosts.
Although the population from Lugala, Uganda was found to be in Hardy- 
Weinberg equilibrium (i.e. undergoing random mating) (Tait 1980), a number of 
later studies on different trypanosome populations showed marked deviations 
from Hardy-Weinberg expectations (Tait et al. 1985; Gibson and Wellde 1985; 
Stevens and Welbum 1993; Hide et al. 1994). The fact that a number of 
populations do not show signs of genetic exchange occurring at random led to 
the proposal that populations of T. brucei, together with a number of other 
parasitic protozoa including Plasmodia, were in fact clonal and that mating did 
not have any significant impact on natural populations (Tibayrenc et al. 1990). A 
more rational explanation for the deviations from Hardy-Weinberg equilibria was 
given by Cibulskis (1992), who interpreted the data from the Lambwe Valley, 
Kenya, by taking into account selection pressures imposed by hosts and 
geographical location. Thus, it was proposed that certain zymodemes were 
better adapted to survive in certain hosts, and that this brought about selection 
pressures for different zymodemes, thereby accounting for the deviations from 
Hardy-Weinberg equilibria. A given set of ecological conditions would therefore 
favour certain zymodemes, which would propagate by asexual, or clonal, 
reproduction. However, a change in these conditions would bring about different 
selection pressures. Genetic exchange would therefore be favoured to allow the 
generation of new zymodemes that were more capable of thriving under this new 
set of conditions (Cibulskis 1992). Although this may appear to contradict the 
initial finding that a natural trypanosome population can undergo random mating 
(Tait 1980), it is more likely that, due to the non-obligatory nature of mating, 
both asexual reproduction and sexual reproduction play significant roles in the 
epidemiology of natural populations, with some geographical locations
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consisting of largely clonal populations and others consisting of randomly mating 
trypanosomes depending on the ecological conditions. The need for further 
investigations into the exact nature and frequency of genetic exchange is 
therefore extremely important in order to elucidate the factors affecting 
"fertility” and how this may affect the spread and inheritance of human infectivity 
and drug-resistance.
1.3.2 Experimental Genetic Exchange
Direct evidence of genetic exchange occurring in trypanosomes was first 
found in a cross between two cloned lines of STIB 247 and STIB 386 (Jenni et 
al. 1986). These stocks are of the subspecies 71 b. brucei and 71 b. rhodesiense 
respectively (Hide et al. 1990). Cloned populations were made from 
trypanosomes that had been cyclically transmitted through a tsetse fly infected 
with a mixture of 247 and 386. These clones showed phenotypes and genotypes 
(detected by isoenzyme electrophoresis and restriction fragment length 
polymorphism (RFLP) analysis respectively) that differed from the isoenzyme 
patterns of either parent and were consistent with these clones being Fj hybrid 
progeny having resulted from the two parental lines having undergone genetic 
exchange during cyclical transmission in the tsetse fly (Jenni et al. 1986). The 
patterns of inheritance of the isoenzyme phenotypes and the RFLPs suggested a 
simple model of genetic exchange involving meiosis of the diploid parents, 
followed by recombination of the haploid "gametes", although it was accepted 
that other models could also explain these results. A number of other genetic 
crosses have since been carried out independently in attempts to elucidate the 
exact processes involved during mating. In order to gain further evidence that 
genetic exchange involved meiosis and syngamy, it was necessary to analyse a 
greater number of cloned progeny for a wider variety of phenotypic and 
genotypic markers. Evidence showing that segregation of alleles occurred at
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several loci, and with recombination occurring between loci, was demonstrated 
independently in a further cross between 247 and 386 (Sternberg et al. 1989) 
and between 71 b. rhodesiense (058) and T. b. brucei (196) (Gibson 1989). 
Following this, three more crosses were carried out with all possible 
combinations, of 247, 386 and another 7. b. brucei clone, TREU 927/4. These 
crosses analysed the inheritance of a number of markers providing further 
evidence of allelic segregation and recombination (Turner et al. 1990). However, 
whether a classical Mendelian system exists with meiosis creating haploid 
gametes which subsequently fuse, or whether meiosis occurs after the fusion of 
diploid nuclei is still not clear (Tait and Turner 1990).
It is still unclear what factor(s) determine a trypanosomes ability to mate. 
Several studies have now demonstrated that genetic exchange is non-obligatory. 
Flies producing hybrid clones also produced clones with the same phenotype and 
genotype as one or the other parent (Sternberg et al. 1989; Gibson 1989; Turner 
et al. 1990). In an attempt to investigate the presence of a mating system, all 
three pairwise combinations of 247 (7. b. brucei), 386 (7. b. rhodesiense) and 
927/4 (7. b. brucei) have been transmitted through tsetse flies with the result 
that all three combinations of parents produced hybrid progeny (Turner et al.
1990). Thus, a simple mating system involving two sexes or fixed mating types 
(i.e. + and -) could not explain these findings, and it has been proposed that there 
may be no barriers to mating (Turner et al. 1990). However, if this were the 
case, self-fertilisation, or genetic exchange between trypanosomes of the same 
stock, would be expected during transmission of a single stock through tsetse 
flies. Self-fertilisation would bring about segregation of heterozygous alleles at 
some loci, bringing about progeny that were homozygous at these loci. 
However, no evidence of segregation at a number of heterozygous loci could be 
found during the single transmission of five stocks through flies (Tait et al.
1989). Evidence for self-fertilisation has, however, been obtained by examining
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cloned progeny from a mixed transmission of 247 and 386. Three metacyclic 
clones that were initially believed to have the 247 parental genotype, were re­
examined, and found to be homozygous at the peptidase Tyr3 locus, which is 
heterozygous in parental 247. Further evidence for self-fertilisation has been 
shown by the alteration of karyotype in four non-hybrid clones from this same 
cross (Tait etal. 1993).
The timing and location of mating is also a matter of some debate. It has 
been proposed that mating actually occurred during transmission of the 
trypanosomes from the tsetse fly to the mammal. This was based on 
measurements of the DNA content of the metacyclic trypanosomes, which 
appeared to have approximately half that of procyclics and bloodstream forms, 
and therefore were thought to be haploid (Zampetti-Bosseler et al. 1986). 
However, since bloodstream forms are diploid, infections derived from single 
haploid metacyclics should be homozygous at all loci and this is clearly not the 
case (Tait et al. 1989; Sternberg et al. 1989; Turner et al. 1990). Furthermore, 
independent measurements using a different method failed to identify metacyclics 
that had a DNA content significantly less than other life-cycle stages (Shapiro et 
al. 1984; Kooy etal. 1989). There is, therefore, overwhelming evidence to show 
that mating occurs within the tsetse fly stages and that this genetic exchange 
involves a reduction division either before or after nuclear fusion. The only 
positive evidence identifying a location for this process has been provided with 
the identification of hybrid trypanosomes isolated from the posterior midgut of a 
tsetse fly infected with 247 and 386 (Schweizer and Jenni 1991). This has been 
further substantiated in the same laboratory, with the formation of hybrid 
procyclic trypanosomes in vitro (Schweizer et al. 1991). However, although it 
would therefore appear on this evidence that genetic exchange occurs in the 
midgut between procyclic trypanosomes and that this hybrid formation can occur 
within the first seven days of the establishment of a mixed midgut infection
31
General Introduction
(Schweizer et a l  1991), a number of attempts by different groups to repeat the 
in vitro mating experiments have proved unsuccessful (Gibson and Whittington 
1993; Buchanan pers. comm.). Furthermore, it is unfortunate that the isoenzyme 
analysis used for the positive identification of procyclic hybrids both in vivo and 
in vitro was carried out on uncloned material, and until a hybrid procyclic clone 
has been identified, it is possible to explain the observed hybrid-type isoenzyme 
bandings as experimental artefacts (Schweizer and Jenni 1991; Schweizer et a l
1991). In a separate study, procyclic trypanosomes and metacyclic trypanosomes 
were cloned from a 10-week old fly that was producing hybrid trypanosomes. 
None of the sixteen procyclic clones were hybrid, whereas nine out of ten 
metacyclics were hybrids (Turner et a l  1990). Furthermore, a recent study has 
used antibiotic-resistance as selectable markers for genetic exchange. (Gibson 
and Whittington 1993). In this study, metacyclic infections were found to 
contain double drug-resistant hybrids whereas, although mixed infections were 
found in the midgut, no double drug-resistant procyclic trypanosomes could be 
identified. Both these studies indicate that mating occurs in the salivary gland 
rather than the midgut of the tsetse fly, contrary to the findings of Schweizer and 
colleagues. The exact location and timing of genetic exchange therefore still 
requires clarification.
In conclusion, therefore, many of the details concerning mating in T. 
brucei remain unresolved. Analysis of the vast majority of the progeny clones 
from mixed transmission experiments, are consistent with a model of non- 
obligatory mating, in which hybrid progeny are the products of a diploid 
Mendelian system of genetic exchange. Future work exploiting drug-resistance 
as selectable markers should allow classical genetics to be used in investigating 
the inheritance of particular phenotypic traits such as drug-resistance.
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1.4 OVERALL AIMS
The ultimate aim of this study was to elucidate the genetic and biochemical 
mechanisms that determine drug-resistance in T. brucei. The work presented 
here can be considered as four separate stages:
1. Generation of cloned lines of trypanosomes in vivo expressing resistance 
to suramin and cymelarsan and the subsequent characterisation of these lines to 
ensure there is no cross-resistance between these two drugs, and the drug- 
resistance phenotypes are stable in the absence of drug pressure during 
transmission through tsetse flies (chapter 2).
2. Development of suitable in vitro assays that could be applied to the rapid
and reliable measurement of the level of drug-resistance in a number of clones 
generated from mixed transmission experiments in order to determine the 
inheritance of drug-resistance during genetic exchange (chapter 3).
3. Demonstration that the cloned drug-resistant lines are 'fertile' and cloned 
progeny, expressing resistance to both cymelarsan and suramin, can be generated 
by co-transmitting a cymelarsan-resistant and a suramin-resistant line through 
tsetse flies (chapters 4 and 5).
4. Investigation of the role of adenosine transporters in the uptake of the
melaminophenyl arsenicals, with particular emphasis on any potential differences 
between melB and melCy (chapter 6).
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Figure 1.1
Life Cycle of T. brucei
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The life cycle of T. brucei consists of at least 6 distinct stages. It can be 
considered in terms of 3 different environments (tsetse salivary gland, 
mammalian host, and tsetse midgut) each of which contains two life cycle 
stages. In each environment, one life cycle stage is able to undergo asexual 
reproduction, thereby establishing a dense infection in the current environment. 
The other stage is unable to divide but is capable of migrating or being 
transmitted to a new environment, whereupon it changes morphology to a 
dividing form, capable of establishing a new infection (adapted from 
Vickerman 1985).
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CHAPTER 2
GENERATION AND CHARACTERISATION OF 
CLONED DRUG-RESISTANT LINES IN  VIVO
2.1 INTRODUCTION
The primary aim of this study was to determine the genetic and 
biochemical basis of drug-resistance in T. brucei, with particular emphasis on the 
mechanisms of resistance to the melaminophenyl arsenicals. It has long been 
recognised that the prolonged use of trypanocides for the treatment of infected 
individuals promotes the development of drug-resistant trypanosomes. In 1929, 
the occurrence of atoxyl-resistant and tryparsamide-resistant strains in clinical 
cases led Yorke to investigate drug-resistance. By generating drug-resistant lines 
of T. b. rhodesiense in laboratory mice using gradually increasing sub-curative 
doses he examined the stability and patterns of cross-resistance of a number of 
trypanocides (Fulton and Yorke 1941). Since these early studies, drug-resistance 
has been investigated using either naturally occurring drug-resistant strains or, 
more frequently, laboratory generated lines.
Melarsoprol-resistance has been shown to develop rapidly in clinical 
cases that suffer relapse infections after the first course, and subsequently receive 
further courses, of melarsoprol treatment (Robertson 1963). It is widely believed 
that such resistance will invariably be associated with resistance to the other 
melaminophenyl arsenicals. There are a number of recent examples, with both 
naturally occurring and laboratory derived drug-resistant lines, of cross­
resistance between the different melaminophenyl arsenicals in vivo (Yarlett et al. 
1991; Fairlamb et al. 1992b). This cross-resistance often extends to the 
diamidines, berenil and pentamidine (Williamson and Rollo 1959; Frommel and 
Balber 1987), and although a degree of cross-resistance between suramin and 
melarsoprol has been observed (Fairlamb et al. 1992b), arsenical-resistance does
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not necessarily confer resistance to suramin (Fulton and Yorke 1941; Gill 1971).
In order to carry out studies on the molecular and biochemical basis of 
drug-resistance, it was necessary to generate and characterise cloned drug- 
resistant lines of trypanosomes. Two cloned trypanosome stocks were chosen for 
use in these studies (STIB 247 and STIB 386) that have been well characterised 
for a range of genetic (karyotype and RFLP) and phenotypic (isoenzyme) 
markers. Previous studies have successfully mated these two stocks by co- 
transmitting them through tsetse flies, and from these co-transmission 
experiments, the inheritance of markers during genetic exchange has been 
determined (Jenni et al. 1986; Sternberg et al. 1989; Tait et al. 1989; Turner et 
al. 1990). Therefore, the generation of drug-resistant lines of STIB 247 and 
STIB 386, followed by genetic crosses between these two drug-resistant lines 
would give us the opportunity to examine the pattern of inheritance of the drug- 
resistance phenotypes on a well characterised genetic background.
This chapter describes the generation and preliminary characterisation of 
cloned lines of these two stocks that have each been selected for resistance to 
each of the two drugs, cymelarsan and suramin. Figure 2.1 summarises the 
procedure through which each unselected, drug-sensitive cloned stock was 
selected for drug-resistance. Each cloned drug-resistant line was subsequently 
characterised in terms of the levels of drug-resistance and the stability of this 
resistance in the absence of drug pressure in mice and after cyclical transmission 
through tsetse flies. The characterisation of each resistant line included a check 
for cross-resistance between the different melaminophenyl arsenicals and 
suramin.
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2.2 MATERIALS AND METHODS
2.2.1 Drugs
The two trypanocidal drugs, cymelarsan (melCy) and suramin, were used 
to generate drug-resistant lines. Two further drugs, melarsoprol (melB) and 
trimelarsan (melW) were used in the in vivo drug-resistance assays. Suramin, 
melCy and melW were dissolved in dddH20  (double-distilled de-ionised water) 
and melB was suspended (by vigorous vortexing to create a milky suspension) in 
peanut oil (Sigma) immediately prior to use. All drugs were administered by 
intra-peritoneal injection. Any unused drug was discarded. Suramin (Bayer AG, 
Batch 738233/1181) was a kind gift from Bayer, Germany. MelCy (Melarsomine 
Dihydrochloride, Batch CP4189) was a kind gift from Rhone Merieux, France. 
MelW (Melarsonyl Potassique) and melB (Arsobal) were kind gifts from Dr. 
Frank Jennings, Glasgow University.
2.2.2 Trypanosome stocks and mice
Two cloned trypanosome stocks were used. These were STIB (Swiss 
Tropical Institute Basel) 247 and STIB 386, hereafter called 247 and 386 
respectively. The 247 line (T. b. brucei) was originally cloned from the primary 
isolate taken from a hartebeest, in 1971, in the Serengeti National Park, Tanzania 
(Jenni et al. 1986). The 386 line was cloned from a stock isolated from a man in 
Daloa in the Ivory Coast and was originally grouped with other West African 
stocks as T. b. gambiense. It has since been found to be indistinguishable from 
East African T. b. rhodesiense stocks and will be considered as such (Hide et al.
1990).
Selection of drug-resistance and routine growth of trypanosomes were 
carried out in adult female CFLP, CD1 or TO Swiss mice, or adult male CFLP
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mice. In vivo assays to determine levels of drug-resistance and cloning were 
conducted using immunosuppressed (cyclophosphamide at a dose of 150mg/Kg 
by i.p. injection 24 hours prior to trypanosome inoculation) adult female Balb/C 
mice.
2.2.3 In Vivo Generation of Drug Resistant Lines of Trypanosomes
All selections were carried out in female adult CFLP or CD1 mice 
immunosuppressed with 250mg/Kg cyclophosphamide 24 hours prior to 
inoculation with trypanosomes. Starting with the cloned unselected trypanosome 
stocks (either 247 or 386), trypanosomes were grown to a parasitaemia of 
greater than 3.2xl07 trypanosomes/ml and then treated with a sub-curative drug 
dose by i.p. injection causing recrudescence of the parasitaemia. Trypanosomes 
from subsequent relapse infections were transferred to one or more 
immunosuppressed mice and when the parasitaemia rose to 3.2xl07 
trypanosomes/ml they were again drug treated at the same or a slightly increased 
dose. Repetition of this sequence eventually generated a population of 
trypanosomes with a high level of drug-resistance. The homogeneity of this 
population could not be guaranteed after the drug-resistance selection, therefore 
each population was recloned by isolating single trypanosomes taken from a 
drop of infected mouse tail blood suspended in approximately 100-200|il guinea 
pig serum. Optical cloning of bloodstream trypanosomes was carried out in a 
cool (10°C) room as described previously (McLintock 1990), with the exception 
that guinea pig serum instead of PSG was added to drops containing single 
trypanosomes.
2.2.4 Cyclical Transmission of Trypanosomes through Tsetse Flies
Three drug-resistant trypanosome lines were cyclically transmitted
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through a strain of Glossirta morsitans that was susceptible to trypanosome 
infection (Maudlin and Dukes 1985). Tsetse flies were infected with bloodstream 
trypanosomes taken either from a cryopreserved stabilate or direct from an 
infected mouse. The infective feeds were prepared as follows:
247MelCyR and 247311^ bloodstream stabilate
lml aliquots of bloodstream trypanosomes taken from infected mice were 
cryopreserved with 7.5% DMSO. Infective feeds were prepared by rapidly 
thawing one aliquot which was then washed once, to remove DMSO, by mixing 
with 10ml Hank's balanced salt solution containing heparin (50units/ml) and 
centrifuging at lOOOg for 10 minutes at 4°C. The trypanosome containing pellet 
was resuspended in approximately 10ml citrated sheep's blood (Advanced 
Protein Products).
386MelCyR bloodstream forms
Infected blood was taken from infected mice with parasitaemias greater 
than 3.2xl07 trypanosomes/ml (preferably with a high proportion of short- 
stumpy forms) with a syringe in which was approximately 0.4ml Hank's balanced 
salts containing heparin (50units/ml) for every 2ml of blood. Infected blood was 
either fed directly to flies or mixed with up to 10ml citrated sheep's blood 
depending on the volume of infective feed required.
Infective feeds were warmed on a tray to 37°C and given to teneral flies 
at trypanosome densities of greater than 2.5x105 trypanosomes/ml by allowing 
the flies to feed through a silicone rubber membrane. Flies were maintained as 
described previously (Hajduk et al. 1981, Turner et al. 1990) in a temperature 
controlled room (26-27°C) in cupboards with a tray of water to create a humid
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environment. Citrated sheep's blood was used for maintenance feeds three times 
each week.
Flies harbouring mature infections were identified by allowing flies over 
18 days old to probe onto microscope slides heated to 37°C. The dried saliva 
was then examined under phase-contrast microscopy for the presence of phase- 
bright metacyclics. Bloodstream infections were re-initiated by allowing flies 
with metacyclic infections to feed directly on Balb/C mice (anaesthetised with 1 
part Hypnovel : 1 part Hypnorm : 2 parts dddH20 - 0.1ml/20g mouse by i.p. 
injection).
2.2.5 In Vivo Assay to Determine Drug-Resistance
An in vivo drug assay was used to assess the levels of drug-resistance of 
the cloned trypanosome lines. Adult female (approximately 20g) Balb/c mice 
were immunosuppressed with 150mg/Kg cyclophosphamide by intraperitoneal 
(i.p.) injection. Twenty four hours later each mouse was inoculated i.p. with 105 
trypanosomes. After a further 24 hours the mice were drug-treated by i.p 
injection. Identical treatment was given to all mice within a group of six, with a 
number of groups allowing a range of drug doses to be given. Starting 3 days 
post-infection and continuing for the next 11 days, tail blood was monitored for 
patent infections using the rapid matching technique (Herbert & Lumsden 1976). 
Drug failure due to drug-resistance was judged to have occurred upon the 
appearance of a patent infection (i.e. greater than 2.5 x 105 trypanosomes/ml).
2.3 RESULTS
2.3.1 Selection History
Figure 2.2(a-d) shows the selection histories for the four drug-resistant
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lines (247MelCyR, 247SurR, 386MelCyR and 386SurR). Drug-resistance was 
selected by incremental increases in the drug pressure. Since the sub-curative 
dose at any given stage of selection could only be estimated, relapse 
trypanosomes were often transferred to more than one mouse so that a range of 
sub-curative doses could be given at each step. So for example, in Figure 2.2(a), 
three mice were initially inoculated with 247 and subsequently treated with 
melCy at 0.05, 0.08 and O.lmg/Kg. Trypanosomes multiplying in the highest 
drug dose, in this case those from the mouse treated with melCy at O.lmg/Kg, 
were transferred to three more mice and the procedure was repeated at higher 
doses. The selections with each drug were stopped when the sub-curative dose 
had reached the maximum dose tolerated by the mice. These maximum tolerated 
doses were 40mg/Kg for melCy (Jennings pers. comm.) and 70mg/Kg for 
suramin (doses above which the physical appearance of the mice deteriorated).
2.3.2 In Vivo Drug-Resistance Assay
The in vivo drug-resistance assay was carried out at four points during 
the process of generating and characterising the drug-resistant clones: before 
selection for drug-resistance; after selection for drug-resistance and recloning; 
after mouse passaging in the absence of drug pressure; and after cyclical 
transmission through the tsetse fly. Figure 2.3(a-d) shows the results of the drug- 
resistance assays carried out on the cloned lines. The bars in the figure represent 
the proportion of mice in each drug-dose group that produced a patent infection 
(i.e. those mice in which the trypanosomes "resisted" drug treatment). The 
results show the large increases in the level of drug-resistance in the cloned drug- 
resistant lines when compared to the unselected stocks. To determine whether 
the drug-resistance phenotypes were stable in the absence of drug pressure, drug 
pressure was removed and the levels of drug-resistance were subsequently 
rechecked. The removal of drug pressure had no measurable effect on the levels
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of drug-resistance, with all four drug-resistant lines expressing stable resistance 
after passaging in mice. 247MelCyR was passaged through 10 mice for 52 days; 
247SurR, 7 mice for 34 days; 386MelCyR, 17 mice for 51 days; and 386SurR, 11 
mice for 41 days. Furthermore, three of the four lines (247MelCyR, 247SurR and 
386MelCyR) were successfully transmitted through tsetse flies, with no loss in 
the levels of their resistance.
The results of the in vivo assays can be expressed in terms of the 
minimum curative dose i.e. the lowest dose required to completely clear the 
infection from all six mice in a group. Table 2.1 expresses the results from Figure 
2.3(a-d) shown as minimum curative doses. MelCy-resistance has increased from 
0.3mg/Kg in 247 and 2.0mg/Kg in 386 to over 40mg/Kg in both melCy-resistant 
lines. Similarly, suramin-resistance has increased from 1.5mg/Kg and 2.0mg/Kg 
in 247 and 386 respectively to over 70mg/Kg in both suramin-resistant lines 
Both melCy-resistant lines and both suramin-resistant lines show stable levels of 
drug-resistance of 40mg/Kg and 70mg/Kg for melCy and suramin respectively.
The existence of cross-resistance between the melaminophenyl arsenicals 
is shown in Table 2.2(a and b). MelCy-resistance has increased by over 130-fold 
for 247 and this gave rise to increases in melB-resistance and melW-resistance of 
over 125-fold and over 50-fold respectively. The 247MelCyR line expressed 
resistance to melB and melW at the maximum tolerated dose of 40mg/Kg for 
both drugs. Table 2.2(b) shows similar patterns of cross-resistance for 
386MelCyR. Although the levels of melB-resistance and melW-resistance for 
386MelCyR were at the maximum tolerated dose (40mg/Kg), the values for the 
relative increases in drug-resistance were lower than 247MelCyR. This is due to 
unselected 386 expressing higher levels of resistance to all three melaminophenyl 
arsenicals compared to unselected 247.
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It is clear from Table 2.3(a-d) that there was no cross-resistance between 
suramin and melCy in any of the four cloned resistant lines. Although 
386MelCyR has shown a very slight increase in resistance to suramin from 
2.0mg/Kg to 2.5mg/Kg (Table 2.3(b)) and 386SurR has shown a similarly small 
increase in melCy-resistance from 2.0mg/Kg to 3.0mg/Kg (Table 2.3(d)), these 
represent increases of only 1.3-fold and 1.5-fold respectively.
2.4 DISCUSSION
Four cloned drug-resistant lines have been generated through the 
selection of drug-resistant sub-populations by incremental increases in drug 
pressure. An in vivo selection was chosen in preference to an in vitro selection to 
more closely parallel drug pressures that would occur in natural populations in 
the field. The in vivo selection fulfils this criterion in a number of ways. Firstly, it 
was carried out in a mammalian murine host in which each drug was more likely 
to retain the same pharmacological activity as in the human host. An in vitro 
selection would not have this advantage. Secondly, the two lines chosen (247 
and 386) were not available in adapted long-term bloodstream culture (although 
they have since been adapted (Sutherland, personal communication)). Therefore, 
an in vitro selection would have had to have been carried out on procyclic 
culture forms, which, on account of the known differences between bloodstream 
and procyclic metabolism, could have resulted in a different mechanism of drug- 
resistance.
The selection procedures were carried out in immunosuppressed mice 
(cyclophosphamide at a dose of 250mg/Kg by i.p. injection 24 hours prior to 
trypanosome inoculation) ). In attempting to mimic drug-resistance selection in 
the field, it was difficult to ascertain whether or not the mice should be 
immunosuppressed. Trypanosomiasis occurs in areas of Africa in which there are
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often also a number of other infections, such as malaria and toxoplasmosis 
(Strickland et a l  1972) that compromise the host immune system, as well as the 
immunosuppression caused by trypanosomiasis itself (Goodwin 1970). 
Therefore, it could be argued that some degree of immunosuppression would 
inevitably be present in infected patients receiving drug therapy in the field, and 
therefore the laboratory selection should be carried out in immunosuppressed 
mice. On a practical level, it has been shown previously that the efficacy of 
melCy treatment in T. evansi is markedly reduced (and the subsequent 
development of melCy-resistance increased) in irradiated mice compared to 
immunocompetent mice (Osman et a l  1992). This loss of efficacy in 
immunosuppressed hosts was also shown with the melaminophenyl arsenical, 
melB (Frommel 1988). The role of suramin and the host immune system has 
been established during the early years of suramin use, with studies using mice 
that were immunosuppressed by splenectomy and blocking their 
reticuloendothelial system with colloidal copper. Similar to the situation with the 
melaminophenyl arsenicals, immunosuppression led to a decrease in suramin 
efficacy and an increase in the rate of development of suramin-resistance (Von 
Jancso and Von Jancso 1934; Von Jancso and Von Jancso 1935). It was 
suggested that immunosuppressed hosts in the field play a significant role in the 
development of drug-resistance, and it was for this reason and for the speed at 
which drug-resistance could be generated that immunosuppressed mice were 
used.
A number of further points deserve to be mentioned with reference to the 
selection procedures. Firstly, the general selection procedure that was employed 
selected for two phenotypes: the desired drug-resistance phenotype; but also a 
monomorphic phenotype. The selection procedure was, in effect, rapid passaging 
of a trypanosome line from one mouse to the next, and this selected for 
trypanosomes with a higher overall growth rate in mice (i.e. either a shorter cell
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cycle or a reduction in the ability to transform to short-stumpy forms, or both 
(Turner 1990). Although no accurate measurements of doubling time were 
made, the resistant clones undoubtedly grew more rapidly in mice, and this was 
especially marked for 386SurR. Furthermore, the drug-resistant lines proved 
more difficult to transform from bloodstream to procyclic culture forms 
compared to the unselected stocks (section 3.3.1),
More specifically, two problems were associated with the generation of 
the suramin-resistant lines. In the immunosuppressed mice, suramin required 
approximately 2 days to clear the trypanosomes from the blood. The first 
attempt to generate a suramin-resistant line was with 386. Trypanosomes were 
taken from mice one day after being treated with suramin, on the assumption that 
they were resistant to the level of drug administered, when in fact the drug had 
not had time to take full effect. Thus, when the trypanosomes were transferred to 
another mouse they had time to recover and multiply. Repetition of this 
procedure resulted in mice being treated with suramin at 70mg/Kg and the 
trypanosomes in the blood one day later were cloned. However these clones 
proved to only have a low level of resistance to suramin (lOmg/Kg) when they 
were rechecked. The procedure for selection described in section 2.2.4 where 
trypanosomes were only taken from subsequent relapse infections after drug 
treatment solved this problem. The second problem associated with the selection 
for suramin-resistance was due to the pharmacology of the drug. Suramin binds 
to plasma proteins and has a half-life of approximately 50 days (Collins et al. 
1986). Consequently, the process of passaging trypanosomes from a suramin 
treated mouse, which will transfer approximately 0.5ml of blood, to another 
mouse, will also transfer suramin bound to blood proteins. This accumulation of 
suramin with the addition of a fresh dose one day after infection could account 
for the finding that 247SurR has a minimum curative dose of greater than 
70mg/Kg although it was apparently only selected to a level of 50mg/Kg. A
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further explanation for this observation could simply be that the mutation that 
was selected for at 50mg/kg also confers resistance at a higher dose than the one 
at which it was selected. This is almost certainly the case with the arsenical- 
resistance in 247MelCyR (section 3.4)
The in vivo assay used was designed so that drug failure would only be 
seen if the trypanosomes had multiplied in the presence of the drug and were 
therefore drug-resistant. The rapid matching technique (Herbert and Lumsden 
1976), used to assess the mouse parasitaemia, was only sensitive to 
parasitaemias greater than 2.5xl05 trypanosomes/ml, and since each mouse 
received only 105 trypanosomes, a patent parasitaemia would only be seen if the 
trypanosomes had multiplied. The parasitaemias were monitored for a full 14 
days following the initial trypanosome inoculation as an immunosuppressed 
mouse inoculated with a single trypanosome of these lines will always produce a 
patent infection within 6-12 days. It may have been possible for some of the 
faster growing lines to multiply at such a rate that there would have been a 
patent infection one day after inoculation. For this reason, tail blood was 
monitored 48 hours after drug administration to allow the trypanocidal action of 
the drugs to take full effect. Finally, to ensure the drug was acting in the 
circulation and not locally in the peritoneal cavity, drug treatment was given 24 
hours after trypanosome inoculation as it takes up to 24 hours for the 
trypanosomes to pass from the peritoneal cavity into the blood circulation.
Table 2.2(a and b) show the minimum curative doses of the 
melaminophenyl arsenicals melCy, melB and melW for the unselected stocks. 
Treatment with melB in clinical cases is carried out at drug doses of between 
1.2g and 3.6mg/Kg (WHO 1986b) and this would be sufficient to cure infections 
of 247 and 386 with minimum curative doses of 0.32 and 0.64mg/Kg 
respectively. In a patient from Uganda infected with T. b. rhodesiense,
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trypanosomes were isolated that required a dose of melB of more than lOmg/Kg 
to cure the infection in mice (Robertson 1963). This patient suffered relapse 
infections after melB and melW treatment, and the persistent use of drug- 
treatment led to the development of melB-resistant trypanosomes that were 
resistant to a dose of melB of 30mg/Kg in mice. Therefore, the minimum 
curative doses presented here for 247MelCyR and 386MelCyR compare 
favourably with the levels of melB-resistance in clinical cases. Minimum curative 
doses for melCy in mice infected with isolates of T. b. brucei vary from 
1.6mg/Kg to 6.3mg/Kg (Zweygarth and Kaminsky 1990). Doses above 
0.5mg/Kg have been found to be sufficient to cure buffaloes naturally infected 
with T. evansi (Lun et al. 1991) and above 0.3mg/Kg for T. evansi infected 
camels (Zelleke et al. 1989). Suramin, on the other hand, is administered to 
infected individuals at doses of approximately 20mg/Kg (Voogd et al. 1993). 
This is far in excess of the minimum curative doses of 1.5 and 2.0mg/Kg for 247 
and 386 respectively (Table 2.1). However, infections with the suramin-resistant 
lines would not be cured by this treatment. Suramin-resistant isolates of T. b. 
brucei have been identified with minimum curative doses greater than 40mg/Kg 
(Zweygarth and Kaminsky 1990) and isolates of T. evansi have been found with 
minimum curative doses of 20mg/Kg compared to sensitive stocks that were 
susceptible to doses between 0.5 and 4mg/Kg (Zhang et al. 1992).
The levels of resistance to the melaminophenyl arsenicals were 
consistently higher in 386 than 247 (Table 2.2(a and b)) The most marked 
difference occurred with melCy, with 247 expressing a level of melCy-resistance 
of 0.3mg/Kg compared to 2.0mg/Kg for 386. One possible explanation for this 
could be that the human-infective nature of 386 (T. b. rhodesiense) would make 
it more likely to have been exposed to sub-curative doses of melB than 247 (T. 
b. brucei) since the melaminophenyl arsenicals are not used to treat T. b. brucei 
infections in animals. Consequently, 386 may have developed a slight degree of
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melB-resistance during its evolution in Africa. Alternatively, this difference may 
reflect only a naturally occurring variation in metabolism between trypanosome 
field populations from which these two isolates were taken.
The results of the in vivo assays show that the four cloned drug-resistant 
lines (247MelCyR, 247SurR, 386MelCyR and 386SurR) express stable resistance 
after they have been passaged through mice for a number of weeks in the 
absence of drug pressure. More significantly, three lines (247MelCyR, 247SurR 
and 386MelCyR) were cyclically transmitted through tsetse flies. This process 
took over 3 weeks and involved at least five distinct differentiation steps 
(Vickerman 1985) all undertaken in the absence of drug pressure. All three lines 
maintained their drug-resistance, thus demonstrating that the drug-resistance 
phenotypes were stable (Table 2.1).
Cross-resistance between the melaminophenyl arsenicals was observed in 
both of the melCy-resistant lines (Table 2.2(a and b)). The in vivo assay was 
unable to measure minimum curative doses above 40mg/Kg, and consequently it 
was impossible to determine possible higher levels of resistance to the 
melaminophenyl arsenicals. Important differences between the levels of drug- 
resistance between the melaminophenyl arsenicals may therefore exist, evidence 
for which can be seen in vitro (chapters 3 and 6). There was no conclusive 
evidence for the existence of cross-resistance between suramin and melCy, in 
agreement with previous findings for suramin and the melaminophenyl arsenicals 
(Gill 1971; Pospichal et al. 1994). One previous study showed a 5.8-fold 
increase in suramin-resistance in a melarsen-resistant line, although no 
explanation was given for this (Fairlamb et al. 1992b). Two lines in the present 
study showed very slight degrees of cross-resistance (a 1.3-fold increase in 
suramin-resistance in 386MelCyR and a 1.5-fold increase in melCy-resistance in 
386SurR). However, the nature of the in vivo assay and the extremely small
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extent to which these two lines expressed cross-resistance does not allow any 
biological significance to be placed on these data with any confidence. It was 
therefore concluded that whatever biochemical mechanisms were being 
employed by the trypanosomes to resist drug treatment, the mechanism(s) 
conferring suramin-resistance are different to those for melCy-resistance. This 
lack of cross-resistance between the two drugs was vital for future studies using 
the drug-resistance phenotypes as selectable markers for genetic exchange.
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Figure 2.1
In Vivo Generation and Characterisation of a Stable Drug-Resistant Clone
The flow diagram shows the stages through which a cloned, stable drug-resistant 
line was generated from an unselected drug-sensitive stock. The drug-resistant 
population was generated in mice through gradual increases in sub-curative drug 
treatment and subsequently cloned to ensure the homogeneity of the drug- 
resistant line. This cloned line was then passaged through mice in the absence of 
drug pressure and cyclically transmitted through tsetse flies to demonstrate the 
stability of the drug-resistance phenotype.
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Figure 2.2(a)
Selection History for 247MelCyR
This diagram plots the course through which the 247 unselected stock was 
passaged in mice and exposed to gradually increasing sub-curative drug doses to 
generate the 247MelCyR clone. The numbers in the figure represent these sub­
curative doses of melCy in mg/Kg body weight. The longer vertical lines indicate 
the point at which trypanosomes from a relapse infection were transferred to a 
further group of mice, with the range of drug doses they subsequently received 
being indicated by the horizontal lines.
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Figure 2.2(b)
Selection History for 247SurR
This diagram plots the course through which the 247 unselected stock was 
passaged in mice and exposed to gradually increasing sub-curative drug doses to 
generate the 247SurR clone. See legend for Figure 2.2(a) for an explanation.
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Figure 2.2(c)
Selection History for 386MelCyR
This diagram plots the course through which the 386 unselected stock was 
passaged in mice and exposed to gradually increasing sub-curative drug doses to 
generate the 386MelCyR clone. See legend for Figure 2.2(a) for an explanation.
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Figure 2.2(d)
Selection History for 386SurR
This diagram plots the course through which the 386 unselected stock was 
passaged in mice and exposed to gradually increasing sub-curative drug doses to 
generate the 386SurR clone. See legend for Figure 2.2(a) for an explanation.
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Figure 2.3(a)
In  Vivo Assay for MelCy-Resistance in 247 and 247MelCyR
The results of the in vivo drug-resistance assays for 247 and 247MelCyR are 
shown graphically as the proportion of mice in each group of six that developed 
patent infections (indicated by the vertical bars). The horizontal axis is a 
logarithmic scale and indicates the dose of melCy (mg/Kg body weight) that was 
administered to each group of mice. The assays were carried out at four points 
during the process of generating and characterising 247MelCyR: before selection 
for drug-resistance; after selection for drug-resistance and recloning; after mouse 
passaging in the absence of drug pressure; and after cyclical transmission through 
the tsetse fly.
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Figure 2.3(b)
In Vivo Assay for Suramin-Resistance in 247 and 247SurR
The results of the in vivo drug-resistance assays for 247 and 247SurR are shown 
graphically. See legend for Figure 2.3(a) for an explanation.
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Figure 2.3(c)
In Vivo Assay for MelCy-Resistance in 386 and 386MelCyR
The results of the in vivo drug-resistance assays for 386 and 386MelCyR are 
shown graphically. See legend for Figure 2.3(a) for an explanation.
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Figure 2.3(d)
In  Vivo Assay for Suramin-Resistance in 386 and 386SurR
The results of the in vivo drug-resistance assays for 386 and 386SurR are shown 
graphically. See legend for Figure 2.3(a) for an explanation with the exception 
that 386SurR was not cyclically transmitted through tsetse flies.
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Table 2.1
Minimum Doses of Drug Required to Cure Infections before and after 
Selection for Drug-Resistance and after Passaging of Resistant Lines 
through Mice and Fly-Transmission
Minimum Curative Dose
MelCy img/Kg) Suramin (mg/Kg)
247MeICyR 386MeICyR 247SurR 3868™*
Unselected Line 0.3a 2.0b 1.5C 2.0d
Resistant Line >40e >40e >70f >708
Resistant Line (passaged) >40e >40e >70f >70f
Resistant Line (fly-transmitted) >40e >40c >70f ND
The results of the in vivo assays for melCy and suramin are expressed in terms of 
the minimum curative doses required to cure mice infected with the unselected 
stocks and the four drug-resistant lines. For each drug-resistant line, the level of 
resistance is given for the drug against which it was generated, and also the level 
of resistance in the unselected line from which it was generated.
8 Doses tested were 0.05, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5 and
l.Omg/Kg
b Doses tested were 0.1, 1.0, 2.0, 5.0 and lOmg/Kg
c Doses tested were 0.1, 0.5, 1.0, 1.5, 2.0mg/Kg
d Doses tested were 0.5, 1.0, 1.5, 2.0 and 2.5mg/Kg
e Dose tested was 40mg/Kg
f Dose tested was 70mg/Kg
8 Doses tested were 20, 30, 40, 50, 60 and 70mg/Kg
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Table 2.2
Cross-Resistance between Melaminophenyl Arsenicals 
(a) in 247MelCyR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
247 247MelCyR
MelCy 0.3 >40 >130
MelB 0.32® >40b >125
MelW 0.8C >40b >50
(b) in 386MeICyR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
386 386MelCyR
MelCy 2.0 >40 >20
MelB 0.64d >40b >63
MelW 3.2C >40b >13
Minimum curative doses are shown for (a) 247 and 247MelCyR and (b) 386 and 
386MelCyR for melCy, melB and melW. The resistance factor shows the degree 
to which the resistant lines have increased their level of drug-resistance and is a 
ratio of the minimum curative doses for the resistant compared to the unselected 
lines.
a Doses tested were 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64 and 
1.3mg/Kg 
b Dose tested was 40mg/Kg
c Doses tested were 0.1, 0.2, 0.4, 0.8 and 1.6mg/Kg
d Doses tested were 0.08, 0.16, 0.32, 0.64 and 1.3mg/Kg
c Doses tested were 0.2, 0.4, 0.8, 1.6 and 3.2mg/Kg
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Lack of Cross-Resistance between Melaminophenyl Arsenicals and 
Suramin
(a) in 247MeICyR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
247 247MelCyR
MelCy 0.3 >40 >130
Suramin 1.5 1.5® 1.0
(b) in 386MelCyR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
386 386MelCyR
MelCy 2.0 >40 >20
Suramin 2.0 2.5b 1.3
(c) in 247SurR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
247 247SurR
Suramin 1.5 >70 >47
MelCy 0.3 0.3C 1.0
(d) in 386SurR
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
386 386801*
Suramin 2.0 >70 >35
MelCy 2.0 3.0d 1.5
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Table 2.3
Lack of Cross-Resistance between Melaminophenyl Arsenicals and 
Suramin
Minimum curative doses together with the resistance factors are shown for (a) 
247 and 247MelCyR, (b) 386 and 386MelCyR, (c) 247 and 247SurR and (d) 386 
and 386SurR for melCy and suramin.
a Doses tested were 0.5, 1.5 and 2.0mg/Kg
b Doses tested were 1.5, 2.0, 2.5 and 3.0mg/Kg
c Doses tested were 0.3 and 0.4mg/Kg
d Doses tested were 2.0, 2.5 and 3.0mg/Kg
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CHAPTER 3
IN VITRO CHARACTERISATION OF 
CLONED LINES
3.1 INTRODUCTION
Since the earliest beginnings of trypanocide development, starting with 
Ehrlich's mouse model infected with T. equinum, there has been a large number 
of different methods used to assess and compare the trypanocidal activity of 
different compounds. More importantly for the present study, a similarly 
extensive array of methods have been used to assess and compare the levels of 
trypanocide-resistance/sensitivity in a wide range of field isolates and laboratory- 
derived trypanosome lines (Kaminsky and Brun 1993). A huge variety of 
screening systems have been employed using both in vivo and in vitro methods, 
with the use of different trypanosome lines or life cycle stages, with different 
hosts or culture systems, and with different criteria, including long-term viability 
(Kaminsky et al. 1989), [3H]-hypoxanthine incorporation (Brun et al. 1989; 
Pospichal et al. 1994) and growth inhibition (Zhang et al. 1992), having been 
used to measure the level of drug-resistance, and this has ultimately made the 
task of comparing data from different sources very difficult if not, in some cases, 
impossible.
The last 20 years has seen the gradual improvement of semi-defined 
media capable of sustaining trypanosome growth in vitro for indefinite periods. 
Particularly important for the present study has been the work initiated by 
Hirumi for bloodstream forms (Hirumi et al. 1977) and improved by Baltz (Baltz 
et al. 1985) and the work by Brun and colleagues for procyclics (Brun and 
Schonenberger 1979). This has led to the design of many in vitro drug-resistance 
assays for T. brucei and other trypanosome species (reviewed in Kaminsky and 
Brun 1993). Ideally, the perfect assay should mimic the environment in which
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the drug interacts with the trypanosome, in other words the body fluids of an 
infected human, and the results should correlate closely with clinical findings. 
Since clinical data is not available for laboratory generated lines (and most of the 
field isolates), the validity of each in vitro assay system should therefore, where 
possible, be judged with reference to parallel in vivo assays, usually carried out 
in mice. Bloodstream cultures offer a distinct advantage over procyclic cultures, 
not only because this in vivo comparison can be made more directly, but more 
importantly, because of the biochemical differences that are known to exist 
between the mammalian and insect stages of trypanosomes, particularly with 
respect to energy metabolism (reviewed in Opperdoes 1985). This point is 
particularly valid in the case of assays involving suramin, which inhibits at least 9 
glycolytic enzymes (Willson et al. 1993) at physiological concentrations (Stein et 
a l 1989) with the activity of many of these glycosomal enzymes being altered in 
the procyclic glycosome compared to the bloodstream glycosome (Hart et a l 
1984). Furthermore, it is believed that suramin is taken up by receptor-mediated 
endocytosis (Fairlamb and Bowman 1980a; Fairlamb and Bowman 1980b), a 
process which does not occur in procyclics (Vickerman 1985). Despite these 
differences, insect-stage trypanosomes are still useful tools for in vitro assays, as 
these differences between bloodstream and procyclics can be exploited in 
investigations into mode of drug action. On a practical level, in vitro growth of 
procyclics is also more readily achieved compared to bloodstream forms. The 
majority of in vitro assays conducted in recent years, however, have involved the 
use of bloodstream cultures (Kaminsky and Brun 1993). One important problem 
associated with many of the bloodstream culture assay systems that have been 
employed has been the necessity of adapting the trypanosomes to culture before 
conducting the assay. This has biological implications with regards to the effect 
this process of adaptation may have upon the biochemistry of the trypanosome. 
It has been shown previously that a line of T. evansi kept in bloodstream culture 
for a prolonged period lost both its kinetoplast and its ability to infect mice
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(Zweygarth et al. 1991). Not only does in vitro adaptation have biological 
implications, but there are practical implications too, due to the time it takes for 
the trypanosomes to adapt to culture, which may take a month or longer. This is 
unsatisfactory in clinical cases, where the rapid diagnosis of drug-resistant 
trypanosomes could have extremely important consequences on the health, and 
perhaps life, of the patient.
The various methods used for in vitro drug-resistance assays have been 
applied to a number of different trypanosome species including T. brucei, T. 
evansi, T. congolense, T. vivax, T. simiae and T. equiperdum. The validity of 
each assay system and their applicability to different drug/strain combinations 
have been reviewed recently (Kaminsky and Brun 1993). Briefly, the conclusion 
of this review was that the "assay to be applied depends largely on the specific 
aim of the study, on the trypanosome stocks available and on the equipment of 
the laboratory". It was the principal aim of the present study to further 
characterise the six lines described in the last chapter (247, 386, 247SurR, 
247MelCyR, 386SurR and 386MelCyR) in terms of their levels of resistance to 
the melaminophenyl arsenicals and suramin and the absence or presence of cross- 
resistance between these compounds. A longer term objective was to study the 
inheritance of drug-resistance in a number of cloned progeny from a cross 
between two lines each expressing a different drug-resistance phenotype. 
Consequently, it was necessary to develop a reliable in vitro assay system that 
closely reflected the results of the in vivo assay for melCy and suramin, and one 
that did not involve the extensive adaptation of cloned lines to axenic culture. 
Furthermore, the in vitro characterisation provided further information about the 
possible mode of action of the drugs.
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3.2 MATERIALS AND METHODS
3.2.1 Drugs
MelCy, melB, melW and suramin were supplied and stored as described 
previously (section 2.2.1). Melarsen oxide (melOx) was a kind gift from Dr. 
Frank Jennings, Glasgow University. MelOx was stored as a solution in 
propylene glycol at 4°C.
3.2.2 Trypanosome Stocks and Mice
Six cloned lines were used: the two unselected sensitive lines (247 and 
386) and the four drug-resistant clones described in the previous chapter 
(247SurR, 247MelCyR, 386SurR and 386MelCyR). Growth of trypanosomes was 
carried out in immunosuppressed (cyclophosphamide at a dose of 250mg/Kg by 
i.p. injection) adult female CFLP, CD1 or TO Swiss mice, or adult male CFLP 
mice.
3.2.3 In  Vitro Cultivation of Trypanosomes
The six cloned trypanosome lines described in chapter 2 were further 
characterised in vitro using two culture systems: an established procyclic culture; 
and a short-term non-adapted bloodstream culture that sustained growth for 48 
hours.
Growth o f Procyclic Trypanosomes
Bloodstream trypanosomes were grown in mice, harvested under sterile 
conditions and transformed to procyclic forms in SDM-79 supplemented with 
10% heat-inactivated foetal calf serum (Gibco) (Brun & Schonenberger 1979)
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plus 3mM cis-aconitate (10pl of cis-aconitate from a 52mg/ml stock solution per 
lml complete medium) at 26°C. Procyclic cultures were then maintained in 
complete SDM-79 (SDM-79 supplemented with 10% heat-inactivated foetal calf 
serum) at 26°C at a trypanosome density between 106/ml and 107/ml. 
Trypanosome growth for the six cloned lines (247, 386, 247MelCyR, 
386MelCyR, 247SurR, and 386SurR) was measured with established procyclic 
cultures that had been transformed and maintained for less than 2 months. 
Trypanosome counts were carried out using an Improved Neubauer 
haemocytometer in octuplicate, every 24 hours, over 5 days from a starting 
density of 106 trypanosomes/ml. The rate of growth, b, over the first 3 days was 
calculated by least squares regression analysis (Minitab Release 8.2 Extended). 
The mean population doubling times (PDTs) were calculated from the growth 
rates using the following equation:
In 2
PDT = ---------------
b
In order to determine if the growth rates of the unselected lines were 
significantly different from those of the drug-resistant lines, statistical 
comparisons were made using analysis of covariance
Procyclic trypanosome stabilates were cryopreserved using procyclics 
from a dense culture (>107 trypanosomes/ml) which were centrifuged at 900g 
for 10 minutes at 4°C. Pellets were resuspended in heat-inactivated foetal calf 
serum containing 10% DMSO to give a final trypanosome density of 107- 108 
trypanosomes/ml. Aliquots of these were then frozen and stored in liquid 
nitrogen.
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Growth o f Bloodstream Trypanosomes
A short-term bloodstream culture system was used that supported 
growth of trypanosomes for at least 48 hours. The medium used was based upon 
that described by Baltz et al. (1985) modified by Mhlanga & Shall (unpublished 
data). The bloodstream culture medium used (hereafter called B.S.C.M) was 
made up in two parts as follows:
INCOMPLETE MEDIUM
Minimum Essential Medium with Earle's salts (Gibco) 1 litre
Non-Essential Amino Acid Concentrate (xlOO) (Gibco) 10ml
Hepes (Sigma) 6.0g
Glucose (BDH) l.Og
Sodium Bicarbonate (BDH) 2.2g
L-Glutamine (Sigma) 0.3g
This was made to a final volume of 1100ml with dddH20  and the pH was 
adjusted to 7.3 with 4M NaOH. It was then filter sterilised through a 0.22pm 
filter and could be stored for up to a maximum of 3 months at 4°C. Immediately 
before use, the incomplete medium was further supplemented to give the 
following final concentrations:
Thymidine (Gibco) O.lmM
Hypoxanthine (Gibco) 0.016mM
Dithiothreitol (BDH) 0.4mM
Sodium Pyruvate (Gibco) 2.0mM
Catalase (Sigma) 1.7p,g/ml
Adenosine (Sigma) 0.04mM
Guanosine (Sigma) 0.02mM
Foetal Calf Serum (Gibco)8 20%(v/v)
Techgen foetal calf serum was used for a small number of growth 
inhibition assays.
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To obtain these final concentrations for the supplements, approximately 
5ml of the following solutions were initially made up in incomplete medium. 
These solutions were made up immediately before use. Any unused solutions 
were discarded:
Dithiothreitol (BDH) 6.17mg/ml
Sodium Pyruvate (Gibco) 22.0mg/ml
Catalase (Sigma) 0.17mg/ml
Adenosine (Sigma) 1.07mg/ml
Guanosine (Sigma) 0.566mg/ml
Equal volumes of these five solutions were mixed together and filter 
sterilised through a 0.22pm nylon filter. 100ml of complete medium was then 
made up from 5ml of this sterile solution, 73ml incomplete medium, 1ml 
Thymidine (xlOO) (Gibco), 1ml Hypoxanthine (xlOO) (Gibco) and 20ml FCS 
(Gibco).
Bloodstream trypanosomes were then harvested from a mouse, with a 
parasitaemia (in logarithmic growth) greater than 3.2 x 107 trypanosomes/ml, by 
cardiac puncture under sterile conditions into a syringe containing 0.1ml heparin 
(500units/ml) in Earle's balanced salt solution. The infected blood was then 
mixed with two volumes of complete B.S.C.M. and spun at room temperature 
for 10 minutes at 150g. The resulting supernatant containing trypanosomes was 
then removed and the trypanosomes were resuspended in complete B.S.C.M. at 
a density of 105 trypanosomes/ml. Cultures were incubated in 5%C02/95%air at 
37°C. Growth of the two sensitive lines, 247 and 386, was measured using an 
Improved Neubauer haemocytometer in octuplicate, approximately every 12 
hours, for V/i days.
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3.2.4 In Vitro Growth Inhibition Assay
The cloned trypanosome lines were assessed for their levels of resistance 
to a number of trypanocides using both established procyclic cultures (suramin, 
melCy, melW, melB and melOx), and short-term, unadapted bloodstream 
cultures (suramin, melCy and melB). For both assay systems, drugs were 
dissolved in the appropriate complete medium and filter sterilised through a 
0.22pm nylon filter immediately before use. Microtitre plates were used to give a 
range of drug concentrations by doubling dilutions, each well receiving a final 
volume of 50pl drug solution, and wells being grouped in fours for quadruplicate 
counts.
Growth Inhibition o f Procyclic Trypanosomes
All dilutions of both trypanosomes and drugs were carried out in 
complete SDM-79. The trypanosomes were resuspended at a density of 2x106 
trypanosomes/ml. 50pl of this was added to each well containing 50pl of drug 
giving a starting density in drug at 0 hours of 106 trypanosomes/ml. The plates 
were covered and incubated at 26°C for 24 hours after which the trypanosomes 
in each well were counted using an Improved Neubauer haemocytometer.
Growth Inhibition o f Bloodstream Trypanosomes
Bloodstream trypanosomes were harvested from a mouse and purified as 
described above. All dilutions of both trypanosomes and drugs were carried out 
in complete B.S.C.M. The trypanosomes were resuspended in complete 
B.S.C.M. to a density of 2xl05 trypanosomes/ml. 50pl of this was added to each 
well containing 50pl of drug giving a starting density in drug at 0 hours of 105 
trypanosomes/ml. The plates were covered and incubated in 5%C02/95%air at
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37°C for 24 hours, after which the trypanosomes were counted using an 
Improved Neubauer haemocytometer.
3.3 RESULTS
3.3.1 In  Vitro Growth of Trypanosomes
Procyclic Growth Curves
Figure 3.1 (a-f) shows the growth curves for the six cloned lines 
described in the previous chapter. Complete SDM-79 supported growth for at 
least 5 days in all six lines. From observing and maintaining the cultures (i.e. 
anecdotal evidence), there appeared to be a tendency for the drug-resistant lines 
(particularly 386SurR) to be more difficult to transform than the sensitive lines 
(particularly 247). The drug-resistant lines also appeared to require fresh 
medium less often than the unselected lines. This slower growth of the drug- 
resistant lines is indicated from the mean population doubling times (PDTs) for 
the six lines shown in Table 3.1, with 247 and 386 having PDTs of 15.7 and 24.7 
hours respectively, compared to PDTs in the drug-resistant lines between 28.2 
and 43.8 hours. Statistical analysis of the data by comparison of regression 
coefficients from the growth curves, showed that these differences in growth 
rate were significant between 247 and 247MelCyR (p<0.001) and 247 and 
247SurR (p<0.01) although the differences in the growth rates between 386 and 
both 386MelCyR and 386SurR were not significant (p>0.1).
Bloodstream Growth Curves
The growth curves over VA days for the two sensitive lines (247 and 
386) from which all the drug-resistant lines were generated are shown in Figure 
3.2(a and b) respectively. In both lines, the complete B.S.C.M. supported 
growth over the first 24 hours and maintained cell viability for the following 24
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hours. Death of the trypanosomes occurred approximately 48 hours after the 
initiation of the culture.
3.3.2 In  Vitro Growth Inhibition Assay
The effective concentrations that inhibited growth by 50% (EC50 values) 
were calculated from the raw data using a method based on that previously 
described (Kaminsky and Zweygarth 1989; Zweygarth and Kaminsky 1990). The 
number of generations (i.e. the number of times the trypanosomes had 
undergone cell division) at different drug concentrations was calculated and 
expressed as a percentage of the number of generations present in the absence of 
drug after 24 hours, using the following equation (Kaminsky and Zweygarth 
1989):
[log (with drug) - log n j
% Growth Inhibition = ------------------------------------  x 100
[log n^ (control) - log n j
^  = number of trypanosomes at time = 0 
n24 = number of trypanosomes after 24 hours
The percentage growth inhibition values at different drug concentrations 
were then used to generate a growth inhibition profile as shown schematically in 
Figure 3.3. A drug concentration range was therefore arrived at with limits 
defined by the growth inhibition curve. Below a certain concentration of drug, 
there was no measurable effect upon growth (100% growth). Conversely, above 
a certain drug concentration, no measurable growth could be seen (0% growth). 
EC5o values were calculated using only the data points lying between 10% and 
90% growth inhibition and approximating these to a straight line calculated by 
linear regression (Minitab Release 8.2 Extended).
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Growth Inhibition due to Arsenicals
Four lines (247, 386, 247MelCyR and 386MelCyR) were assessed for the 
levels of their resistance to four different melaminophenyl arsenicals (melCy, 
melW, melB and melOx) using procyclic culture forms. Each line/drug 
combination was carried out in triplicate. Figure 3.4(a-d) shows examples of 
growth inhibition profiles in procyclic culture of the four melaminophenyl 
arsenicals with 247 and 247MelCyR. It can be seen that in the drug-resistant line, 
resistance to melB was expressed to a much lesser extent than the expression of 
resistance to melCy, melW and melOx. This low level of expression of melB- 
resistance seen in procyclic culture was also seen in bloodstream culture (Figure 
3.5(a-b)). Furthermore, a similar pattern of growth inhibition profiles was seen 
with 386 and 386MelCyR. The effective concentrations required to inhibit 
growth by 50% were calculated from the growth inhibition assays, and these 
EC50 values are shown in Table 3.2. The r2 values shown indicate how closely 
the data points between 10% and 90% growth inhibition in each assay could be 
approximated to a straight line. Most of the r2 values from the regression 
analyses lie in the region of 0.8 or greater. In most instances, comparison within 
triplicate experiments shows the range of EC50 values from the highest to lowest 
to be equivalent to one doubling dilution or less. The one exception to this can 
be seen with the combination of 386MelCyR and melB. Here, the range of 
0.25|liM  to 1.8pM represents almost three doubling dilutions. Comparison of 
values between different lines and drugs can be more easily seen in Table 3.3, 
with only the average EC50 values from triplicate experiments being shown. For 
both 247 and 386, the data suggests that melCy was the most potent inhibitor of 
growth, with values of 0.060|nM and 0.025pM for 247 and 386 respectively, 
compared to 7.0pM and 0.98pM for the same lines with melB. This relatively 
high concentration required for melB to inhibit growth in the sensitive lines is 
particularly noticeable with 247. However, the most noticeable findings from the
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growth inhibition studies shown in Table 3.3 was the differences seen in the 
degree of cross-resistance between the different melaminophenyl arsenicals. 
MelCy-resistance increased by 520-fold from 0.060pM for 247 to 31pM in its 
resistant derivative, 247MelCyR (Table 3.4). Similarly, a 560-fold increase in 
melCy-resistance was seen between 386 and 386MelCyR. This accounts for 
increases in resistance in both cases that is equivalent to more than 9 doubling 
dilutions (a 512-fold resistance factor being equivalent to 9 doubling dilutions in 
the growth inhibition assays). A large amount of cross-resistance was also seen 
to melW and melOx in both melCy-resistant lines. However, this was not the 
case with melB, the melaminophenyl arsenical used to treat sleeping sickness in 
clinical cases. For both resistant lines, comparison with the sensitive lines, from 
which they were derived, showed only slight increases in melB-resistance (2.3- 
fold and 1.3-fold for the 247MelCyRand 386MelCyR lines respectively).
The growth inhibition profiles in bloodstream culture of 247 and 
247MelCyR for melCy and melB are shown in Figure 3.5(a and b), illustrating 
the point that although the sensitive line has similar low levels of resistance to 
both drugs, the resistant line expresses resistance to melCy to a much greater 
extent than it does to melB. Table 3.5 shows the EC50 and r2 values for the 
bloodstream growth inhibition assays for all six lines with melCy, melB and 
suramin (which will be dealt with separately). The experiments were carried out 
in triplicate except in three cases where only duplicates were carried out. Most 
of the data between repeat experiments for the two melaminophenyl arsenicals 
were within a 2-fold range, although in some cases the variability was greater 
than this. The EC50 values for 386 with melCy ranged from 0.012fjM to 
O.llfiM, which was a 9-fold range and equivalent to more than three doubling 
dilutions. Examination of the average EC50 values (Table 3.6) show that the two 
sensitive lines required similar concentrations of both melCy and melB 
(approximately 0.05}iM) to inhibit growth by 50%. MelCy-resistance was
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expressed in bloodstream culture forms with differences in resistance between 
the resistant and sensitive lines being 87-fold and 24-fold for 247:247MelCyR 
and 386:386MelCyR respectively (Table 3.4). However these differences in 
melCy-resistance were not as marked as they were in procyclics, being an order 
of magnitude lower (EC50 values of 2.7pM for 247MelCyR bloodstream forms 
compared to 31pM for 247MelCyR procyclics). The lack of cross-resistance 
between melB and melCy that was found in procyclics was also found in 
bloodstream culture forms, with concentrations of melB of only 0 .13pM for 
247MelCyR and 0.12pM for 386MelCyR required to inhibit growth by 50%. 
These accounted for increases in resistance of 2.1-fold and 1.4-fold respectively 
(Table 3.4).
Growth Inhibition due to Suramin
Figure 3.6(a and b) illustrates the distinct lack of expression of suramin- 
resistance in procyclic culture for both 247SurR and 386SurR. An extremely high 
concentration of suramin was required to inhibit growth in procyclic cultures 
(Table 3.7). Taking the data as a whole, the EC50 values range from 64jiM to 
320|liM for all four lines assayed (247, 386, 247SurR and 386SurR). The EC50 
values from within a set of triplicate experiments are again generally within a 2- 
fold range although 386 shows a range greater than 4-fold, equivalent to two 
doubling dilutions. Six out of twelve r2 values are greater than 0.9, with the 
lowest being 0.557. The average EC50 values are shown in table 3.8. It is clear 
that not only were procyclics extremely insensitive to suramin with EC50 values 
of the order of 100|liM, but also that the levels of resistance did not increase in 
the suramin-resistant lines (Table 3.8).
A very different picture was seen with the effect of suramin on 
bloodstream culture forms (Figure 3.6(c and d)), where it is clear that suramin-
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resistance was expressed in both suramin-resistant lines. The data from within 
triplicate experiments was fairly repeatable (Table 3.5), although, as with the 
bloodstream EC50 values for the melaminophenyl arsenicals, the experiments 
tend to be noticeably less repeatable than the procyclic assays. The average EC50 
values for 247 and 386 (Table 3.6) show that bloodstream culture forms are 
approximately 200-fold more sensitive to growth inhibition by suramin than their 
procyclic counterparts, with EC50 values of 0.97pM for 247 and 0.44pM for 
386 compared to 190fiM and llOpM for the procyclics respectively. Unlike the 
procyclics, suramin-resistance was expressed in bloodstream culture forms, with 
resistance factors of 20 for 247SurR compared to 247 and 150 for the equivalent 
comparison between 386 and 386SurR.
Cross-Resistance between Suramin and MelCy
In the search for a suitable assay for the analysis of clones generated 
from a cross between a suramin-resistant line and a melCy-resistant line, it was 
necessary to show that the lack of cross-resistance between suramin and melCy 
found in vivo could also be shown in vitro. Cross-resistance between suramin 
and melCy in procyclics was not investigated due to the finding that suramin- 
resistance was not expressed in procyclics. Table 3.6 shows that both suramin- 
resistant lines in bloodstream culture had very similar levels of resistance to 
melCy (0.038pM and 0.039pM for 247SurR and 386SurR respectively) when 
compared to their sensitive counterparts (0.03 lpM  and 0.046pM for 247 and 
386 respectively). There was however some indication of slight cross-resistance 
between suramin and melCy when the melCy-resistant lines were assessed for 
their levels of suramin-resistance. A suramin concentration of 2.2|iM was 
required for 50% growth inhibition of 247MelCyR, approximately twice as much 
required for 247, and 386MelCyR required 5-fold more suramin than 386 to be 
inhibited to the same extent. Nevertheless, this apparent increase in suramin-
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resistance in the melCy-resistant lines was substantially lower than the increase in 
the suramin-resistant lines.
3.4 DISCUSSION
This chapter examined the merits of a 24-hour growth inhibition assay 
using either procyclics or short-term bloodstream cultures to assess the levels of 
resistance to melaminophenyl arsenicals and suramin. The procyclic cultures 
showed relatively high mean population doubling times compared to previous 
findings (for example Brun and Schonenberger 1979). Nevertheless, there was 
an indication that the resistant lines grew more slowly in procyclic cultures 
compared to the unselected lines. This might have had important consequences 
during the co-transmission through tsetse flies of two lines with different growth 
rates.
The use of EC50 values as criteria for assessing the levels of drug- 
resistance was chosen as it provides a fairly rapid and reliable method that easily 
distinguishes between drug-resistant and sensitive clones and one that was also 
sufficiently sensitive to identify intermediate levels of resistance. Twenty-four 
and 48 hour drug incubation studies have been applied to different drugs for a 
number of different trypanosome species in vitro. However, these studies have 
not all expressed levels of drug-resistance in EC50 values. In one study, levels of 
resistance to a range of drugs was measured in terms of the maximum 
concentration that still allowed trypanosomes to grow at 100%, and the 
minimum concentration required to totally kill cultures after 24 hours (Zhang et 
al. 1992). During the earlier stages of the present study, a large number of 
assays were carried out in vitro using this latter method of measuring drug- 
resistance, namely the lowest drug concentration in which no motile 
trypanosomes could be seen after a 24 hour incubation. Although the use of
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trypanosome death is undoubtedly a more attractive yard-stick to measure the 
effectiveness of a trypanocide than inhibition of growth, in practice it was 
extremely difficult to accurately assess the end-point of such an assay. On the 
whole, arsenical-resistant trypanosomes could be separated from sensitive 
trypanosomes in procyclic culture using this assay but the data from bloodstream 
cultures, particularly with suramin, was too variable to be used with any 
confidence and the method was subsequently discarded in favour of the growth 
inhibition assay. The method used to measure EC50 values in the present study 
was based on a previously published method (Kaminsky and Zweygarth 1989). 
This latter study calculated the EC50 values from the growth inhibition graphs 
using the minimum y} method. Attempts at repeating this method were 
unsuccessful because insufficient information on the method of data analysis was 
given in the original publication (Kaminsky and Zweygarth 1989). Therefore, the 
data points between 10% and 90% growth were approximated to a straight line. 
Although the relationship between growth and drug concentration was 
undoubtedly not linear over the whole range of drug concentrations, it was 
acceptable to approximate the values between 90% and 10% growth to a 
straight line as can be seen by the r2 values in tables 3.2, 3.5 and 3.7. A total of 
104 assays were carried out, 55 of which had r2 values greater than 0.9. 
Furthermore, the range of the EC50 values within triplicate repeats was found to 
be within one doubling dilution in the majority of cases. In experiments where 
the range was more marked, such as the 9-fold range seen in the combination of 
386 and melCy in bloodstream culture, the highest EC50 value in the sensitive 
line (0.1 lpM) was still 10-fold lower than the lowest EC50 value in the resistant 
line (l.lfiM ). In this respect the growth inhibition assay with bloodstream 
trypanosomes was more than adequate in distinguishing between sensitive and 
resistant lines for both melCy-resistant lines and both suramin-resistant lines. The 
same could not be said for the procyclic assays, in which the suramin-resistant 
lines could not be distinguished from sensitive lines.
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Apart from melB, arsenical-resistance was undoubtedly expressed in 
procyclic culture, although it was equally clear that suramin-resistance was not. 
Insect stage trypanosomes for in vitro drug-resistance assays have been used 
previously with conflicting results. Forty-eight hour growth inhibition assays 
have been carried with T. congolense for isometamidium chloride (samorin) and 
diminazene aceturate (berenil) using procyclic cultures using a similar method to 
the one described in the present study (Elrayah and Kaminsky 1991). For both 
drugs, differences between drug-resistant and sensitive lines that were detected 
in vivo were not seen with in vitro procyclic cultures. Another study comparing 
bloodstream and procyclic cultures of T. congolense isolates also showed a loss 
of expression of berenil-resistance and samorin-resistance in procyclic cultures 
(Brun and Rab 1991). This latter study used [3H]hypoxanthine incorporation 
rather than growth inhibition to measure the levels of drug-resistance. It was 
possible that the T. congolense procyclics did not express samorin-resistance or 
berenil-resistance in the same way that suramin-resistance and melB-resistance 
was not expressed in T. brucei procyclics in the present study. However, the 
[3H]hypoxanthine incorporation assay was also used in a similar study on the 
effect of samorin and berenil on bloodstream and procyclic cultures of T. 
congolense (Ross and Taylor 1990). In this study both samorin-resistance and 
berenil-resistance that was expressed in vivo, was also found to be expressed in 
bloodstream and procyclic cultures. However, on the whole, it would appear 
that the use of insect-stage cultures is not reliable enough for the routine 
screening of trypanosomes from a range of sources.
Bloodstream cultures appear to offer the best system with which to 
assess the levels of drug-resistance in vitro. The EC50 values from the in vitro 
bloodstream assays closely reflected the minimum curative doses from the in 
vivo assays with suramin and the melaminophenyl arsenicals, with the notable 
exception of the lack of expression of melB-resistance in culture. Thus, the
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melCy-resistant lines expressed resistance to melW both in vivo and in vitro, and 
similarly, the suramin-resistant lines also expressed resistance in bloodstream 
trypanosomes both in vivo and in vitro. The almost total absence of cross­
resistance between suramin and melCy seen in vivo was also found with the in 
vitro bloodstream cultures. The slight increase in suramin-resistance found in 
both 247MelCyR and 386MelCyR in vitro, was 2-fold and 5-fold respectively. 
This may be due to experimental variation, but it is interesting to note that a 
slight increase in suramin-resistance was also seen in the 386MelCyR line in vivo. 
The in vitro bloodstream assay and the method used to calculate the EC50 values 
was therefore sufficiently accurate to be used in place of the in vivo assay for the 
assessment of melCy-resistance and suramin-resistance. Consequently, it was 
suitable to be used for the analysis of the inheritance of drug-resistance during a 
cross between melCy-resistant and suramin-resistant lines.
The EC50 values for melCy for the sensitive lines are similar to 
previously published values. One study with six T. b. brucei isolates had a range 
of EC50 values from 0.008pM to 0.054pM (Zweygarth and Kaminsky 1990), 
with the latter value coinciding with a minimum curative dose in vivo of 
6.3mg/Kg. However, studies in other trypanosome species have given different 
values, such as those found in T. simiae of greater than lpM  (Zweygarth et al. 
1993) and between 6.4nM and 17nM for five stocks of T. evcmsi (Zweygarth 
and Kaminsky 1990). However, the first of these two studies did not carry out in 
vivo comparisons and could have used an arsenical-resistant isolate. Similarly, 
the latter study was carried out with susceptible T. evansi isolates with minimum 
curative doses in mice of less than 0.4mg/Kg. A different study on T. evansi and 
T. equiperdum conducted experiments similar to the present study but expressed 
the results differently. However, from the data given, it can be estimated that for 
all eight T. evansi isolates and all three T. equiperdum isolates, EC50 values were 
approximately 0.01 p.M for melCy (Zhang et al. 1992). None of these isolates
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expressed melCy-resistance in vivo. The same study also investigated levels of 
suramin-resistance, which again could be estimated to be between 0.1 pM and 
lpM, similar to the values for 247 and 386. A T. evansi isolate with suramin- 
resistance was found to have an EC50 value of 15pM, which was comparable to 
the 247SurR (19pM) and 386SurR (63 pM) lines (Kaminsky and Zweygarth 
1989). However, the same study showed that two lines of T. brucei that were 
sensitive to suramin in mice had very low EC50 values of 0.068pM and 
0.017pM, which was over an order of magnitude lower than those for 247 and 
386 (0.97pM and 0.44pM respectively). Unfortunately, only the fact that they 
were suramin-sensitive in vivo was given and not the minimum curative doses, 
which could have also been lower than those for 247 and 386. However, in 
conclusion, previously published values are not too far removed from the values 
for the six lines used in this study, thus providing further support for the 
methods used.
Selection of melCy-resistance in vivo could only be carried out to the 
maximum tolerated dose of 40mg/Kg, and similarly, the two melCy-resistant 
lines could only be assayed in vivo at a maximum of 40mg/Kg. However, there 
was no such constraint for the in vitro assays and it was interesting to note that 
in bloodstream culture, the resistance factor for 247MelCyR:247 for melCy was 
noticeably larger than for 386MelCyR:386. Although it is questionable whether 
the in vitro bloodstream assay was sensitive enough for this difference to be real 
and not just due to experimental variation, there may be some significance in the 
fact that in vivo 247 had a lower level of sensitivity to melCy (0.3mg/Kg) than 
386 (2.0mg/Kg) prior to selection of drug-resistance. Consequently, it was 
reasonable to expect the selection of melCy-resistance in vivo to produce a 
247MelCyR line with a greater relative increase in resistance than a 386MelCyR 
line, thus providing an explanation for the differences in resistance factors seen 
in vitro.
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The resistance factors for the melaminophenyl arsenicals (Table 3.4) 
show the expected patterns of cross-resistance with the notable exception of 
melB. In both procyclic and bloodstream cultures, cross-resistance between 
melCy and melB is virtually absent. It is the generally held assumption that for all 
melaminophenyl arsenicals to be active, they must first be converted to melarsen 
oxide (Berger and Fairlamb 1994). It is this active melarsen oxide, that binds to 
intracellular dithiols such as trypanothione, that is responsible for the
trypanocidal actions of the drugs and explains the existence of cross-resistance
between the melaminophenyl arsenicals (for example see Fairlamb et al. 1992b; 
Pospichal et al. 1994). The lack of cross-resistance between melCy and melB in 
vitro was therefore unexpected. There are two possible explanations for this 
observation. Although melB-resistance is expressed in vivo, it is possible that the 
actual levels of melB-resistance were considerably lower than the levels of 
melCy and melW-resistance and it was the limitations of the in vivo assays, in 
which the mice could only tolerate maximum doses of arsenicals of 40mg/Kg, 
that made it impossible to detect the higher levels of melCy-resistance and 
melW-resistance compared to melB-resistance. Consequently, a situation may 
exist where the levels of melCy-resistance and melW-resistance in vivo were 
much higher than 40mg/Kg although it was not possible to measure these levels. 
There is some evidence for this limitation in the in vivo assay with the 
comparison of the in vitro data between 247MelCyR and 386MelCyR. The 
247MelCyR line had higher average EC50 values for the melaminophenyl
arsenicals in five out of six cases in both procyclic and bloodstream cultures
compared to the 386MelCyR line, although the in vivo assay could not 
distinguish between these two lines. Therefore, the in vitro assay may simply be 
picking up a difference between melB and melCy that occurs in vivo but one that 
can not be detected in mice. An alternative explanation for the absence of melB- 
resistance in vitro lies with the different possible mechanisms of uptake of the 
melaminophenyl arsenicals. MelB is highly soluble in lipids compared to melCy
81
In Vitro Characterisation of Cloned Lines
and melW which are both water soluble. It has recently been proposed that all 
melaminophenyl arsenicals are taken up by the trypanosomes by a common 
purine transporter (Carter and Fairlamb 1993). Furthermore, this same study 
found this adenosine transporter to be altered or down-regulated in some way in 
an arsenical-resistant line, thereby bringing about a decrease in drug uptake and 
accounting for the drug-resistance phenotype. The role of this transporter will be 
dealt with in more detail in chapter 6. Briefly, the melCy-resistant lines in this 
study may also possess altered purine transporters. Arsenical-resistance is 
expressed in vivo because the bloodstream trypanosomes are exposed to fairly 
high concentrations of arsenical (approximately 10pM) immediately after 
injection of the drug, which rapidly falls within less than one hour (Burri et al. 
1993). It is over this short period after injection that the sensitive trypanosomes 
are killed, and during which the arsenical-resistant trypanosomes do not take up 
the drug in sufficient amounts to be killed. Similar concentrations that were 
found in the serum immediately after drug injections were capable of lysing the 
sensitive bloodstream trypanosomes in vitro. Arsenical-resistant trypanosomes 
were not lysed at these concentrations in vitro (Burri et al. 1993; Yarlett et al. 
1991; chapter 6). However, the 24 hour incubations presented here with 
arsenicals in bloodstream culture were carried out at much lower concentrations 
than those required to lyse the trypanosomes. Although melCy, melW, melB and 
melOx may all be taken up by the adenosine transporter or some other active 
transport mechanism, the high lipid solubility of melB also allows it to slowly 
diffuse over the cell membrane. This diffusion is not rapid enough to have an 
effect during short exposures to melB, such as occurs in vivo. However, a 24 
hour exposure is sufficiently long for the diffusion of melB to negate the effect 
of an altered uptake mechanism. Hence, the arsenical-resistant lines do not 
express melB-resistance over 24 hours in vitro. There are other possible 
explanations for this lack of melB-resistance, involving more than one route for 
arsenical uptake. This will be dealt with in chapter 6.
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The other notable feature of the EC50 values was the extremely high 
concentrations of suramin required to inhibit procyclic growth (Table 3.8). 
These concentrations of above 0.1 mM are undoubtedly not physiological and in 
many ways the procyclics can actually be considered to be totally insensitive to 
suramin. The simplest explanation of this observation lies with the procyclics 
energy metabolism. A recent study summarised data from different sources and 
found that a number of glycolytic enzymes from bloodstream trypanosomes were 
inhibited by suramin at physiological concentrations (Willson et al. 1993). 
Furthermore, suramin has been found to decrease glycolytic activity in vivo 
(Fairlamb and Bowman 1980a). A number of the glycolytic enzymes found in the 
glycosome were altered in procyclics (Hart et al. 1984), thus providing a 
possible explanation for the almost total lack of suramin-sensitivity in the 
procyclic cultures. A second possible explanation for the lack of suramin- 
resistance in procyclic culture could be that suramin simply does not enter 
procyclics whether they are resistant or not. Suramin uptake appears to be via 
receptor-mediated endocytosis (Fairlamb and Bowman 1980b; Vansterkenberg 
1993). Since endocytosis occurs in bloodstream forms but not in procyclics, if 
suramin is solely reliant on endocytosis for entry into the trypanosome, it may 
not be surprising that suramin had virtually no activity against procyclics except 
at extremely high, non-physiological concentrations (>0.1 mM).
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Figure 3.1
Procyclic Cultures: Growth Curves 
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Figure 3.1
Procyclic Cultures: Growth Curves
(a) in 247
(b) in 386
(c) in 247MelCyR
(d) in 386MelCyR
(e) in 247SurR
(f) in 386SurR
Cultures were initiated in 96 well plates at starting trypanosome densities of 
106/ml and counted in octuplicate every 24 hours for 5 days. The vertical axis 
represents the density of the trypanosome culture on a logarithmic scale, plotted 
against time (days). Vertical bars are ± 2 Standard Errors (Minitab Release 8 
Extended).
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Figure 3.2
Short-Term Bloodstream Cultures: Growth Curves 
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Figure 3.2
Short-Term Bloodstream Cultures: Growth Curves
(a) in 247
(b) in 386
Cultures were initiated in 96 well plates at starting trypanosome densities of 
105/ml and counted in octuplicate approximately every 12 hours for VA days. 
The vertical axis represents the density of the trypanosome culture on a 
logarithmic scale, plotted against time (hours). Vertical bars are ± 2 Standard 
Errors (Minitab Release 8 Extended).
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Figure 3.3
Calculation of EC50 Values by Linear Regression!
Growth (%)
100
Drug concentration
Method used to calculate EC50 values from the growth inhibition profiles.
The growth data (vertical axis) was plotted against increasing drug 
concentration, and the values between 10% and 90% growth were 
approximated to a straight line by linear regression. The drug concentration at 
which growth was inhibited by 50% was calculated from the regression 
equation.
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Figure 3.4
Procyclic Cultures: Growth Inhibition Profiles of 247 and 247MelCyR
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Figure 3.4
Procyclic Cultures: Growth Inhibition Profiles of 247 and 247MelCyR
(a) with MelCy
(b) with MelB
(c) with MelW
(d) with MelOx
Percentage growth inhibition (vertical axis) in procyclic cultures, with increasing 
concentrations of melaminophenyl arsenicals, plotted on a logarithmic scale 
(horizontal axis). The differences in levels of drug-resistance can be seen 
between 247, shown as open circles (o), and 247MelCyR, shown as closed circles 
(•)•
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Figure 3.5
Bloodstream Cultures: Growth Inhibition Profiles of 247 and 247MelCyR
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Pattern of growth inhibition (vertical axis) in bloodstream cultures, with increasing 
concentrations (logarithmic horizontal scale) of (a) melCy and (b) melB. The lack 
of expression of melB-resistance in bloodstream cultures can be seen with 
comparison between the unselected line and melCy-resistant line.
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Figure 3.6
Procyclic Cultures: Growth Inhibition Profiles and Lack of Expression 
of Suramin-Resistance
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Figure 3.6
Procyclic Cultures: Growth Inhibition Profiles and Lack of Expression of 
Suramin-Resistance
(a) in 247 and 247SurR
(b) in 386 and 386SurR
Percentage growth inhibition (vertical axis) in procyclic cultures with increasing 
concentrations of suramin, plotted on a logarithmic scale (horizontal axis). The 
lack of expression of suramin-resistant lines, shown as closed circles (•), can be 
seen with comparison to the unselected lines, shown as open circles (o).
Bloodstream Cultures: Growth Inhibition Profiles and Expression of 
Suramin-Resistance
(c) in 247 and 247SurR
(d) in 386 and 386SurR
Percentage growth inhibition (vertical axis) in bloodstream cultures with 
increasing concentrations of suramin, plotted on a logarithmic scale (horizontal 
axis). The differences in the levels of suramin-resistance in the suramin-resistant 
lines, shown as closed circles (•), can be seen with comparison to the unselected 
lines, shown as open circles (o).
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Table 3.1
Procyclic Cultures: Mean Population Doubling Times over the First 3 Days
Trypanosome Line Mean population Doubling Time 
(hours)
247 15.7
386 24.7
247MeICyR 43.8
386MelCyR 34.7
247SurR 29.3
3868™* 28.2
The average population doubling times for the six cloned lines in procyclic 
culture were calculated from octuplicate counts taken every 24 hours over the 
first 3 days.
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Table 3.3
Procyclic Cultures: Average EC50 values for Melaminophenyl Arsenicals
Trypanosome Line Average ECso values
MelCy (m-M) MelB (pM) MelW (pM) MelOx (pM)
247 0.060 7.0 0.13 0.069
386 0.025 0.98 0.19 0.14
247MelCyR 31 16 100 20
386MelCyR 14 1.3 15 44
The average EC50 values of the four melaminophenyl arsenicals for the two 
unselected lines (247 and 386) and the two melCy-resistant lines (247MelCyR 
and 386MelCyR) in procyclic culture.
Table 3.4
Levels of Arsenical-Resistance Expressed in Different Assay Systems
Resistance Assay Drug Resistance Factor
Employed 247: 247MelCyR 3 8 6 :386MelCyR
MelCy 520 560
In Vitro MelB 2.3 1.3
Procyclic MelW 770 79
MelOx 290 310
In Vitro MelCy 87 24
Bloodstream MelB 2.1 1.4
MelCy >130 >20
In Vivo MelB >125 >63
MelW >50 >13
The relative increases in drug-resistance of the melCy-resistant lines compared to 
the unselected lines from which they were generated are shown as resistance 
factors. The data for the in vitro assays were taken from Tables 3.3 and 3.6. In 
vivo data were taken from the results of the in vivo assays in the previous 
chapter (Table 2.2 (a and b)).
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Table 3.5
Bloodstream Cultures: EC50 and r2 Values for Melaminophenyl Arsenicals 
and Suramin
Trypanosome ECso and r2 Values
Line MelCy MelB Sur
(UM) r2 (UM) r2 (uM) r2
0.017 0.989 0.13 0.803 0.67 0.755
247 0.030 0.708 0.033 0.823 1.0 0.989
0.048 0.913 0.020 0.767 1.2 0.55
0.018 0.990 0.021 0.842 0.15 0.715
386 0.108 0.938 0.083 0.811 0.52 0.984
0.012 1.000 0.15 0.902 0.54 0.996
3.0 0.825 0.093 0.888 3.5 0.932
247MelCyR 1.0 0.738 0.16 0.938 1.1 1.000
4.0 0.951 0.13 0.811 2.2 0.998
1.1 0.766 2.5 1.000
386MelCyR 1.2 0.882 0.083 0.983 3.6 0.914
1.1 0.787 0.16 0.928 0.38 0.899
16 1.000
247SurR 0.040 0.979 ND ND 17 0.998
0.036 0.996 23 0.784
3868™* 0.032 0.990 ND ND 84 1.000
0.046 1.000 42 1.000
The EC50 and r2 values of melCy, melB and suramin for the two unselected lines 
(247 and 386), the two melCy-resistant lines (247MelCyR and 386MelCyR) and 
the two suramin-resistant lines (247SurR and 386SurR) in bloodstream culture.
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Table 3.6
Bloodstream Cultures: Average EC50 values for Melaminophenyl
Arsenicals and Suramin
Trypanosome Line Average ECso Values
MelCy (pM) MelB (pM) Sur (pM)
247 0.031 0.061 0.97
386 0.046 0.085 0.44
247MelCyR 2.7 0.13 2.2
386MelCyR 1.1 0.12 2.2
247SurR 0.038 ND 19
386SurR 0.039 ND 63
The average EC50 values of melCy, melB and suramin for the two unselected 
lines (247 and 386), the two melCy-resistant lines (247MelCyR and 386MelCyR) 
and the two suramin-resistant lines (247SurR and 386SurR) in bloodstream 
culture.
Table 3.7
Procyclic Cultures: EC50 and r2 Values for Suramin
Trypanosome
Line
ECso and r2 Values
Suramin (pM) r2
140 0.557
247 120 0.961
64 0.932
190 0.842
386 320 0.757
69 0.970
91 0.958
247 Sur* 220 0.923
130 0.958
386SurR
84
84
98
0.750
0.686
0.859
The EC50 and r2 values of suramin for the two unselected lines (247 and 386) 
and the two suramin-resistant lines (247SurR and 386SurR) in procyclic culture.
Table 3.8
Procyclic Cultures: Average EC50 values for Suramin
Trypansome Line Average ECso Values
Suramin (pM)
247 110
386 190
247SurR 150
386 Sui* 89
The average EC50 values of suramin for the two unselected lines (247 and 386) 
and the two suramin-resistant lines (247SurR and 386SurR) in procyclic culture.
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CHAPTER 4
GENERATION OF HYBRID TRYPANOSOMES 
EXPRESSING RESISTANCE TO CYMELARSAN 
AND SURAMIN
4.1 INTRODUCTION
Chapters 2 and 3 described the generation and characterisation of four 
cloned lines expressing resistance to either suramin or melCy. These drug- 
resistance phenotypes were shown to be stable in the absence of drug pressure 
after cyclical transmission through tsetse flies. The four drug-resistant lines were 
generated from 247 and 386 - lines known to be capable of undergoing non- 
obligatory genetic exchange during co-transmission through tsetse flies (Jenni et 
al. 1986). Previous co-transmission experiments with 247 and 386 generated 
cloned hybrid trypanosomes that had characteristic phenotypes (isoenzymes) and 
genotypes (RFLPs and karyotypes) indicating that genetic exchange had occurred 
(Jenni et al. 1986; Sternberg et al. 1988; Sternberg et al. 1989; Turner et al. 1990)
A recent study has exploited drug-resistance as selectable markers to 
identify hybrids (Gibson and Whittington 1993). In this study, procyclic culture 
forms of two trypanosome lines (KP2, T. b. brucei and 058, T. b. rhodesiense) 
were each transfected with a plasmid construct (neo and hph) conferring resistance 
to neomycin and hygromycin respectively. Those trypanosomes that had been 
successfully transformed were selected with G418 for neomycin-resistance and 
with hygromycin for hygromycin-resistance, and subsequently transmitted 
separately through tsetse flies to generate bloodstream clones. Co-transmission of 
these two cloned lines resulted in metacyclic infections containing hybrid 
trypanosomes that were identified due to their expression of resistance to both 
G418 and hygromycin. Southern hybridisation with probes for the neo and hph 
genes showed that the double drug-resistant clones contained both genes (Gibson
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and Whittington 1993). This study demonstrated that selectable markers could be 
used successfully to identify hybrid trypanosomes produced during co-transmission 
experiments.
This chapter describes how drug-resistant lines of 247 and 386 were used 
in co-transmission experiments in order to show that the drug-resistant lines 
retained their "fertility" and were able to produce trypanosomes expressing the 
hybrid phenotype (i.e. double drug-resistant). The drug-resistant phenotypes of the 
transfected lines in the previous study were known to result from the insertion of 
the drug-resistant genes into one of a pair of homologous chromosomes (Gibson 
and Whittington 1993) whereas the exact natures of the genotypes in the melCy- 
resistant and suramin-resistant lines were unknown. However, the use of lines 
generated to genuine trypanocides, rather than antibiotics, allows both for the 
exploitation of drug-resistance as selectable markers as well as the simultaneous 
investigation into the inheritance of drug-resistance during genetic exchange. 
Furthermore, the two lines (247 and 386), from which the drug-resistant lines were 
generated, have been well characterised in terms of the inheritance of a wide 
variety of markers (reviewed in Tait et al. 1993).
4.1.1 Experimental Design
Figure 4.1 illustrates the procedure through which two drug-resistant 
cloned lines were used in co-transmission experiments, and the subsequent 
screening of the metacyclic populations to identify those flies producing double 
drug-resistant trypanosomes. Teneral tsetse flies, in batches of approximately 100, 
were given an initial infective feed containing a mixture of two trypanosome lines, 
each with a different drug-resistance phenotype (in this case 247SurR and 
386MelCyR). Infected flies over 18 days old were screened for the presence of 
salivary gland infections by allowing flies to probe and deposit saliva onto
96
Generation of Hybrid Trypanosomes Expressing Resistance to Cymelarsan and Suramin
microscope slides. In order to determine the nature of the metacyclic infections in 
terms of the drug-resistance phenotypes present, those flies producing metacyclic 
trypanosomes were each allowed to feed on a mouse. Trypanosomes from the first 
parasitaemic wave in infected mice were transferred to three mice, mouse 1 of 
which was treated with melCy only, mouse 2 with suramin only, and mouse 3 with 
both melCy and suramin (Figure 4.1). The drug doses chosen allowed drug- 
resistant trypanosomes to grow, but were sufficient to kill drug-sensitive 
trypanosomes. Consequently, by monitoring the infections in the mice after drug 
treatment, the drug-resistance phenotypes present in the metacyclic infections 
could be deduced, as shown in Figure 4.1. Trypanosomes growing in mouse 3, 
which was treated with both melCy and suramin, must therefore have a double 
drug-resistance phenotype, which would suggest they were the products of genetic 
exchange between 247SurR and 386MelCyR. Depending on the genetic nature of 
drug-resistance, genetic exchange might also be expected to produce hybrid 
progeny that were sensitive to both drugs, although this screen would be unable to 
detect double drug-sensitive trypanosomes.
4.2 MATERIALS AND METHODS
4.2.1 Drugs
The two trypanocidal drugs suramin and melCy were used to screen for 
drug-resistant trypanosomes after cyclical transmission through tsetse flies. Both 
drugs were supplied and stored as described previously (section 2.2.1).
4.2.2 Trypanosome Stocks and Mice
A total of 1510 tsetse flies were used in 17 separate mixed transmission 
experiments in an attempt to generate hybrid trypanosomes. The two lines used 
(247SurR and 386MelCyR) have been described previously (chapters 2 and 3).
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Adult female Balb/C mice (approximately 20g body weight) were used for all 
aspects of the drug screening.
4.2.3 Assessment of the Rate of Clearance of Infections from Mice
An in vivo assessment was conducted to determine the speed with which 
the two trypanocides, melCy and suramin, were each able to clear trypanosome 
infections from mice, and the effect of the size of the trypanosome inoculation had 
on the rate of clearance. Two lines were assessed: 247MelCyRft (post fly- 
transmission (GUP 3650)) and 24SurRft (GUP 3621). Trypanosomes from a rising 
parasitaemia were taken from an adult female TO Swiss mouse 
(immunosuppressed with cyclophosphamide 24 hours previously at a dose of 
250mg/Kg by i.p. injection) and transferred to Balb/C mice (immunosuppressed 
with cyclophosphamide at a dose of 150mg/Kg by i.p. injection). Groups of six 
Balb/C mice each received different numbers of trypanosomes between 101 and 
107/mouse. Twenty four hours after inoculation with trypanosomes, each mouse 
then received drug treatment of either suramin at a dose of 5mg/Kg or melCy at a 
dose of 5mg/Kg by i.p. injection. The parasitaemias were monitored with the rapid 
matching technique (Herbert and Lumsden 1976) for up to 13 days post drug- 
treatment.
4.2.4 Infection of Tsetse Flies
Teneral tsetse flies were infected with either bloodstream trypanosomes or 
procyclic trypanosomes at a final trypanosome density of lx l0 6 to 6.3x107 
trypanosomes/ml in batches of approximately 100. Batches and individual flies 
were given unique numbers. The life cycle stage (bloodstream or procyclic) and 
the source of these trypanosomes (bloodstream stabilate, bloodstream infections in 
mice or established procyclic cultures) used to infect the tsetse flies are
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summarised in Table 4.1.
Batch No's 25700, 26100 & 27500
Flies in batch no.'s 25700 and 26100 were fed an initial infected feed of 
trypanosomes taken directly from two infected mice. The parasitaemias of each 
mouse were measured with a haemocytometer and the blood from the mice was 
mixed with titrated sheep's blood to give an infective feed containing the two 
trypanosome lines, 247SurR and 386MelCyR, in a 1:1 ratio. This was then warmed 
on a tray at 37°C and fed to teneral tsetse flies through a silicone membrane. 
Infected tsetse flies were maintained on citrated sheep's blood as described 
previously (Hajduk et al. 1981; Turner et al. 1990). Flies in batch no. 27500 were 
also given an infective feed of trypanosomes taken from mice but containing 
247SurR and 386MelCyR in a 1:2 ratio instead of the normal 1:1 ratio.
Batch No's 26300, 26400, 26500, 26600, 27000, 27100, 27200, 28000,
28100, 28200 & 28300
Flies in batch no.'s 26300 to 27200 were given bloodstream trypanosomes 
taken from cryopreserved samples (stabilated using 7% DMSO) containing a 1:1 
mixture of the two stocks. The stabilates (either GUP 3599 or GUP 3606) were 
resuspended in citrated sheep's blood and fed to tsetse flies as described above. 
Flies in batch no.'s 28000 to 28300 were also fed trypanosomes taken from 
cryopreserved samples. These flies were fed in a similar manner to that just 
described except that the two drug-resistant lines were cryopreserved separately in 
10% glycerol. The stabilates were then sent to Roger Barker in the Tsetse 
Research Laboratories, Bristol, where they were mixed in a 1:1 ratio before being 
fed to tsetse flies.
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Batch No's 27700 & 27900
Flies in batch no.'s 27700 to 27900 were fed an infected feed of 
trypanosomes taken from established procyclic cultures. Complement-containing 
serum was removed from citrated sheep's blood by washing the blood twice in 
serum-free buffer. Each wash was carried out by mixing the blood with two 
volumes of sterile Hank's balanced salt solution containing heparin (50units/ml) 
and centrifuging at 200g for 10 minutes at 4°C. The resulting pellet of red blood 
cells was then mixed with procyclics and heat-inactivated serum in a ratio of 1 part 
red blood cell "slurry" : 1 part procyclic culture (cell density > 107/ml) : 1 part 
heat-inactivated foetal calf serum (Gibco). This was then fed to tsetse flies as 
described above, with procyclics retaining their viability, as judged by motility, at 
37°C for at least 45 minutes.
4.2.5 Identification of Double Drug-Resistant Trypanosomes
Flies harbouring salivary gland infections were identified by allowing flies 
over 18 days old to probe onto microscope slides heated to 37°C. The dried saliva 
was then examined under phase-contrast microscopy and scored for the presence 
of proventricular forms and phase-bright metacyclics. Flies with metacyclic 
infections were individually fed on Balb/C mice (anaesthetised with 1 part 
Hypnovel: 1 part Hypnorm : 2 parts dddH20 - 0.1ml/20g mouse by i.p. injection). 
As many parasites as possible were taken from each subsequent infection by 
cardiac puncture, and were then transferred to 3 immunosuppressed 
(cyclophosphamide at a dose of 150mg/Kg by i.p. injection) Balb/C mice. After 24 
hours, each mouse received a dose of trypanocide by i.p. injection as follows: 
mouse 1 was given 5mg/Kg suramin; mouse 2 was given 5mg/Kg melCy; mouse 3 
was given both 5mg/Kg suramin and 5mg/Kg melCy. Tail blood from each mouse 
was monitored for a patent infection (above 2.5 x 105 trypanosomes/ml) for up to
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14 days, using the rapid matching technique (Herbert and Lumsden 1976). This 
screen identified flies as having produced mature infections with either single, 
mixed or hybrid (double drug-resistant) phenotypes (Figure 4.1).
4.3 RESULTS
4.3.1 Rate of Clearance of Trypanosomes
The procedure used to screen the metacyclics produced from the co- 
transmission experiments meant that the size of the trypanosome inoculum into 
each of the three Balb/C mice varied depending on the degree of the parasitaemia 
in the donor mouse originally infected by the tsetse fly. Consequently, it was 
necessary to examine the effect that the size of the trypanosome inoculum had on 
both the rate of clearance of drug-sensitive lines and the rate of development of a 
patent infection with drug-resistant lines in drug treated mice.
Table 4.2 shows how rapidly patent infections of two fly-transmitted lines 
(247MelCyRft and 247SurRft) appeared in the presence of the drugs to which they 
expressed resistance (melCy and suramin respectively). As expected, the larger the 
trypanosome inoculum, the sooner the infection became patent. The appearance of 
patent infections of 247MelCyRft occurred between 4 and 6 days after treatment 
with melCy at a dose of 5mg/Kg when the inoculum size was only 101 
trypanosomes/mouse, whereas the infections were patent the day after drug 
treatment for inoculum sizes of 107 trypanosomes/mouse. Similar values were 
obtained with the suramin-resistant line in the presence of suramin at a dose of 
5mg/Kg, with infections becoming patent the day after drug-treatment with an 
inoculum size of 107 trypanosomes/mouse, and taking up to 12 days with and 
inoculum of 101 trypanosomes/mouse.
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MelCy appeared to clear the infections of melCy-sensitive (247SurRft) 
trypanosomes very efficiently, with inoculum sizes up to and including 107 
trypanosomes/mouse being cleared within the first 24 hours after drug-treatment 
(Table 4.3). This is not the case for infections of 247MelCyRft after treatment with 
suramin. Five out of 6 mice given 107 trypanosomes showed patent infections 24 
hours after suramin treatment. These infections were cleared by the following day. 
Although a similar experiment was not carried out with the (fly-transmitted) 
melCy-resistant line used in the co-transmission experiments (386MelCyRft), it 
would be expected that the rate of clearance of infection with this line would be 
similar after suramin treatment, since the minimum curative doses of suramin for 
both melCy-resistant lines were similar (1.5mg/Kg and 2.5mg/Kg for 247MelCyR 
and 386MelCyR respectively, chapter 2).
4.3.2 Generation of Hybrid Trypanosomes
Only 9 of the 17 batches that were infected with 247SurR and 386MelCyR 
produced metacyclic trypanosomes. Of these 9 batches, only 3 were identified as 
having produced trypanosomes with hybrid double drug-resistance phenotypes. 
The 14 batches that failed to produce hybrids will be dealt with briefly, followed by 
a more detailed account of the 3 successful co-transmissions. Table 4.1 
summarises the results of the in vivo drug screens for all 17 batches. The process 
of feeding an infected tsetse fly on a mouse meant that only a sample of the 
metacyclic population could be screened, and it was possible that unidentified 
phenotypes were present in the fly that did not enter the mouse. Nevertheless, the 
drug-resistance phenotypes identified in the mouse screen gave an indication of the 
natures of the metacyclic populations in the tsetse flies. Single parental infections 
were identified when trypanosomes grew only in the presence of one drug in the 
mouse screen; mixed infections grew in both mice treated with a single drug but 
not in the mouse treated with both melCy and suramin; whereas hybrid infections
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were identified as growing in the double drug treated mouse (Figure 4.1).
Unsuccessful Attempts at Generating Hybrids
No hybrids were identified in the first 9 batches, all of which were infected 
with bloodstream 247SurR and 386MelCyR at a ratio of 1:1. However, the first 
batch (25700) produced three flies with mature infections all of which developed 
into mixed phenotype infections (both 386MelCyR and 247SurR were present in 
the metacyclics). Three batches (27000, 27100 and 27200) produced mature 
infections consisting of only suramin-resistant trypanosomes (247SurR only). Of 
the 4 batches infected in Bristol with trypanosomes from stabilates, 2 failed to 
produce hybrids. Batch no. 28000 produced 7 flies all with the suramin-resistant 
parental phenotype. Batch no. 28100 also contained 7 flies producing only 
247SurR by itself, along with one fly producing a mixed infection.
Flies in batch no.'s 27700 to 27900 were infected with procyclic 
386MelCyR and 247SurR at a ratio of 1:1. All 3 batches produced no mature 
infections.
Successful Attempts at Generating Hybrids
Flies in batch no. 27500 were infected with bloodstream 386MelCyR and 
247SurR at a ratio of 2:1. The flies in this batch produced infections with a variety 
of phenotypes. One fly produced only suramin-resistant trypanosomes (247SurR 
parental only), two produced mixed infections (both 247SurR and 386MelCyR), 
and two flies produced a population of trypanosomes which was resistant to both 
suramin and melCy given together. Table 4.4 gives details of the course of the 
salivary gland infections in the 5 flies that were successfully screened in batch no. 
27500. Fly 27514 was not identified as having produced a mature infection until
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day 39, and was fed only once on a mouse, producing melCy-resistant 
trypanosomes (386MelCyR only). The other four flies all produced mixed 
infections, with trypanosomes, expressing the hybrid phenotype, appearing in two 
flies at the same time as the appearance of a mixed infection (day 27 in fly 27543 
and day 39 in fly 27568). The mouse screen identified double drug-resistant 
trypanosomes on four separate occasions. The previously described nomenclature 
(Sternberg et al. 1989), incorporating the fly number with the first two digits 
deleted together with the day post infection, has been used to refer to flies and 
trypanosomes on particular days. For example, trypanosomes from fly 27568 on 
day 39 post infection are referred to as 568/39; the fly on this day is referred to 
with an T' prefix, i.e. F568/39). The parasitaemias in the drug treated mice from 
the mouse screens are shown in Table 4.5. On all four occasions that hybrids were 
identified in batch no. 27500, the patent infections arising in mice treated with both 
drugs, were very transient, lasting only one or two days and at only barely patent 
levels (parasitaemias of 106/ml or less). However, with F543/27, /28 and /31, 
trypanosomes were identified in the double drug treated mice between up to 4 and 
6 days after treatment with both melCy and suramin. This is in comparison to the 
results obtained with the rate of clearance of infection studies (section 4.3.1), in 
which suramin-resistant trypanosomes were cleared within 1 day by melCy, and 
similarly, melCy-resistant trypanosomes were cleared within 2 days by suramin 
(Table 4.3). The mouse screen also identified trypanosomes in the double drug- 
treated mouse infected with 568/39. However, these were only seen at barely 
patent levels the day after double drug treatment, similar to the situation observed 
with high levels of trypanosome inoculum of 247MelCyRft, in which a curative 
dose of suramin (5mg/Kg) was unable to clear the infection 1 day after drug 
treatment, but cleared the infection on the following day (Table 4.3).
Batch no. 28200 produced three flies with trypanosomes of suramin- 
resistance phenotype only, and three with mixed salivary gland infections, two of
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which also produced infections that were double drug-resistant. The patterns of 
infections in these 6 flies are shown in Table 4.6. The results of the mouse screens 
for the two occasions on which double drug-resistant trypanosomes were 
identified, F201/43 and F205/43, are shown in Table 4.7. In both cases when 
double drug-resistant trypanosomes were identified, the parasitaemias were at 
barely patent levels (2.5x10s trypanosomes/ml), and trypanosomes were identified 
only one day after drug treatment. This compares to the parasitaemias observed in 
the melCy-only treated mice and in particular the suramin-only treated mice, in 
which relatively high levels of infection were observed 1 and 2 days after drug 
treatment.
Batch no. 28300 produced two flies with mature infections that survived 
long enough to be fed on mice (Table 4.8). One fly produced only suramin- 
resistant parental trypanosomes, whilst one fly showed evidence of having hybrid 
trypanosomes, with double drug-resistance being evident in F301/54 (Table 4.9), 
although this did not appear again during the subsequent 17 days of the flies life. 
Furthermore, no melCy-resistant trypanosomes were identified throughout the life 
of either of the two flies.
4.4 DISCUSSION
Double drug-resistant trypanosomes have been generated by co- 
transmitting through tsetse flies two "fertile" lines each expressing resistance to a 
single drug. These trypanosomes were identified, using the in vivo mouse screen 
described, by exploiting the drug-resistance phenotypes as selectable markers. 
247SurR and 386MelCyR were chosen as the two lines used to generate double 
drug-resistant trypanosomes. The other alternative combination of lines available at 
that time was 386SurR and 247MelCyR. This combination was not used due to the 
relative unsuitability of 386SurR on two counts - it was relatively difficult to
105
Generation of Hybrid Trypanosomes Expressing Resistance to Cymelarsan and Suramin
transform this line to procyclics and, possibly for the same reason, attempts at 
transmitting the cloned line through tsetse flies had so far proved unsuccessful. 
However, even with 247SurR and 386MelCyR, a number of problems were 
encountered during the course of generating hybrids. In particular, it would appear 
(not surprisingly) that the nature of the initial infective feed had a very marked 
effect on the type of mature infection that the flies produced. The later attempts at 
generating hybrids were generally far more successful than earlier attempts, and 
therefore the changes made to the initial infective feeds will be discussed in 
chronological order.
The first two attempts at generating hybrids (batch no.'s 25700 and 26100) 
were fed with 247SurR and 386MelCyR in a 1:1 ratio with trypanosomes taken 
directly from mice (Table 4.1). It was occasionally difficult to synchronise two 
different trypanosome infections in mice with each other and also with the hatching 
of tsetse flies, and consequently the use of pre-mixed stabilates was employed. The 
first stabilate (GUP 3599) was probably of poor quality, since it produced no 
mature infections in approximately 400 flies infected with it. The second stabilate 
(GUP 3606) appeared to be of better quality, although it favoured the production 
of 247SurR (batch no.'s 27000 to 27200).
It was assumed that the most important factor affecting the lack of success 
of hybrid production was the difficulty of transmitting 386MelCyR through tsetse 
flies, and hence 386MelCyR and 247SurR were not present together at the correct 
"fertile" stage of the life cycle. This can be seen clearly by examining the results 
from the mouse screens in all nine co-transmission experiments that produced 
mature infections (Table 4.1). A total of thirty-seven flies harbouring mature 
infections were successfully screened, with 24 of these producing 247SurR only 
and only 1 producing 386MelCyR only. There are two events in the trypanosome's 
life cycle in the vector that are crucial for successful transmission to occur. The
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first step is the successful establishment of a procyclic infection in the midgut from 
one, or more than one, short-stumpy form(s). The next step is the transformation 
to, and the successful migration of, one or more proventricular form trypanosomes 
to establish an infection in the salivary gland (Vickerman 1985). The relative 
difficulty of fly-transmitting both the drug-resistant lines generated from 386 
occurs, therefore, because of a comparative low rate of success either in the 
establishment of a midgut infection or in the establishment of a salivary gland 
infection. Both of these factors are probably important. On purely anecdotal 
evidence, the in vitro transformation of 386MelCyR bloodstream forms to 
procyclic culture forms appeared to be more difficult than the transformation of 
247SurR, although this was as likely to be due to the difficulty of obtaining large 
numbers of short-stumpy forms of 386MelCyR in mice, as it was to be due to a 
relative inability of these short-stumpy forms to transform to procyclics. However, 
it has also been found that a midgut infection of unselected 247 was more likely to 
give rise to a metacyclic infection than a midgut infection of unselected 386 
(Maudlin and Welbum pers. comm.). Irrespective of whether mating occurs in the 
tsetse midgut, as proposed by Jenni et al. (1991) or in the salivary gland, as 
suggested by Gibson and Whittington (1993), the use of two lines with differences 
in fly-transmissibility will undoubtedly favour the production of metacyclic 
infections of one line. In an attempt to alleviate this problem, the next batch of flies 
(27500) was infected with 247SurR and 386MelCyR at a ratio of 1:2 using 
trypanosomes taken from mice. The production of 4 flies with mixed infections, 
two of which also produced trypanosomes with the hybrid phenotype, seemed to 
support the use of an initial infective feed that was weighted, in terms of numbers, 
towards the line that transmitted less favourably through flies. However, although 
this may be the reason for the appearance of mixed and double drug-resistant 
infections, there may be a more important factor influencing the production of 
these mixed infections. 3 86MelCyR trypanosomes for the infective feed were taken 
from a mouse on day 5 of infection. The parasitaemia was 2.5xl08/ml and had
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peaked 2 days previously. However, 247SurR trypanosomes were taken from a 
mouse at a parasitaemia of 5xl08/ml on day 4 of an infection that had not yet 
peaked (or was at its peak). Therefore, the most significant factor concerning the 
infective feed was that 386MelCyR was taken from mice when it consisted 
predominantly of short-stumpy form trypanosomes (as judged by sight on a wet 
blood film), and therefore it was far more capable of transforming to procyclics 
than in previous attempts, when trypanosomes had been taken from mice with 
rising parasitaemias (predominantly non-transforming long-slender forms). This 
may not be particularly important in co-transmission experiments with lines that 
are relatively easy to transmit (such as 247, 386, 247MelCyR and 247SurR), but 
with more difficult lines it may have a considerable effect.
As a consequence of this finding, it was assumed that the use of procyclics 
for the infective feed would further enhance the prospects of generating hybrids. 
However, the next 3 batches (no.'s 27700 to 27900) infected with procyclics in a 
1:1 ratio failed to produce mature infections. However, it was possible that this 
was due to insufficient washing of the red blood cells to remove the complement- 
containing serum during the preparation of the red blood cell 'slurry' for the 
infective feeds.
The final 4 batches (28000 to 28300) were infected with bloodstream 
trypanosomes taken from cryopreserved samples. The stabilates were prepared 
using trypanosomes taken from mice with predominantly short-stumpy infections. 
These 4 batches produced 5 flies with mixed infections, 3 of which also produced 
hybrids. However, 15 of the 22 mature infections that were tested were of a single 
phenotype only (247SurR). It would therefore appear that although the use of 
predominantly short-stumpy infections increases the chances of generating hybrids, 
it may also be valid to argue that weighting the infective feed in favour of 
386MelCyR is also an important factor. This could be achieved either simply in
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terms of relative numbers or by disadvantaging 247SurR by not taking them from a 
predominantly stumpy population. Both these alternatives essentially amount to the 
same, namely that in terms of short-stumpy forms present in the infective feed, for 
lines that are more difficult to transmit, it appears to be better to have larger 
numbers.
The results of the in vivo screens that are summarised in Tables 4.5, 4.7 
and 4.9 showed 7 separate occasions when the double drug-resistant trypanosomes 
were identified. Fly 27543 produced trypanosomes with double drug-resistance on 
3 consecutive occasions, whilst the other 4 times that the double drug-resistant 
phenotype was identified occurred in 4 different flies on isolated occasions. It 
would appear that these 4 isolated occasions, on which trypanosomes with the 
hybrid (double drug-resistance) phenotype were found, were actually false 
positives. This conclusion has been arrived at for a number of reasons. Close 
examination of the actual parasitaemias in the mice that were given both drugs 
shows that for fly 27543, on all 3 occasions the parasitaemia was sub-patent for up 
to 4 days post drug treatment, prior to the emergence of a patent infection (Table 
4.5; F543/27, /28, and /31). This shows categorically that the trypanosomes had 
survived treatment with both trypanocides, were multiplying in the mouse after this 
drug-treatment, and were therefore definitely double drug-resistant trypanosomes. 
On only one other occasion (F301/54) were trypanosomes found to have 
multiplied after treatment with both melCy and suramin (Table 4.9). However, for 
2 weeks previous to this, and for over 2 weeks after this, the mouse screen 
identified only suramin-resistant trypanosomes, with no indication of melCy- 
resistant metacyclic trypanosomes being present at any time during the life of the 
fly (Table 4.8). Furthermore, the increase in parasitaemia was seen immediately 
after treatment with both drugs and not after a period of sub-patency. Finally, all 
attempts at rescreening these 'double drug-resistant' trypanosomes by transferring 
them to further mice failed to identify anything other than suramin-resistant
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trypanosomes only. For these reasons, F301/54 almost certainly produced 247SurR 
trypanosomes only. On the 3 other occasions when putative double drug-resistant 
trypanosomes were identified (F568/39, F201/43 and F205/43) the parasitaemias 
were evident only on the day after drug-treatment (Tables 4.5 and 4.7). The 
studies on the effect of the size of the trypanosome inoculum on the rate of 
clearance of infection showed that although melCy was very efficient at clearing 
melCy-sensitive trypanosomes, mice infected with suramin-sensitive trypanosomes 
may still have patent infections the day after suramin treatment when infected with 
106 trypanosomes or more (Table 4.3). Consequently, the 3 occasions on which 
trypanosomes were observed at barely patent levels the day after treatment with 
both drugs may in fact be due to melCy-resistant, suramin-sensitive trypanosomes 
that have not been fully cleared from the circulation by the action of suramin, and 
were not, therefore, double drug-resistant trypanosomes.
It would appear, therefore, that only one fly (Fly 27543) produced double 
drug-resistant trypanosomes, possibly as a result of genetic exchange between 
247SurR and 386MelCyR. Unfortunately, a number of attempts were made to 
rescreen the unselected populations (from the donor mice) that had been 
cryopreserved. No double drug-resistant trypanosomes could be identified in these 
rescreening attempts. Although this may indicate that the fly had not, in fact, 
produced double drug-resistant trypanosomes, it was more likely that the process 
of cryopreservation killed these trypanosomes. The low levels and transient nature 
of the parasitaemias observed in the double drug treated mice (F543/27, /28, and 
/31) indicate that the double drug-resistant trypanosomes were comparatively small 
in number, relative to trypanosomes expressing a single drug-resistance phenotype, 
and/or have a low growth rate compared to the trypanosomes with parental drug- 
resistance phenotypes. Consequently, the populations of trypanosomes that were 
cryopreserved from the unscreened donor mice would contain only a very small 
proportion of double drug-resistant trypanosomes. Cryopreservation, and the
110
Generation of Hybrid Trypanosomes Expressing Resistance to Cymelarsan and Suramin
subsequent thawing, renders over 99% of trypanosomes non-viable (Barry and 
Turner, unpublished results), and this process may have been sufficient to kill the 
few double drug-resistant trypanosomes that were present in the sample of blood 
used for cryopreservation. It is important therefore not to rely on cryopreservation 
to maintain the integrity of a trypanosome population with mixed phenotypes, and 
instead it would be better to passage double drug-resistant trypanosomes in order 
to obtain a sufficiently high parasitaemia from which clones can be generated.
In conclusion, the results of the co-transmission experiments indicate that 
the low transmissability of 386MelCyR posed a problem for the generation of 
double drug-resistant trypanosomes. The use of infective feeds containing 
predominantly short-stumpy forms appeared to go some way towards alleviating 
this problem, as this would be expected to increase the probability of establishing a 
mixed infection in the tsetse midgut. With respect to the identification of flies 
producing double drug-resistant trypanosomes, consideration must be given to the 
fact that suramin may not clear all the trypanosomes within 24 hours, and only 
those trypanosomes that have multiplied after drug treatment should be considered 
drug-resistant. Furthermore, trypanosomes identified as double drug-resistant 
should be passaged and subsequently cloned in order to prove double drug- 
resistant trypanosomes are indeed products of genetic exchange.
i l l
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Figure 4.1
Experimental Procedure for the Generation of Double Drug-Resistant 
Trypanososomes
247SurR 386MelCyR
Parental phenotypes MSSR MRSS
Possible progeny 
phenotypes MSSR MRSS MRSR MSSS
Drug treatment MelCy Suramin MelCy and Suramin
Possible phenotypes 
in patent infections MRSS MRSR MSSR MRSR MRSR
This figure outlines the protocol used in the co-transmission experiments. 
The two drug-resistant trypanosome lines, 247SurR and 386MelCyR, have 
the two phenotypes, MsSR and MRSs respectively. Flies producing mature 
infections were allowed to feed on a mouse, with the subsequent bloodstream 
infection being transferred to 3 mice. The parasitaemias emerging in these 
mice after drug treatment indicated the drug-resistance phenotypes present in 
the metacyclic populations.
MRSs MelCy-resistant and suramin-sensitive 
MsSR MelCy-sensitive and suramin-resistant 
MRSR MelCy-resistant and suramin-resistant 
MsSs MelCy-sensitive and suramin-sensitive
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Table 4.5
Screening the Drug-Resistant Phenotypes present in Metacyclic 
Populations of Flies in Batch No. 27500
F514/39
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.6 8.4
Suramin 0 0 0 0 0 0 0 0 0
MelCy and Suramin 0 0 0 0 0 0 0 0 0
F543/27
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.6 8.4 8.4 8.4
Suramin 0 0 0 6.0 6.6 0
MelCy and Suramin 0 5.4 0 5.4 5.4 0 0
F543/28
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 8.4 8.7
Suramin 0 0 0 6.3 0 0
MelCy and Suramin 0 0 5.4 0 0 0
F543/31
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.3 7.5 8.4 8.4 8.1 8.1
Suramin 0 0 0 0 0 0 0 0 0
MelCy and Suramin 0 0 5.7 0 0 0 0 0 0
F556/28
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 5.4 7.2 8.1 8.1
Suramin 8.4 8.7
MelCy and Suramin 0 0 0 0 0 0 0
F556/33
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 8.1 8.4
Suramin 7.5 8.4
MelCy and Suramin 0 0 0 0 0 0 0 0
F556/40
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 5.4 7.5 8.4
Suramin 7.2 7.8 8.7
MelCy and Suramin 0 0 0 0 0 0
Facing 117
Generation of Hybrid Trypanosomes Expressing Resistance to Cymelarsan and Suramin
F557/27
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 0 0 0 0 0
Suramin 7.5 8.7
MelCy and Suramin 0 0 0 0 0 0 0
F557/31
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 6.0 7.8 8.1
Suramin 7.2 8.1 8.7
MelCy and Suramin 0 0 0 0 0 0 0
F557/33
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 8.4
Suramin 5.4 7.8 8.7
MelCy and Suramin 0 0 0 0 0 0 0
F568/35
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 0 8.1 7.8
Suramin 0 0 0 0 0
MelCy and Suramin 0 0 0 0 0
F568/39
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.6 8.7
Suramin 5.4 0 0 0 0 0 0
MelCy and Suramin 5.4 0 0 0 0 0 0
These tables show the results of the mouse screens used to identify the drug- 
resistance phenotypes present in the metacyclic populations of 5 flies in batch no. 
27500. The numbers in the tables are the parasitaemias (antilog 
trypanosomes/ml) in the drug treated mice monitored for up to 13 days after 
drug treatment. The parasitaemias were measured using the rapid matching 
technique (Herbert and Lumsden 1976), which was unable to detect 
parasitaemias lower than 2.5xl05 trypanosomes/ml.
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Table 4.7
Screening the Drug-Resistant Phenotypes present in Metacyclic 
Populations of Flies in Batch No. 28200
F201/43
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.3 7.8
Suramin 7.8 8.7
MelCy and Suramin 5.4 0 0 0 0 0 0 0 0 0
F205/43
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 6.6 7.8
Suramin 8.7
MelCy and Suramin 5.4 0 0 0 0 0 0 0 0 0
These tables show the results of 2 mouse screens in which trypanosomes were 
identified in mice treated with both melCy and suramin. In both cases, infections 
in the double drug treated mice were just at patent levels and transient, lasting 
only one day. See legend for Table 4.5 for explanation
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Table 4.9
Screening the Drug-Resistant Phenotypes present in Metacyclic 
Populations of Flies in Batch No. 28300
F301/54
Drug Days Post Drug Treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
MelCy 0 0 0 0 0 0 0 0
Suramin 7.2 7.8
MelCy and Suramin 6.0 7.8
This table shows the results of the mouse screen to identify the drug-resistance 
phenotypes in the metacyclic population of F301/45. Trypanosomes were 
identified at high levels in the double drug treated mouse, and the parasitaemia 
increased. However, no trypanosomes were observed in the mouse treated with 
melCy only. See legend for Table 4.5 for explanation
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CHAPTER 5
ANALYSIS OF CLONED PROGENY TO 
DETERMINE THE INHERITANCE OF 
DRUG-RESISTANCE
5.1 INTRODUCTION
The inheritance of a variety of phenotypic (isoenzyme) and genotypic 
(RFLP) markers has been investigated in a number of genetic crosses of T. 
brucei stocks (reviewed in Tait et al. 1993). Analysis of cloned progeny from 
these crosses have provided substantial evidence for the existence of a diploid 
Mendelian system of mating involving meiosis and recombination and 
segregation of alleles (Sternberg et al. 1989; Turner et al. 1990; Gibson et al.
1992). Karyotype analysis has also been used to investigate genetic exchange in 
T. brucei. The use of pulsed-field gel electrophoresis (PFGE) has allowed many 
of the details of the genome of T. brucei to be elucidated, and approximately 
80% of the chromosomes have been identified using different running conditions 
to separate chromosomes ranging in size from approximately 150kb to 5.7Mb 
(Van der Ploeg et al. 1989; Gottesdiener et al. 1990). The chromosomes have 
been grouped into three different categories, according to their size and their 
pattern of inheritance during genetic exchange. The mini-chromosomes (50- 
150kb), of which there are approximately one hundred (Van der Ploeg et al. 
1989), and the intermediate chromosomes (150kb-800kb) are not diploid and do 
not follow a Mendelian pattern of inheritance (Wells et al. 1987; Gibson 1989). 
However, most, if not all, the larger chromosomes (800kb to 5.7Mb) are 
thought to be diploid. Separation of these larger chromosomes, followed by 
probing of Southern blots with gene-specific probes, has shown that there are at 
least 14 large chromosomes, and that these chromosomes can be shown to 
belong to 7 homologous pairs (Gottesdiener et al. 1990). Analysis of the 
inheritance of the larger chromosomes has provided further evidence for them
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being homologous pairs. Co-transmission of two stocks of T. b. brucei (196 and 
J10) through tsetse flies produced cloned hybrid trypanosomes with karyotypes 
different to either parent (Gibson and Garside 1991). Novel karyotypes have 
also been observed in hybrid progeny from a genetic cross between 247, T. b. 
brucei, and 386, T. b. rhodesiense (Tait et al. 1993), and between 058, T. b. 
rhodesiense, and KP2, T. b. brucei, (Gibson and Whittington 1993). Southern 
blotting and hybridisation with gene-specific probes showed that the 
homologous chromosomes in the parents from these genetic crosses had 
segregated, recombined and were inherited by the hybrid clones in a manner 
generally consistent with a Mendelian system of genetic exchange in a diploid 
organism. Such measurements that have been made on bloodstream and insect 
stages have shown that parental and progeny clones of T. brucei possess similar 
DNA contents (Wells et al. 1987; Kooy et al. 1989; Gibson et al. 1992; Tait et 
al. 1993). Further evidence for a mating system involving meiosis either before 
or after nuclear fusion has come from nuclear DNA measurements (Sternberg 
and Tait 1989). However, a number of anomalous results, inconsistent with 
Mendelian inheritance in a diploid organism, have also been observed. The DNA 
contents of some hybrid progeny have been found to be higher than those of the 
parents (Jenni et al. 1986; Gibson et al. 1992), and this has been explained in 
some cases by aberrant genetic exchange events involving the fusion of diploid 
and haploid nuclei to produce triploid progeny (Gibson et al. 1992). 
Furthermore, chromosome size changes have been observed in some diploid 
chromosomes (Tait et al. 1993), although this may not necessarily be a product 
of mating (Gibson et al. 1991). Despite these anomalies, karyotype analysis of a 
number of genetic crosses to date upholds a mating system in which the mini 
and intermediate chromosomes do not segregate in a diploid Mendelian manner, 
whereas, in the main, the larger chromosomes (>800kb) belong to homologous 
pairs, segregate and are inherited in a diploid Mendelian system involving 
meiosis and karyogamy.
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The patterns of mating observed between different trypanosome stocks 
appear to indicate that there are no barriers to mating, or that mating is 
controlled by a mating type locus that is heterozygous in at least some stocks 
(Tait et al. 1993). Genetic exchange has been demonstrated between all 
pairwise combinations of three cloned stocks (i.e. 247 x 386, 247 x 927/4, and 
386 x 927/4) (Turner et al. 1990), and although there has been no evidence for 
genetic exchange occurring during the cyclical transmission of single 
trypanosome stocks through tsetse flies (Tait et al. 1989), self-fertilisation 
(selfing) has been shown to occur during the co-transmission of two stocks that 
have undergone genetic exchange (Tait et al. 1993). Whether selfing can 
actually occur during single stock transmissions but has not yet been observed, 
or actually requires the presence of a second stock, perhaps to induce meiosis, 
still remains to be clarified. Nevertheless, due to the non-obligatory nature of 
genetic exchange, cloned progeny from co-transmission experiments can be 
considered to belong to one of three categories: "parental", the product of 
asexual propagation through the fly; "hybrid", the product of genetic exchange 
between two different stocks; or "selfer", the product of genetic exchange 
between trypanosomes of the same stock.
Parental clones have all the properties, in terms of karyotype and 
genotypic and phenotypic markers of one or other of the parental stocks used in 
the co-transmission experiments, and appear to be, in essence, clones of the 
parent. Hybrid progeny inherit some of the properties of both parental stocks, 
and can be identified from the inheritance of markers that are homozygous but 
different in the parents, in which case the hybrid clones exhibit heterozygous 
patterns (Figure 5.1(a)). Selfers are the products of self-fertilisation, and 
although they may, by chance, inherit all the properties of the parental stock, 
some will show homozygous patterns for markers in which the parent is 
heterozygous (Figure 5.1(b)).
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5.1.1 Experimental Design
Hybrid formation has been demonstrated during the co-transmission of 
247 and 386 (Sternberg et al. 1989; Turner et al. 1990) and further analysis of 
the cloned progeny has shown that selfing also occurred with 247 (Tait et al.
1993). Since not all selfers can be identified from the limited number of markers 
of genetic exchange available, the drug-resistance phenotypes of the lines 
described previously (chapter 2) have been used as selectable markers in order 
to identify selfers that have inherited both drug-resistance phenotypes. A three- 
way co-transmission experiment was conducted, involving the two drug- 
resistant lines of 247 (247MelCyR and 247SurR), together with 386MelCyR. It 
was intended that a successful three-way co-transmission of these lines through 
tsetse flies would generate both hybrid trypanosomes and products of self­
fertilisation, as well as parental progeny. Hybrid trypanosomes would be 
generated from genetic exchange between 247MelCyR and 386MelCyR, or 
247SurR and 386MelCyR, whereas products of self-fertilisation would be 
generated from genetic exchange between 247MelCyR and 247SurR. 
Identification of trypanosomes expressing double drug-resistance to both melCy 
and suramin would indicate that mating had occurred during cyclical 
transmission, and analysis of the inheritance of isoenzymes and karyotype in the 
cloned progeny would indicate whether these double drug-resistant 
trypanosomes were hybrids or selfers. Analysis of the pattern of inheritance of 
the drug-resistance phenotypes would also provide information on the genetic 
basis of melCy-resistance and suramin-resistance in terms of the number of loci 
and alleles controlling drug-resistance, and indicate whether the inheritance of 
drug-resistance is dominant or recessive. Depending on this exact genetic nature 
of drug-resistance in parental lines, other drug-resistance phenotypes would be 
expected to be present in the products of mating, such as double drug-sensitive 
progeny, although the screening procedure used was not designed to identify
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these.
The design of this experiment was similar to that of previous co­
transmissions. Flies infected with trypanosomes were screened for the presence 
of mature infections. The drug-resistance phenotypes in the metacyclic 
populations were determined by allowing metacyclic producing flies to feed on 
mice to produce bloodstream trypanosomes which were subsequently 
transferred to 3 mice that were given melCy, suramin, and melCy plus suramin 
as described previously (4.2.5). This screen would identify trypanosomes 
expressing resistance to both melCy and suramin, and therefore the progeny that 
could potentially be detected using the drug screening assays employed were 
247SurR x 386MelCyR hybrids and 247SurR x 247MelCyR selfing products.
5.2 MATERIALS AND METHODS
5.2.1 Drugs
The two trypanocidal drugs melCy and suramin were used to screen for 
drug-resistant trypanosomes after the cyclical transmission of mixtures. MelCy 
and suramin were obtained and stored as described previously (2.2.1).
5.2.2 Trypanosome Stocks and Mice
Three trypanosome lines were used from established procyclic cultures 
These three lines (247MelCyR, 247SurR and 386MelCyR) have been described 
previously (chapters 2 and 3).
Adult female Balb/C mice (approximately 20g body weight) and adult 
female CFLP mice were used for screening the trypanosome populations after 
fly transmission.
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5.2.3 Infection of Tsetse Flies
A single co-transmission experiment was conducted. A batch (No. 
28400) of 101 teneral tsetse flies was infected with all three lines of procyclic 
trypanosomes in a ratio of 1:1:1 in a three-way mixed transmission experiment 
(247MelCyR x 247SurR x 386MelCyR). The flies were infected and given 
maintenance feeds as described in the previous chapter (4.2.3).
5.2.4 Identification of Double Drug-Resistant Trypanosomes
Flies harbouring mature infections were identified as described 
previously (4.2.5). The bloodstream trypanosomes from mice infected by flies 
harbouring metacyclic infections were screened for the presence of melCy- 
resistance, suramin-resistance and double drug-resistance to both melCy and 
suramin as described previously (4.2.5).
5.2.5 Generation of Cloned Trypanosomes
Cloned progeny were generated from two flies (F444 and F466) 
between 51 days and 63 days after the flies had been given the initial infective 
feed of 247MelCyR, 247SurR and 386MelCyR. A total of 23 clones were 
generated, some of which were isolated from drug-treated mice, and the 
remainder were isolated from unselected trypanosome populations. Bloodstream 
clones were isolated from infected tail blood suspended in approximately 100- 
200jil of guinea pig serum as described previously (2.2.3; McLintock 1990). A 
single metacyclic clone was isolated by allowing a metacyclic producing fly 
(F466/63) to feed directly from approximately 500|_il guinea pig serum in a 
shallow well heated to 37°C. This process resulted in the guinea pig serum 
containing some of the metacyclics from the fly's saliva. In order to increase the
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density of the trypanosomes, the guinea pig serum containing metacyclics was 
centrifuged at 3000g for 2 minutes and most of the supernatant was removed to 
leave approximately lOOpl volume of serum, in which the metacyclics were 
gently resuspended. Optical cloning of metacyclics was then carried out as for 
bloodstream trypanosomes as described previously (2.2.3).
5.2.6 Analysis of Isoenzymes
Isoenzyme analysis was conducted with the parental lines of 
trypanosomes and the cloned progeny from the co-transmission experiment. 
Four isoenzyme phenotypes were examined: three were analysed by starch gel 
electrophoresis (isocitrate dehydrogenase (ICD), alkaline phosphatase (AP), 
tyrosyl-tyrosyl-tyrosine peptidase (Tyr^)) and one was analysed by isoelectric 
focusing (malic enzyme B (MEB)). The buffers used to make the gels, the 
running conditions and the enzyme-specific stains used were as described 
previously (Tait et al. 1984). However, the procedure used to obtain 
trypanosome lysates was slightly different to that described previously. 
Trypanosomes were purified from infected blood by anion-exchange 
chromatography (Lanham and Godfrey 1970) and washed twice in PBSG (pH 
7.4). Approximately lOOpl (packed cell volume) of trypanosomes were stored in 
eppendorfs at -70®C. Before use, these trypanosome pellets were allowed to 
thaw on ice, after which they were vortexed with an approximately equal 
volume of Trypanosome Lysis Buffer (TLB: lOmM Tris-HCl, ImM EDTA, 2% 
(v/v) TRITON-X 100, 154pg/ml dithiothreitol, pH 7.5). A process of freeze- 
thawing was conducted twice to ensure the trypanosomes had lysed by freezing 
in liquid nitrogen, thawing on ice, and finally vortexing thoroughly, after which 
the lysates were centrifuged at 12000g for 10 minutes at 4°C. The resulting 
supernatants were used to soak inserts of Whatman 3MM paper (ICD, AP and 
Tyr3) or cellulose acetate (MEB) for 10-15 minutes, after which the inserts were
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applied to the gels in preparation for electrophoresis.
Analysis of the isoenzyme (ICD) phenotypes of unselected populations 
in procyclic culture (SDM-79 supplemented with 10% HIFCS) was also 
conducted in order to determine which trypanosome lines were present in the 
metacyclic populations. Bloodstream trypanosomes were obtained directly from 
mice infected by a fly and transformed to procyclic culture as described 
previously (3.2.3). Procyclic trypanosomes from established cultures were 
washed in PBSG, pH 7.4, and stored as pellets in eppendorfs at -70°C. 
Isoenzyme electrophoresis was conducted on these uncloned populations as 
described above for the cloned progeny. This analysis would not distinguish 
between 247MelCyR and 247SurR, nor would it identify the products of selfing 
between these two lines. However, it would be able to identify the presence of 
mixed infections of the 247-derived lines and 386MelCyR, as well as the 
products of genetic exchange (hybrids) between either of the two 247-derived 
lines and 386MelCyR.
5.2.7 Karyotype Analysis
Samples of DNA were prepared by lysing and deproteinising purified 
trypanosomes suspended in agarose blocks. Trypanosomes were purified by 
anion-exchange chromatography (Lanham and Godfrey 1970) after which they 
were washed and resuspended in PBSG, pH 7.4, to give a final trypanosome 
density of 1.5x109 trypanosomes/ml. A 1% (w/v) solution of Low Melting Point 
Agarose (LMA) (Difco) was prepared and cooled to 37°C whilst the 
trypanosome suspension was warmed to 37°C. Two volumes of LMA solution 
were mixed with 1 volume of trypanosome suspension to give a final 
trypanosome density of 5x108 trypanosomes/ml, which was pipetted into 
moulds and allowed to set for approximately 10 minutes at 4°C to create
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trypanosome-containing agarose blocks. The trypanosomes were lysed in situ by 
incubating the blocks in 5ml of 0.5M EDTA, pH 9.0, 1% (w/v) sodium lauryl 
sarcosine, 0.5mg/ml proteinase K for 20 minutes at room temperature followed 
by 48 hours at 50°C. Digested protein was removed by washing the blocks three 
times in 50mM EDTA, pH 8.0. Blocks were stored in 50mM EDTA, pH 8.0, at 
4°C.
The DNA blocks were inserted into a 1% (w/v) agarose gel made with 
l .lg  electrophoresis grade agarose (BRL) dissolved in 110ml of TB(0.1)E 
(0.09M Tris-borate, O.lmM EDTA, pH 8.0). Separation of chromosomes was 
conducted using an LKB Pulsaphor unit with a hexagonal electrode array with 
approximately 3 litres of TB(0.1)E as the running buffer. Two different running 
conditions were chosen, both using a voltage of 80V:
Condition Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6
A B A B A B A B A B A B
1 900 12 750 12 700 24 600 24 500 48
2 1200 24 1000 24 900 24 800 24 700 24 600 24
For each phase, column A shows the pulse time (seconds), while column B 
shows the duration of the phase (hours).
Gels were stained with ethidium bromide (0.5pg/ml in 0.5xTBE) for 
approximately 1 hour followed by destaining for approximately 1 hour in 
dddH20.
5.2.8 In  Vitro Assessment of Drug-Resistance of Cloned Progeny
A number of the cloned progeny were analysed for the level of their
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resistance to melCy and suramin. The method used was similar to that 
previously described (3.2.4). Briefly, trypanosomes were grown in 
immunosuppressed mice and transferred to a short-term bloodstream culture 
medium, in which they were exposed to a range of drug concentrations in order 
to assess the effective concentration (EC50 value) that inhibited growth over 24 
hours by 50% (3.3.2).
5.3 RESULTS
5.3.1 Drug-Resistance Phenotypes of Metacyclic Populations
A total of 101 tsetse flies were infected in the three-way co-transmission 
experiment. Salivary gland infections of metacyclic trypanosomes were 
identified in 18 flies as defined by phase-contrast microscopy of dried saliva 
probes (2.2.4). Seven of these flies survived long enough to be fed on 
anaesthetised mice to produce bloodstream infections. Bloodstream infections 
were produced on a total of 30 separate occasions, and these were screened in 
the mouse assay (5.2.5) to determine the drug-resistance phenotypes of the 
metacyclic populations (Table 5.1). Unlike previous co-transmission 
experiments (chapter 4), the number of times each of the two drug-resistance 
phenotypes appeared was approximately equal, with melCy-resistance and 
suramin-resistance being observed in 24 and 21 samples of the metacyclic 
populations respectively. In 10 of the uncloned samples in which melCy- 
resistance was observed, the isoenzyme (ICD) phenotypes were analysed on 
starch gel electrophoresis (5.2.7). Table 5.1 shows the results of the isoenzyme 
analysis for some of the uncloned samples. On 10 occasions that melCy- 
resistance was observed, only the ICD phenotype of the 247-derived lines was 
observed, indicating that melCy-resistance observed in the mouse screen 
resulted from the presence of 247MelCyR and not 386MelCyR. The previous 
co-transmission experiments of 247SurR and 386MelCyR produced metacyclic
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populations that were predominantly suramin-resistant resulting from the 247- 
derived line (chapter 4). However, it would appear from both the isoenzyme 
and drug screen data (Table 5.1) that the use of the two different drug-resistant 
lines of 247 (247MelCyR and 247SurR) in the present co-transmission 
experiment produced mature infections expressing melCy-resistance at an 
approximately equal frequency to suramin-resistance.
Trypanosomes growing in the presence of both melCy and suramin were 
identified from the mouse screen in 10 samples of metacyclic populations (Table 
5.1). However, on 7 of these occasions, a low level of infection (106 
trypanosomes/ml or lower) was seen only one day after drug-treatment, and no 
patent infections were observed thereafter. Evidence of trypanosomes increasing 
in number after exposure to both drugs was seen on the other 3 occasions, 2 of 
which occurred with infections derived from the same fly (F466/51 and /59). Fly 
28435 produced double drug-resistant trypanosomes on day 51 post infection, 
with trypanosomes appearing in a mouse 6 days after treatment with both melCy 
and suramin, following a period of 5 days of sub-patent parasitaemia. Similarly 
with F466/51, a period of sub-patency preceded the emergence of a patent 
infection in a double drug treated mouse. In the case of F466/59, one day after 
double drug treatment parasites were present at a density of 5x105 
trypanosomes/ml, after which a period of sub-patency lasting 8 days elapsed, 
followed by a period of rapidly rising parasitaemia up to 3.2xl07 
trypanosomes/ml.
5.3.2 Generation of Unselected and Selected Cloned Progeny
Fly 28444
Figure 5.2 illustrates the generation of a total of 6 clones derived from 
fly 28444. Two of these clones (444/62 bell and bcl2) were isolated from a
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mouse infected by the fly on day 62 post infection, and were not exposed to 
drug prior to cloning (i.e. isolated from unselected populations). Clones 
444/62SR bell and bcl2 were isolated from a suramin-resistant population, 
whereas clones 444/54MRSR bell and bcl2 were isolated from a mouse that was 
initially treated with suramin, and the relapse infection was subsequently treated 
with melCy.
Fly 28466
A total of 17 clones were derived from fly 28466, one of which was a 
metacyclic clone, and the remainder were bloodstream clones (Figure 5.3). Ten 
of these clones were isolated from unselected populations in mice (466/59 bcll- 
8, and 466/61 bell and bcl2), and 6 were isolated from mice treated with both 
melCy and suramin. Bloodstream clones 466/51MRSR bell and bcl2 were taken 
from a trypanosome population that had been selected twice with both drugs at 
doses of 5mg/Kg. The other 4 clones (466/61MRSR bell-4) were isolated from 
drug selected populations that had been exposed to melCy at a dose of 
4.8mg/Kg and suramin at a dose of 24mg/Kg. These drug treatments 
represented doses that were 16-fold higher than the minimum curative doses of 
melCy and suramin in the unselected drug-sensitive line, 247.
5.3.3 Inheritance of Isoenzyme Phenotype in Cloned Progeny
The inheritance of 4 isoenzymes was analysed in the cloned progeny. 
Examples of the analyses conducted for each isoenzyme are shown in Figures 
5.4, 5.5, 5.6 and 5.7 for ICD, AP, MEB and Tyr3 respectively. In each figure, a 
schematic diagram of the stained gel has been included, showing the isoenzyme 
bands and their interpretation in terms of the allelic variants present in the 
cloned progeny.
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The isoenzyme data for all 4 phenotypes are summarised in Table 5.2, 
The data are expressed using the established method of identifying genotypic 
variants as numbers to represent the variant alleles present. Of the 23 clones 
isolated, 20 were analysed, 17 of which were identified, from the ICD and AP 
phenotypes, as possessing the phenotypic characteristics of 247 (genotypic 
variant 1). The other clone (466/59 bcl5) possessed the 386MelCyR ICD 
phenotype (genotypic variant 2) and was presumed to be the parental 
386MelCyR line. Hybrid trypanosomes would have been identified at the ICD 
and AP loci, since both isoenzymes are homozygous but different in the parents, 
and hybrids would have been heterozygotes, and would have expressed multiple 
banding patterns (genotypic variant 1-2) (see Figure 5.1(a)). No hybrids were 
detected. Of the 17 clones identified with a 247 parental phenotype from their 
ICD and AP isoenzymes, 11 were analysed at the Tyr3 locus. Products of selfing 
between 247MelCyR and 247SurR would have a 50% probability of being 
homozygous (genotypic variants either 2 or 4), assuming random recombination 
of alleles, at a locus which was heterozygous in the parent, such as Tyr3. 
Unfortunately, analysis of the Tyr3 phenotype in all 11 clones showed that they 
all possessed the parental, heterozygous phenotype (genotypic variant 2-4). 
Therefore, there was no evidence for selfing having taken place based on 
isoenzyme analysis.
5.3.4 Inheritance of Karyotype in Cloned Progeny
In order to interpret the pulsed field gels, it is necessary to deal briefly 
with some of the details of the genome of the two cloned lines, 247 and 386, 
from which the drug-resistant lines were generated. A number of the large 
chromosomes have been identified, ranging in size from approximately l-3Mb 
(Tait et al. 1993; Tait, Buchanan, Hide and Turner, unpublished data). Probing 
Southern blots with gene-specific probes has shown that these chromosomes
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belong to 5 homologous pairs. Figure 5.8 is a composite of a number of 
separate experiments for these markers, showing the different bands that have 
been resolved and identified as belonging to the homologous chromosomes (A- 
E).
It is clear from Figure 5.8 that the chromosomes within a homologous 
pair are not always the same size as each other. For example, whereas 
chromosome A, in the 386-derived lines, consists of two similar sized 
homologues that cannot be resolved by PFGE (band 1), the comparable 
chromosome A in the 247-derived lines consists of 2 different sized homologues 
that are resolved as two bands (bands 1 and 2) (Figure 5.8). Assuming a system 
of mating involving meiosis and recombination, products of genetic exchange 
between one of the 247-derived lines and 386MelCyR could be identified from 
the karyotype of cloned progeny that would possess a chromosome A consisting 
of one homologue the same size as band 1 of 386MelCyR and the other 
homologue the same size as one or the other of bands 1 or 2 of the 247-derived 
line. Similarly, self-fertilisation between 247MelCyR and 247SurR would 
produce some cloned progeny with an identical karyotype to the parent, and 
some cloned progeny that have inherited two homologues of the same size. This 
would result in the loss of one band, and the doubling of intensity (with 
ethidium-staining) of the other band, thereby identifying the products of selfing 
(Tait et al. 1993).
The two running conditions that were employed in PFGE experiments 
were able to separate the chromosome bands to different extents. Condition 1 
was only able to separate chromosomes smaller than approximately 2Mb in size, 
with the remainder of the large chromosomes remaining unresolved either in the 
compression zone or in the application slot. This can be seen clearly in Figure 
5.9. The schematic diagram (Figure 5.9(a)) focuses on 2 lanes (lanes 5 and 7),
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which correspond to 386 and 247 respectively. It can be seen that only the 
lower size bands were resolved (bands 1-4 of 247, and bands 1-3 o f 386). 
However, condition 2 was able to resolve the higher molecular weight bands, 
although this was at the expense of a decrease in the resolution of the smaller 
bands. Figure 5.10 (a) shows the separation of all seven bands of 247 (lane 13), 
although bands 6 and 7 were not easily distinguishable.
The karyotypes of 247 and the two drug-resistant lines, 247MelCyR and 
247SurR, were identical with respect to the large chromosomes (Figures 5.9(b) 
and 5.10(b)). However, whereas 386 and 386SurR possessed identical 
karyotypes, 386MelCyR had a noticeably smaller chromosome at band no. 2 
compared to 386. This reduction in size of chromosome band 2 could be 
crudely estimated to be 200Kb, from approximately 1.5Mb in 386 to 
approximately 1.3Mb in 386MelCyR (Figure 5.9(c)).
Figure 5.10(c) shows examples of the karyotype analyses conducted on 
the cloned progeny using the running condition, 2. Taking into account the 
differences in sample concentration (with lower loadings causing faster 
migration), all these progeny clones possessed the 247 parental karyotype. 
Figure 5.11 shows a different set of clones analysed using condition 1. Although 
the majority of cloned progeny were shown to possess the 247 parental 
karyotype (Figure 5.11(a)), one particular clone (466/59 bcl5) possessed the 
distinct karyotype of 386MelCyR (lane 7, Figure 5.11(b)). Comparison between 
this sample and that of 386SurR (lane 5) clearly shows the smaller chromosome 
band 2 of 466/59 bcl5, indicating that this clone possessed the same karyotype 
as 386MelCyR.
The results of the karyotype analysis are summarised in Table 5.3. 
Eighteen progeny clones were found to possess the 247 parental karyotype,
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with only 466/59 bcl5 possessing the 386melCyR karyotype. Since condition 1 
only separated the first 4 large chromosome bands in 247, this meant that the 
inheritance of only 2 homologous pairs (A and B) could be investigated. The 
use of condition 2 allowed the inheritance of a further homologous pair, E 
(bands 6 and 7), to be examined. With either condition, the 2 homologous pairs, 
C and D, could not be resolved (bands 5a and 5b). Consequently, there was a 
limited number of markers available, and unfortunately the karyotype analysis 
did not identify the products of selfing, even with the clones isolated from a 
double drug-resistant population.
5.3.5 Inheritance of Drug-Resistance in Cloned Progeny
Ten of the cloned progeny were analysed for their inheritance of the 
melCy-resistance and suramin-resistance phenotypes (Table 5.4). The results are 
expressed as EC50 values, and converted to the degrees of increase in drug- 
resistance compared to the drug-sensitive parents from which they were 
derived. Nine of the 10 progeny clones analysed possessed a 247 parental 
karyotype and isoenzyme phenotype. These clones all expressed melCy- 
resistance, with levels of resistance being between 27-fold and 190-fold greater 
than the unselected 247 line, compared to an 87-fold increase in melCy- 
resistance in the 247MelCyR line. Most of the levels of melCy-resistance in the 
cloned progeny were approximately half the levels in the 247MelCyR line. The 
one exception to this was seen in clone 466/59 bcl8, in which the EC50 value of 
6.0|iM was over twice that of the 247MelCyR line (EC50 value of 2.7(iM).
Suramin-resistance was not expressed in the clones derived from 
unselected populations, with EC50 values ranging between 0.38jiM and 1.4pM, 
compared to 0.97pM in the unselected 247 line. However, there was a 
noticeable amount of suramin-resistance in the 4 clones isolated from a double
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drug-resistant population (466/61SRMR bell-4). Levels of suramin-resistance 
were found to lie between 1.6-fold and 6.9-fold greater than the level of 
suramin-resistance in the unselected 247 line. However, this was in comparison 
to a 20-fold increase in suramin-resistance found in 247SurR and consequently, 
these 4 double drug-resistant clones appeared to express only partial resistance 
to suramin.
5.4 DISCUSSION
Examination of the drug-resistance phenotypes present in the mature 
infections in the flies' salivary glands showed that melCy-resistance and suramin- 
resistance were identified at approximately equal frequencies. Furthermore, 
these uncloned populations were examined for their ICD phenotypes, which can 
distinguish between infections consisting of only 247, only 386, mixed and 
hybrid infections. All the uncloned populations from the flies' salivary glands 
expressed the 247 parental ICD phenotype. This, therefore, indicates that the 
occurrence of melCy-resistance in the mature populations was largely a result of 
247MelCyR and not 386MelCyR Previous co-transmission experiments with 
247SurR and 386MelCyR produced mature infections that contained a majority 
of suramin-resistant trypanosomes, presumably because the 247SurR line 
transmitted more successfully than 386MelCyR. The use of two different 247- 
derived drug-resistant lines in the present study, produced more balanced 
mature infections in terms of the drug-resistance phenotypes present, possibly 
since it would be predicted that both the 247-derived lines would be easier to 
transmit than the 386-derived lines.
The isoenzyme phenotypes and karyotypes of a total of 21 progeny 
clones were analysed, with all but one (466/59 bcl5) being identified as identical 
to the 247-parental clones. Assuming there was no selection pressure for the
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products of selfing between 247MelCyR and 247SurR, it should be possible to 
identify selfers at a number of loci. The Tyr3 phenotype was heterozygous in the 
247-derived lines, and consequently there was a 50% probability of the product 
of selfing being homozygous at this locus (Figure 5.1(b)). Eleven progeny 
clones were analysed at the Tyr3 locus, none of which expressed a homozygous 
phenotype, although it was possible that these clones were not all different to 
each other, since they were generated on only 5 different occasions, and may 
therefore only represent 5 different clones. Furthermore, only 2 sets of clones 
were generated from double drug-resistant populations. Therefore, assuming 
these selected populations consisted of selfers, it was possible that only 2 
different "selfer" clones were being analysed, each with a 50% chance of being 
homozygous at the Tyr3 locus. Analysis of the karyotype of the cloned progeny 
was equally unsuccessful in identifying the products of selfing. Three sets of 
homologous pairs have been resolved (chromosomes A, B and E) in the 247 
derived lines (Tait, Buchanan, Hide and Turner, unpublished data, Figure 5.8). 
The differences in size of the homologues means that novel karyotypes might 
result from selfing between 247MelCyR and 247SurR (Tait et al. 1993; 5.3.4) 
Double drug-resistant clones were isolated from three different drug selected 
populations, and on the pessimistic assumption that the clones generated on 
each of these occasions were the same, it therefore follows that only 3 different 
selfer clones expressing resistance to both melCy and suramin were analysed. 
However, separation of homologues would be expected to be identified in 50% 
of cases for each of the chromosome pairs. Two homologous pairs 
(chromosomes A and B) were analysed in the clones generated from 
466/59Mr Sr , three homologous pairs (chromosomes A, B and C) were 
analysed in the clones generated from 466/61MRSR, and the same three 
homologous pairs were also analysed in the clones generated from 
444/54Mr Sr . Consequently, 3 pairs of homologous chromosomes were 
analysed, together with 2 alleles at the Tyr3 locus. This is essentially an analysis
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of 4 loci for which 247 is heterozygous, and segregation of alleles was not 
observed at any of these loci..
Table 5.5 summarises all the isoenzyme, karyotype and drug screening 
analysis for the cloned progeny. Evidence of selfing having occurred was seen 
only from the drug-resistance phenotypes of the cloned progeny assessed in 
vitro, and the uncloned populations assessed in vivo. Four clones, 466/61MRSR 
bell-4, were isolated from a population of bloodstream trypanosomes that had 
been treated with melCy and suramin at doses that were 16-fold higher than the 
minimum curative doses for the unselected 247 line. The EC50 values for these 
clones indicated that they expressed resistance to both melCy and suramin. 
MelCy-resistance varied between approximately 50% and 90% of that found in 
the parental 247MelCyR line. Suramin-resistance, however, was expressed at 
lower levels, with EC50 values approximately 10-30% of those for the suramin- 
resistant parental line, 247SurR. Of the 6 other progeny clones that were 
assessed, all 5 clones that were identified, from isoenzyme and karyotype 
analysis, as being 247-derived expressed melCy-resistance, and appeared not to 
express suramin-resistance. This may indicate that they were in fact parental 
clones of 247MelCyR, although the possibility that they were selfers can not be 
ruled out. One clone in particular, 466/59 bcl8, expressed a high level of melCy- 
resistance, with an EC50 value of 6.0pM, over double that of the 247MelCyR 
line. Although the genetic nature of melCy-resistance is not known, it may be 
predicted that some of the products of selfing between two 247MelCyR 
trypanosomes may express this high level of resistance to melCy. For example, 
if melCy-resistance is determined by a single dominant mutation in the parental 
247MelCyR line, then one of the products of selfing would be a double melCy- 
resistant phenotype.
The appearance of a large deletion in one chromosome (band 2) of the
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386MelCyR line is particularly interesting. Chromosome size alterations have 
been observed previously and were considered as products of mitotic division 
(Gibson and Garside 1991). However, a recent study has demonstrated the 
stability of the 386 karyotype after multiple passages in mice, multiple passages 
in culture and cyclical transmission through tsetse flies (Tait et al. 1994). 
Although the possibility that the reduction in size may be due to mitosis cannot 
be ruled out, it is tempting to consider the deletion as a direct consequence of 
melCy-resistance. If this were the case, a genetic cross between 386MelCyR and 
a melCy-sensitive line would generate progeny expressing melCy-resistance only 
if they also inherited the altered chromosome, thereby providing a powerful 
handle for direct studies into the genetic basis of melCy-resistance.
The relatively low level of expression of suramin-resistance in the cloned 
progeny could be explained in a number of ways. The possibility that suramin- 
resistance was generated during the initial in vivo screening in mice cannot be 
ruled out. Suramin treatment of 5mg/Kg represents only a 3-fold greater dose 
than the minimum curative dose for 247MelCyR (chapter 2). Indeed, the initial 
stages of selection of the 247SurR line were conducted at a dose of lmg/Kg 
followed by a dose of 5mg/Kg (Figure 2.2(b)). It is feasible, therefore, that the 
presence of double drug-resistant trypanosomes in the mouse screen could have 
resulted from a selection pressure of suramin at 5mg/Kg on parental infections 
of 247MelCyR only. However, the four clones (466/61MRSR bell-4) were 
isolated from a mouse infected with the unselected trypanosome population, 
466/61, and treated with melCy and suramin at drug doses 16-fold greater than 
the minimum curative drug doses, amounting to suramin at a dose of 24mg/Kg. 
In light of the selection history of 247SurR (Figure 2.2(b)) it would be 
extremely unlikely that a suramin-resistant mutant of 247MelCyR would have 
increased from being sensitive to a minimum curative dose of 1.5mg/Kg up to 
greater than 24mg/Kg during what is essentially a single selection step.
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Therefore, although the use of suramin at a dose of 5mg/Kg in the drug screen 
may be questionable, the four clones (466/61MRSR bell-4) are likely to be the 
genuine products of genetic exchange between 247MelCyR and 247SurR The 
low levels of suramin-resistance found in the in vitro drug screen, compared to 
the consistently higher relative levels of melCy-resistance, may indicate the 
existence of multiple alleles controlling suramin-resistance. The original 
selection procedure was certainly more arduous for suramin-resistance 
compared to melCy-resistance, and this may be an indication of a more 
incremental increase in suramin-resistance involving multiple mutations. Cloned 
progeny resulting from genetic exchange would therefore not necessarily be 
expected to inherit all the alleles conferring suramin-resistance, and this would 
result in a range of levels of suramin-resistance, lower than the parental 247SurR 
line, which possesses all the mutant alleles.
In conclusion, the evidence from the in vitro assays and the in vivo 
screens suggests that double drug-resistant trypanosomes were generated, 
presumably from mating between melCy-resistant and suramin-resistant lines. 
Furthermore, the ICD phenotypes of the uncloned populations, together with 
the isoenzyme phenotypes and karyotypes of the cloned progeny indicate that 
the double drug-resistant trypanosomes were produced from mating between 
247MelCyR and 247SurR, rather than 386MelCyR and 247SurR. Unfortunately, 
the other markers of genetic exchange (isoenzymes and karyotype), did not 
identify any products of selfing, although the relatively limited number of 
markers available does not prove that selfing did not occur.
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Figure 5.1
Identification of Products of Genetic Exchange by Isoenzyme Analysis
(a) Hybrids
A
Origin
Phenotypes
Genotypes
Parent 1 Hybrid Parent 2
(b) Selfers
+
A
Origin
Phenotypes
€ Genotypes
Parent Selfer 1 Selfer 2
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Figure 5.1
Identification of Products of Genetic Exchange by Isoenzyme Analysis
(a) Hybrids
Hybrid trypanosomes can be identified by the isoenzyme phenotype in which the 
parents are homozygous but different. Hybrids from genetic exchange between 
these parents will be heterozygous, which, for a dimeric enzyme such as 
isocitrate dehydrogenase as illustrated here, produces a triple-banded pattern.
(b) Selfers
The process of selfing in a parental line in which a given marker is 
heterozygous, would be expected to produce some progeny that are 
homozygous (as shown) and others that remain heterozygous (not shown).
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Figure 5.4
Analysis of Isocitrate Dehydrogenase Phenotype in Cloned Progeny
+
A
Origin
Genotypic
Variants
Clones
This figure shows an example of the results of analysing the ICD 
phenotype in the two unselected lines (386 (lane 1) and 247 (lane 2)) 
and three progeny clones (466/59 bcl2 (lane 3), 466/59 bcl4 (lane 4) and 
466/59 bcl7 (lane 5)). A schematic interpretation of the gel is shown 
beneath the photograph, indicating the genotypic variants in each cloned 
line.
386 247 466/59 466/59 466/59 bc!2 bcl4 bcl7
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Figure 5.5
Analysis of Alkaline Phosphatase Phenotype in Cloned Progeny
Origin
Genotypic 2
Variants
Clones 386 247
(not shown)
1 1 1
466/59 466/59 466/59
bcl2 bcl4 bcl7
This figure shows an example of the results of analysing the AP 
phenotype in the two unselected lines (386 (lane 1) and 247 (lane 2)) 
and three progeny clones (466/59 bcl2 (lane 3), 466/59 bcl4 (lane 4) and 
466/59 bcl7 (lane 5)). A schematic interpretation of the gel is shown 
beneath the photograph, indicating the genotypic variants in each cloned 
line. The photograph does not show the 386 sample, although it is 
included in the schematic diagram to show the difference between the 
parental lines.
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Figure 5.6
Analysis of Malic Enzyme B Phenotype in Cloned Progeny
+
A
Origin
Genotypic 2-3 3 3 3 3
Variants
r ln „ .  nAn 466/51 466/51 444/54Clones 386 247 mRsR MRgR m rs r
bell bcl2 bell
This figure shows an example of the results of analysing the MEB 
phenotype in the two unselected lines (386 (lane 1) and 247 (lane 2)) 
and three progeny clones (466/51MRSR bell (lane 3), 466/51MRSR 
bcl2(lane 4) and 444/54MRSR bell (lane 5)). A schematic interpretation 
of the gel is shown beneath the photograph, indicating the genotypic 
variants in each cloned line.
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Figure 5.7
Analysis of Tyrosyl-Tyrosyl-Tyrosine Peptidase Phenotype in Cloned Progeny
+
A
Origin
Genotypic
Variants
Clones
This figure shows an example of the results of analysing the Tyr3 
phenotype in the two unselected lines (386 (lane 1) and 247 (lane 2)) 
and four progeny clones (466/51MRSR bell (lane 3), 466/51MRSR 
bcl2(lane 4), 444/62 bell (lane 5) and 444/54MRSR bell (lane 6)). A 
schematic interpretation of the gel is shown beneath the photograph, 
indicating the genotypic variants in each cloned line.
2-4 2-4 2-4 2-4 2-4 2-4
386 247 466/51 466/51 444/62 444/54MRSR MRSR bell MrSr
bell bcl2 bell
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Figure 5.8
Separation of Large Chromosomes of 247 and 386 by PFGE
Slot
3.0Mb
247
Compression
Zone
386
Compression
Zone
c I
E 
D
2.2Mb C & D
5b
5a
B
■ // / / / / / / / / ,
1.5Mb
1.125Mb
B
■ ' / / / / / / / / / /
1 A IM M I
A schematic diagram of the separation and identification of some of the 
large chromosomes of the two unselected lines, 247 and 386, from which all 
the drug-resistant lines were generated. It is a composite illustration taken 
from results of ethidium stained gels and gene-specific probing of Southern 
blots (Tait, Buchanan, Hide and Turner, unpublished data). The letters 
indicate bands in which homologues have been identified. The numbers of 
the resolved bands that are referred to in the text are consistent with the 
scheme shown above. The different patterns of shading indicate which 
chromosomes are hybridised with specific single copy or closely linked 
multiple copy DNA probes.
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Figure 5.9
Karyotype Analysis of Parental and Progeny Clones
386 Bands 1 2 3 4 5 6 7 8 247 Bands
Band 4
Band 3 
Band 2
Band 1
Karyotype analysis of 466/59 bcl5 (lane 2), 386MelCyR (lane 3), 386SurR 
(lane 4), 386 (lane 5), 247SurR (lane 6) and 247 (lane 7) using running 
condition 1 (see text) to separate chromosomes of approximately l-2Mb in 
size. Three diagrams of this ethidium stained gel are given for ease of 
comparison of different tracks. The band numbers refer to the resolved 
bands with reference to the two unselected parental lines, 247 and 386 (see 
Figure 5.8).
Band 3 
Band 2
Band 1
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Figure 5.9
(a) Karyotype Analysis of 247 and 386
1 2 3 4 5 6 7 8
_  _  ----- ---  _ Application Slot
( ] i—i i—i i (=□ mm Compression Zone
The separation of the large chromosomes below 2Mb in size are shown in bold 
for 247 (lane 7) and 386 (lane 5). Only the first 4 chromosome bands of 247 and 
the first 3 bands of 386 can be resolved using running condition 1. Chromosomes 
larger than 2Mb remain unresolved in the compression zone.
(b) Karyotype Analysis of 247 and 247SurR
1 2 3 4 5 6 7 8
--------------------- Application Slot
c=] c i c=j m mm warn Compression Zone
The karyotypes of 247 (lane 7) and 247SurR (lane 6) for the first 4 large 
chromosomes are shown in bold. The suramin-resistant line can be seen to have 
an identical karyotype to the unselected line, 247, from which it was generated.
(c) Karyotype Analysis of 386 and 386MelCyR
1 2 3 4 5 6 7 8
-  — — — Application Slot
□  ■■ tn bb cm du Compression Zone
=3 — =  —
The karyotypes of 386 (lane 5) and 386MelCyR (lane 3) for the first 3 large 
chromosomes are shown in bold. It is clear that chromosome 2 in the melCy- 
resistant line was smaller than that in the unselected line, 386.
Figure 5.10
Karyotype Analysis of Parental and Progeny Clones
1 2 3 4 5 6 7 8 9 10 11 12 13 14 247 Bands
^  Band 7 
Band 6
Band 5b 
Band 5a
^  Band 4
Band 3 
Band 2
Band 1
Karyotype analysis of 247MelCyR (lane 1), 444/62 bcl2 (lane 3), 444/ 62 
bell (lane4), 444/54MRSR bcl2 (lane 5), 444/54MRSR bell (lane 6), 466/63 
mcll (lane 7), 466/61 bcl2 (lane 8), 466/59 bcl7 (lane 9), 466/59 bcl4 (lane 
10), 466/59 bcl3 (lane 11), 466/59 bcl2 (lane 12) and 247 (lane 13) using 
running condition 2 (see text) to separate chromosomes of approximately 1 - 
3Mb in size. Three diagrams of this ethidium stained gel are given for ease 
of comparison of different tracks. The band numbers refer to the resolved 
bands with reference to the unselected parental line, 247 (see Figure 5.8).
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Figure 5.10
(a) Karyotype Analysis of 247
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Application Slot 
Compression Zone
The separation of the large chromosomes of 247 (lane 13) up to 3Mb in size are 
shown in bold. A total of 8 chromosome bands can be resolved using running 
condition 2, although this is at the expense of compressing the lower molecular 
weight bands 1-4.
(b) Karyotype Analysis of 247 and 247MelCyR
Application Slot 
Compression Zone
1 2 3 4 5 6 7 8 9 10 11 12 13 14
The karyotypes of 247 (lane 13) and 247MelCyR (lane 1) are shown in bold. The 
melCy-resistant line can be seen to have an identical karyotype to the unselected 
line, 247, from which it was generated.
(c) Karyotype Analysis of Cloned Progeny
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Application Slot 
Compression Zone
The karyotypes of 247 (lane 13) and a number of cloned progeny (lanes 3-12) are 
shown in bold. All the cloned progeny can be seen to have an identical karyotype 
to 247, and there was no evidence of selfing having occured. The lane numbers 
refer to the different clones as shown opposite. 1_,
Figure 5.11
Karyotype Analysis of Parental and Progeny Clones
386 Bands
Karyotype analysis of 247SurR (lane 2), 444/54M RSR bcl2 (lane 3), 
444/54MRSR bell (lane 4), 386SurR (lane 5), 466/59 bcl7 (lane 6), 466/59 
bcl5 (lane 7), 466/59 bcl4 (lane 8), 466/59 bcl2 (lane 9), 466/62SR bell (lane 
10), 444/62 bcl2 (lane 11), 466/62 bell (lane 12) and 247 (lane 13) using 
running condition 1 (see text) to separate chromosomes of approximately 1- 
2Mb in size. Two diagrams of this ethidium stained gel are given for ease of 
comparison of different tracks. The band numbers refer to the resolved 
bands with reference to the unselected parental lines, 247 and 386 (see 
Figure 5.8).
247 Bands
Facing 153
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Figure 5.11
(a) Karyotype Analysis of Cloned Progeny
Application Slot 
Compression Zone
The karyotypes of 247 (lane 13) and 8 cloned progeny (lanes 2,3,6, and 8-12) are 
shown in bold. All these cloned progeny can be seen to have an identical 
karyotype to 247, and there was no evidence of selfing having occured. The lane 
numbers refer to the different clones as shown opposite.
(b) Karyotype Analysis of Clone 466/59 bc!5
Application Slot 
Compression Zone
The karyotypes of 386SurR (lane 5) and 466/59 bcl5 (lane 7) are shown in bold. 
The progeny clone 466/59 bcl5 can be seen to have the distinct karyotype of the 
melCy-resistant line, 386MelCyR (see Figure 5.9(c)).
1 2 3 4 5 6 7 8 9 10 11 12 13 14
1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Table 5.2
Isoenzyme Analysis of Trypanosome Clones
Trypanosome Clone ICD AP MEg Tyr3
247 1 1 3 2-4
386 2 2 2-3 2-4
247MR 1
386MR 2
247SR 1
386SR 2
466/51MRSR bcl 1 1 3 2-4
466/51MRSR bcl 2 1 3 2-4
466/59 bcl 1
466/59 bcl 2 1 1 3 2-4
466/59 bcl 3 1
466/59 bcl 4 1 1 3 2-4
466/59 bcl 5 2
466/59 bcl 6 1 1 3 2-4
466/59 bcl 7 1 1 3 2-4
466/59 bcl 8 1
466/61 bcl 1 1
466/61 bcl 2 1 1 3 2-4
466/61MRSR bcl 1 1
466/61MRSR bcl 2
466/61MRSR bcl 3
466/61MRSR bcl 4
466/63 mcl 1
444/54MrSr bcl 1 1 1 3 2-4
444/54MRSR bcl 2 1 1 3 2-4
444/62 bcl 1 1 1 3 2-4
444/62 bcl 2 1 1 3 2-4
444/62SR bcl 1 1
444/62Sr bcl 2
This table shows the isoenzyme phenotypes of each trypanosome clone. The 
numbers represent the genotypic variants, single numbers corresponding to 
homozygotes, and double numbers corresponding to heterozygotes. Clone 
466/59 bcl 5 was identified as possessing the 386-type phenotype, and was the 
only clone to be identified that was not expressing a 247-type phenotype.
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Table 5.3
Karyotype Analysis of Trypanosome Clones
Trypanosome Clone Karyotype
247 247
386 386
247MR 247
386MR 386M*
247SR 247
386SR 386
466/51MRSR bcl 1 247“
466/51MRSR bcl 2 247a
466/59 bcl 1 247
466/59 bcl 2 247
466/59 bcl 3 247“
466/59 bcl 4 247“
466/59 bcl 5 386MR
466/59 bcl 6 247“
466/59 bcl 7 247
466/59 bcl 8 247“
466/61 bcl 1 ND
466/61 bcl 2 ND
466/61MRSR b ell 247
466/61MrSr bcl 2 ND
466/61MrSr bcl 3 247
466/61MRSR bcl 4 247
466/63 mcl 1 247
444/54MrSr bcl 1 247“
444/54MRSR bcl 2 247
444/62 bcl 1 247“
444/62 bcl 2 247
444/62Sr bcl 1 247“
444/62SR bcl 2 ND
The karyotype of each trypanosome clone was determined by PFGE. Nineteen 
cloned progeny were analysed, 18 of which were found to possess the same 
karyotype as the 247 parental line (shown as 247). One clone possessed the 
distinct karyotype of the melCy-resistant line of 386 (shown as 386MelCyR).
a Only chromosomes below approximately 2.0Mb in size were 
analysed (i.e. chromosomes A and B).
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Table 5.4
Inheritance of Drug-Resistance Phenotypes in Trypanosome Clones
MelCy EC50
(mM)
Suramin ECS0 
(mM)
Resistance
Phenotype*
247 0.031 0.97 Mxl Sxl
386 0.046 0.44 Mxl Sxl
247MR 2.7 2.2 Mx87 Sx2.3
247SR 0.038 19 Mxl.2 Sx20
3861^ 1.1 2.2 Mx24 Sx5
386SR 0.039 63 Mx0.85 Sxl40
466/59 bcl 1 2.2 1.4 Mx71 Sxl.4
466/59 bcl 2 0.84 0.38 Mx27 Sx0.39
466/59 bcl 3 1.2 0.98 Mx39 Sxl.O
466/59 bcl 5 2.2 0.98 Mx48* Sx2.2*
466/59 bcl 8 6.0 0.70 Mxl90 Sx0.72
466/61SRMR bcl 1 2.4 1.6 Mx77 Sxl.6
4 6 6 /6 1 8 ^  bcl 2 1.5 5.5 Mx48 Sx5.7
466/61SRMR bcl 3 1.5 4.1 Mx48 Sx4.2
466/61SRMR bcl 4 1.8 6.7 Mx58 Sx6.9
466/63 mcl 1 2.0 0.45 Mx65 Sx0.46
The levels of melCy-resistance and suramin-resistance are shown as EC50 values 
(pM), as determined in short-term bloodstream cultures.
a The drug-resistance phenotypes are expressed as the degree of 
increase in resistance compared to the sensitive parental line 
from which they were generated. The phenotypes of the clones 
were compared to the sensitive 247 line, except 466/59 bcl5, 
which was compared to the sensitive 386 line (since 466/59 bcl5 
was identified as a 386-derived clone from isoenzyme and 
karyotype analysis).
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Purine Transport and Arsenical Uptake
CHAPTER 6
PURINE TRANSPORT AND ARSENICAL UPTAKE
6.1 INTRODUCTION
The introduction of the melaminophenyl arsenicals by Friedheim in the 
1940s provided the first opportunity for late-stage sleeping sickness to be cured. 
Melarsen, and its derivative melarsen oxide (melOx), were first synthesised in 
1939, and were the first of the melaminophenyl arsenicals to be introduced 
(Friedheim 1948). Shortly after this, melB, a trivalent derivative of melOx, was 
introduced as a less toxic alternative (Friedheim 1949). Since then, trivalent 
water soluble derivatives of melOx have been synthesised. MelW was found to 
have no clear advantage over melB (Apted 1970). More recently melCy has been 
introduced and licensed for use in animal trypanosomiasis (Zelleke et ah 1989; 
Lun et ah 1991), but clinical trials with melCy in humans have not been 
conducted, leaving melB the only melaminophenyl arsenical in routine use for the 
treatment of sleeping sickness. There are very few alternatives to melB for 
treating late-stage sleeping sickness, although nifurtimox has proven effective 
against T. b. gambiense late-stage infections (Pepin et ah 1989) as has DFMO 
(McCann et al. 1981b). There has been little work conducted, however, on the 
effectiveness of nifurtimox against T. b. rhodesiense, and although treatment of 
experimental late-stage T. b. rhodesiense infections with DFMO has been found 
to be curative (McCann et ah 1981a), clinical trials have proved disappointing 
(Van Nieuwenhove 1992). Consequently, melB remains arguably the most 
important drug in use to cure late-stage sleeping sickness, almost 50 years after 
it was first introduced. It follows therefore, that the occurrence of melB-resistant 
cases of both T. b. rhodesiense and T. b. gambiense infections poses a serious 
problem, and necessitates the need for further investigations into both the mode 
of action of the different melaminophenyl arsenicals and the underlying 
biochemical mechanisms of arsenical-resistance.
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It is a widely held belief that the melaminophenyl arsenicals melB, melW 
and melCy interact with the same targets through the active form of the drugs - 
trivalent melarsen oxide (Berger and Fairlamb 1994). All three compounds 
consist of a trivalent melarsen oxide moiety bound to a dithiol-containing group 
(or two identical monothiol-containing groups in melCy). Since melCy, melB and 
melW must each dissociate to become active compounds, it would be reasonable 
to assume that the ease with which dissociation occurs may influence their 
trypanocidal activity. In melCy, melOx is bound to two cysteamine molecules, 
whereas in melB and melW, melOx is bound to a single molecule of either 2,3- 
dimercaptopropanol or 2,3-dimercaptosuccinate respectively. Each of these 
bound thiols has a different affinity for melarsen oxide. The association constants 
Ka and the equilibria are shown below:
MelB <=> 2,3-dimercaptopropanol + melOx Ka = 7.93 x lO^M '1
MelW <=> 2,3-dimercaptosuccinate + melOx Ka = 4.50 x 1010M_1 
Data from Fairlamb et al. (1989)
The situation with melCy is slightly different. MelCy is unstable in 
aqueous solution, immediately forming a mixture of melCy (43%), melCy with 
only one cysteamine moiety (24%), melOx (33%) and free cysteamine (Berger 
and Fairlamb 1994). However, no association constant has been determined for 
melCy, as the method used to measure the relative amounts of the products of 
dissociation was reported to be unsuitable to calculate an accurate association 
constant.
An important intracellular target for melOx has been identified as 
trypanothione (Try[SH]2) with melOx binding to the sulphydryl groups of
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trypanothione to form melT (Fairlamb et al. 1989). This study also calculated the 
association constant for melOx and trypanothione:
MelT <=> Try[SH]2 + melOx Ka = 1.21 x lC^M'1
MelB, melW and melCy are thought to interact with trypanothione in a 
similar way, with the formation of melT being brought about through the binding 
of the trivalent melarsen oxide moiety with trypanothione. In the case of melOx, 
this is brought about directly. In the cases of melB and melW, this occurs in 
conjunction with the dissociation of either 2,3-dimercaptopropanol or 2,3- 
dimercaptosuccinate respectively. The affinity of trypanothione for melOx is 
much lower than the affinity of the dithiols for melOx, with the Ka for melT 
being three orders of magnitude lower than that of melB and melW. However, 
the formation of melT from trypanothione and melOx is maintained due to the 
fact that both 2,3-dimercaptopropanol and 2,3-dimercaptosuccinate can readily 
diffuse out of the cell, thereby increasing the dissociation of melB and melW to 
release free melOx (Fairlamb et al. 1989). In the case of melCy, although direct 
evidence is not available, it is assumed that the reaction is essentially the same, 
with the dissociation of melCy releasing cysteamine instead of a dithiol (Berger 
and Fairlamb 1994). At this point it is important to recognise that trypanothione 
(with the formation of melT) is not the only potential intracellular target of the 
arsenical drugs and their primary mode of action still remains to be clarified. 
Pyruvate kinase has been shown to be inhibited by arsenicals (Flynn and 
Bowman 1974) and Ehrlich noted in the early stages of trypanocide development 
that arsenicals can interact with a number of sulphur containing compounds 
(Voegtlin et al. 1923). More recently, another major intracellular dithiol, 
dihydrolipoamide, was found to bind to melarsen oxide with an association 
constant of 5.47 x 109M_1, about 500-fold more stable than the association of 
melOx with trypanothione (Fairlamb et al. 1992a). However, although not all the
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important targets for melaminophenyl arsenicals may yet be known, the view that 
they interact with the targets in the same way, via melarsen oxide, remains the 
most widely accepted assumption (Berger and Fairlamb 1994).
This chapter is concerned mainly with the mode of uptake of the 
melaminophenyl arsenicals melB, melOx and melCy. Recent studies have 
identified a purine transporter as being responsible for melB and melOx uptake, 
and furthermore, it has been proposed that alteration of this transporter accounts 
for a decrease in drug-uptake and consequently brings about arsenical-resistance 
in T. brucei (Carter and Fairlamb 1993). In a broader context, altered drug 
accumulation has been found to be responsible for drug-resistance in a number of 
parasites for a wide variety of drugs. Pentamidine, for example, has been shown 
to be taken up by a specific active transport system in T. b brucei (Damper and 
Patton 1975). Differences in drug-uptake were seen to correlate with 
pentamidine-resistance in strains of both T. b. brucei and T. b. rhodesiense, and 
a similar correlation between uptake and pentamidine-resistance was seen when 
procyclics were compared to bloodstream forms (Damper and Patton 1976). 
Another study, employing flow cytometric analysis with multidrug-resistant T. b. 
brucei and T. b. rhodesiense, showed that the resistant lines accumulated two 
diamidines (DAPI and Hoechst 33342) less than the sensitive lines (Frommel and 
Balber 1987). The explanation for this observation was that some alteration in 
the trypanosome membrane reduced the amount of drug that accumulated in the 
trypanosome. A study with nifurtimiox-resistant strains of T. cruzi, also 
suggested that reduced accumulation of the drug rather than metabolic 
alterations were responsible for drug-resistance (Tsuhako et a l  1991). Reduced 
accumulation of isometamidium chloride was given also given as the explanation 
for drug-resistance in lines of T. congolense (Sutherland et al. 1991), and later 
studies indicated that an increase in drug-efflux as well as decreased drug-influx 
were involved in drug-resistance (Sutherland 1992). Increased drug-efflux rather
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than decreased drug-influx has been found to be responsible for decreased drug 
accumulation in multidrug-resistant cancer cells (Gottesman and Pastan 1988). 
Verapamil has proven to be a very useful tool in determining whether reduced 
drug-accumulation is a consequence of decreased drug-influx or increased drug- 
efflux. Verapamil was shown to be effective in blocking extrusion pumps (P- 
glycoproteins), and in some cases of multi-drug-resistant cells, such as the cancer 
cells just mentioned, verapamil was found to reverse drug-resistance (Gottesman 
and Pastan 1988). Furthermore, verapamil, has been shown to reverse 
nifurtimox-resistance in T. cruzi in vitro, again suggesting that the mechanism of 
resistance was through increased drug-efflux rather than decreased influx (Neal 
et al. 1989). However, verapamil was unable to reverse resistance to samorin 
and berenil in a study with multidrug-resistant T. b. brucei suggesting that 
increased drug efflux was not responsible for drug-resistance in this case 
(Kaminsky and Zweygarth 1991).
A recent study on arsenical-resistance in T. b. brucei provided evidence 
that the melaminophenyl arsenicals were taken up by an adenosine transporter, 
and that this transporter was altered or down regulated in an arsenical-resistant 
line (Carter and Fairlamb 1993). The bloodstream form of the sensitive line had a 
total adenosine uptake of 10.7 ±1.1 pmol/108cells/sec whereas the resistant line 
had a rate of uptake of only 1.9 ± 0.3 pmol/108cells/sec. The rapid melOx- 
induced lysis of the sensitive line could be blocked by adenine and adenosine but 
not inosine. It was concluded that two specific adenosine transporters existed 
(PI and P2), and that these could be distinguished by their specificity for uptake 
of inosine (PI) and adenine (P2) respectively. Furthermore, it was the P2 
transporter that was responsible for melOx and melB uptake, and this P2 
transport was virtually absent in the arsenical-resistant line. It was found that the 
arsenical-resistant line also expressed cross-resistance to the diamidines 
(Fairlamb et al. 1992b), consistent with a number of previous reports
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(Williamson and Rollo 1959; Frommel and Balber 1987). Since the diamidines 
also blocked melOx-induced lysis, it has been suggested that the P2 adenosine 
transporter was responsible for the uptake of berenil and pentamidine, as well as 
the melaminophenyl arsenicals (Fairlamb et al. 1992b). This chapter investigates 
the validity of these proposals using the arsenical-sensitive line (247) and the 
independently generated arsenical-resistant line (247MelCyR).
6.2 MATERIALS AND METHODS
6.2.1 Drugs and Chemicals
MelCy, melB, and melOx were supplied and stored as described 
previously (section 3.2.1). Pentamidine (pentamidine isethionate), and silicone 
oil (75 centistokes, 1.05g/ml) were kind gifts from Prof. Alan Fairlamb, London 
School of Hygiene and Tropical Medicine. Berenil (diminazene aceturate), 
phenyl arsenoxide, adenine, adenosine and inosine were supplied by Sigma. [3H]- 
adenosine (56Ci/mmol) was supplied by Amersham. Picofluor 40 scintillation 
fluid was supplied by Canberra Packard. Pentamidine and adenosine were stored 
desiccated at 4°C. Berenil, phenyl arsenoxide, inosine and adenine were stored at 
room temperature.
6.2.2 Trypanosomes Stocks, Mice and Rats
Two cloned lines of trypanosomes were used in this study. 247 was taken 
from the original stabilate (GUP 3536) that was used to generate the drug- 
resistant lines of 247, and 247MelCyR was taken from the original cloned 
stabilate, GUP 3611. Adult female Balb/C mice were used in the in vivo drug- 
resistance assays. Adult female CFLP mice and adult male and female Sprague- 
Dawley rats were used to grow trypanosomes.
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6.2.3 In Vivo Assay to Determine Drug Resistance
The in vivo assays were conducted as described previously (chapter 2). 
The drug-sensitive stock (247) and the drug-resistant stock (247MelCyR) were 
assessed for the levels of their resistance to pentamidine and berenil. Both drugs 
were desolved in dddH20  immediately before use. Drugs were administered by 
i.p. injection.
6.2.4 In Vitro Lysis of Trypanosomes with Arsenical Drugs
Lysis o f  Bloodstream Trypanosomes
To grow trypanosomes for lysis studies, four adult female mice were 
immunosuppressed (cyclophosphamide at a dose of 250mg/Kg by i.p. injection 
24 hours prior to trypanosome inoculation), infected with trypanosomes, and 
parasites from populations in exponential growth were combined to create new 
stabilates, cryopreserved in 0.5ml aliquots. One aliquot was then used to infect 
an immunosuppressed (cyclophosphamide at a dose of 50mg/Kg by i.p. injection 
24 hours prior to trypanosome inoculation) adult Sprague-Dawley rat. The 
resulting parasites were transferred to six immunosuppressed rats, from which 
the trypanosomes for the lysis studies were taken. Trypanosomes were purified 
from infected blood by anion-exchange chromatography (Lanham and Godfrey 
1970) and collected into 100ml Carter's Balanced Salt Solution on ice (CBSS: 
25mM Hepes, 120mM NaCl, 5.4mM KC1, 0.55mM CaCl2, 0.4mM M gS04, 
5.6mM Na2HP04, l l . lmM  glucose, 5mg/l phenol red, pH 7.4: Fairlamb et al. 
1992b). The trypanosome suspension was centrifuged at lOOOg for 10 minutes at 
4°C, resuspended in CBSS at a trypanosome density of 108/ml and kept on ice. 
Arsenical-induced lysis at 37°C was measured on a spectrophotometer (Yarlett 
et al. 1991; Fairlamb et al. 1992b). Briefly, as the trypanosomes lysed in the 
presence of arsenical, so more light was transmitted, and this decrease in
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absorbance was measured at a wavelength of 750nm. By this method, arsenical- 
induced lysis can be followed spectrophotometrically for up to 1 hour. Four 
arsenical drugs were used: melCy (dissolved in dddH20), melOx, melB and 
phenyl arsenoxide (all dissolved in dimethyl formamide). The sensitivity of 247 
and 247MelCyR to lysis by each of these arsenicals was assessed at a final 
trypanosome density of 107/ml over 30 minutes in a range of drug 
concentrations. The effect of addition of adenine, adenosine, inosine, berenil and 
pentamidine on the arsenical-induced lysis of the drug-sensitive line (247) was 
also investigated as described previously (Carter and Fairlamb 1993). All OD750 
measurements were made using buffer (CBSS) as a blank, and each experiment 
contained a control sample containing only trypanosomes in CBSS and solvents.
Lysis o f Procyclic Trypanosomes
Procyclic trypanosomes (247 only) were grown in complete SDM-79. 
Arsenical-induced lysis was measured as for bloodstream trypanosomes at 
trypanosome densities of 107/ml. However, the lysis of procyclic trypanosomes 
was carried out over 1 hour in two different media at either 26°C or 37°C. 
Trypanosome cultures in logarithmic growth were spun at lOOOg for 10 minutes 
at 4°C and resuspended at a trypanosome density of 108/ml. Depending on the 
medium used to carry out the lysis experiment, the trypanosomes were 
resuspended in either SDM-79 (without adenosine) or CBSS and stored on ice.
6.2.5 Adenosine Uptake in Bloodstream Trypanosomes
Adenosine uptake studies were carried out on bloodstream trypanosomes 
using tritiated adenosine as described previously (Carter and Fairlamb 1993). 
Two separate studies were carried out to investigate the nature of the purine 
transporters and their role in arsenical resistance.
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Rate o f  Adenosine Uptake in 247 and 247MelCyR
The rate of adenosine uptake was measured over the first seven seconds 
after the addition of [3H]-adenosine, in both 247 and 247MelCyR. Purified 
trypanosomes were obtained as for the lysis studies, and resuspended at a 
trypanosome density of 108/ml in CBSS containing 1% BSA. CBSS (with 1% 
BSA) containing a final concentration of total adenosine (labelled and unlabelled) 
of 2pM and lpM  NaOH was overlaid on lOOpl of silicone oil in a series of 
eppendorfs pre-warmed to 25°C. 100pi of pre-warmed cells were pipetted onto 
the radiolabelled solutions at one second intervals. The trypanosomes mixed 
sufficiently with the radiolabelled solution due to the small volumes involved and 
the turbulent act of pipetting the trypanosomes onto the radiolabelled solutions. 
Adenosine uptake was stopped by centrifuging at high speed on an eppendorf 
microfuge for 2 minutes. This rapidly pelleted the trypanosomes through the oil 
leaving any radiolabel that had not been taken up in the aqueous supernatant. 
The resulting supernatants of oil and aqueous layer were removed by first 
removing the aqueous layer and washing the eppendorf sides twice in cold PBS 
to remove all traces of any radiolabel that had not been taken up by the 
trypanosomes, and then careftilly removing the oil layer. Each pellet was then 
vortexed in 100pi of 2% TRITON-X scintillation grade (made up in dddH20 ) 
and left overnight at 4°C. The radioactivity present in each pellet was then 
measured with 1ml Picofluor 40 scintillation fluid in a Beckman LS 6000LL. The 
amount of total adenosine taken up by the trypanosomes was calculated for each 
time point between 2 and 7 seconds. The rate of uptake of total adenosine 
(pmol/108cells/sec) was then calculated by linear regression. The adenosine 
uptake experiments were carried out in duplicate, and the means were calculated.
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Characterisation o f Adenosine Transport
The purine transporters responsible for adenosine uptake in 247 and 
247MelCyR were characterised with respect to uptake of adenine and inosine. 
The procedure employed was similar to that used to measure the overall rate of 
adenosine uptake. However, only the amount of adenosine uptake over 5 
seconds was measured. The inhibition of [3H]-adenosine uptake by adenine and 
inosine was determined by including a range of concentrations of each in the 
solutions containing the radiolabel. The results were expressed in terms of the 
extent by which adenine and inosine inhibited adenosine uptake compared to 
control samples. Each experiment for 247 was carried out in duplicate, and 
means were calculated. Duplicate experiments were not conducted with 
247MelCyR.
6.3 RESULTS
6.3.1 Pentamidine and Berenil Resistance In Vivo
The results of the in vivo assays for 247 and 247MelCyR with berenil and 
pentamidine are shown in Table 6.1. The results are expressed as minimum 
curative doses i.e. the lowest dose required to completely clear the infection 
from all 6 mice in a group (section 2.3.2). This table also shows the resistance 
factors for each drug calculated as a ratio of the level of resistance in the melCy- 
resistant line (247MelCyR) compared to the unselected drug-sensitive line (247). 
It can be seen that there is a marked degree of cross-resistance between the 
arsenicals and both berenil and pentamidine. There is a lesser amount of cross- 
resistance between melCy and berenil (resistance factor of 16) than there is 
between melCy and pentamidine (resistance factor of greater than 63). 
247MelCyR was resistant to a dose of pentamidine of lOOmg/Kg, the maximum 
tolerated dose in mice (Carter pers. comm.).
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6.3.2 Arsenical Induced Lysis
Bloodstream Trypanosomes
The lysis data for 247 is shown graphically in Figures 6.1 to 6.6, showing 
the decrease in absorbance at 750nm over 30 minutes after addition of arsenical 
drug. The susceptibility of 247 to arsenical-induced lysis to all four arsenicals can 
be seen in figures 6.1(a-d). Comparison of these four graphs shows that 
approximately equivalent rates of lysis occurred with markedly different 
concentrations of the four arsenicals. MelOx brought about rapid lysis of 247 at 
concentrations of 5pM and above (Figure 6.1(a)). The rate of lysis was markedly 
increased with same concentration of melCy (Figure 6.1(b)), and indeed, only 
lpM  melCy was necessary to bring about lysis at a roughly comparable rate to 
that brought about by 5pM melOx. The differences in potency of the 
melaminophenyl arsenicals was even more noticeable with melB (Figure 6.1(c)), 
which required approximately a 25-fold greater concentration to bring about 
lysis similar to that seen with lpM  melCy. Phenyl arsenoxide, which is essentially 
melOx without the melamine ring, lysed the trypanosomes in less than 5 minutes 
at concentrations of 0.1 pM and greater, and was undoubtedly more potent than 
all the melaminophenyl arsenicals (Figure 6.1(d)). Consequently, within the 
melaminophenyl arsenicals, melCy was noticeably the most potent, requiring a 
concentration 5 times lower than melOx, and 25 times lower than melB to bring 
about similar degrees of lysis. Alternatively, a comparison of the effects of I jliM  
of the different melaminophenyl arsenicals showed that at this concentration, 
melCy was able to bring about much quicker lysis than the same concentration of 
melOx, while lpM  of melB was incapable of lysing the trypanosomes after 30 
minutes.
In a previous study, the uptake mechanisms for the arsenical drugs were 
characterised by investigating which compounds blocked lysis, with the inference
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being that lysis was reduced or blocked by those compounds that competed for 
transport with the arsenical (Carter and Fairlamb 1993). In the present study, the 
effect of adenine, adenosine, inosine, pentamidine and berenil on arsenical 
induced lysis was investigated. The maximum amount of excess of these 
compounds was different for each of the arsenicals used, due to the different 
arsenical concentrations that were employed to bring about similar degrees of 
lysis. In the unselected line, 247, addition of adenosine or adenine to the lysis 
medium protected the trypanosomes, in a concentration dependant manner, from 
lysis by melOx and melCy (Figures 6.2(a and b) and 6.3(a and b)). In these 
instances, a 40-fold excess of either adenosine or adenine brought about total 
protection over 30 minutes at 37°C. For melB-induced lysis, however, a similar 
40-fold excess of adenosine or adenine had no measurable effect on lysis 
(Figures 6.2(c) and 6.3(c)). A similar situation occurs with phenyl arsenoxide, in 
which even 1000-fold excesses of adenosine and adenine were unable to bring 
about any noticeable decrease in the rate of lysis (Figures 6.2(d) and 6.3(d)). 
Inosine had no measurable effect on lysis, regardless of the arsenical employed. 
At inosine concentrations of 100-fold greater than melOx and melCy (Figures 
6.4(a) and 6.4(b)), 40-fold greater than melB (Figure 6.4(c)) and 1000-fold 
greater than phenyl arsenoxide (Figure 6.4(d)) the decreases in absorbance were 
maintained at the same rates as those in samples with no inosine.
It has been proposed that the melaminophenyl arsenicals share a common 
uptake mechanism with the diamidines (Fairlamb et a l  1992b). Like adenosine 
and adenine, increasing amounts of berenil and pentamidine protected 247 from 
the lysis caused by melOx and melCy, although full protection was not seen even 
with diamidine concentrations of 100-fold more than the arsenicals (Figures 
6.5(a and b) and 6.6(a and b)). Interestingly, although neither adenosine, adenine 
or inosine could block melB-induced lysis, both berenil and pentamidine were 
able to partially protect the trypanosomes from melB (Figures 6.5(c) and 6.6(c)).
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At 40-fold excess, berenil and pentamidine protected the trypanosomes to an 
approximately equal extent, whether the arsenical was melB, melOx or melCy. 
One further interesting result was found with phenyl arsenoxide. Berenil, like 
adenosine, adenine and inosine, could not protect the trypanosomes from lysis by 
phenyl arsenoxide even when they were present at concentrations of 0.1 mM, 
1000-fold greater than the concentration of phenyl arsenoxide (0.1 (iM) (Figures 
6.2(d), 6.3(d), 6.4(d) and 6.5(d)). However, 1000-fold excess of pentamidine 
was able to prevent some cells lysing in the presence of 0.1 pM phenyl 
arsenoxide, after an initial period of rapid lysis (Figure 6.6(d)).
Figure 6.7(a-d) shows the lysis of the resistant line (247MelCyR) by the 
four arsenicals. Arsenical-resistance was expressed in the lysis assay to all four 
arsenicals, although to different extents. All concentrations of melOx, up to and 
including lOOpM, had no noticeable effect on 247MelCyR (figure 6.7a). On the 
other hand, lOpM melCy was unable to lyse the cells over 30 minutes, although 
there was a slight degree of lysis at 50jiM melCy (Figure 6.7(b)) Similarly, with 
melB, IOjiM had no noticeable effect on lysis, whereas 50^M melB brought 
about partial lysis (Figure 6.7(c)). In comparison to the melaminophenyl 
arsenicals, the trypanosomes expressed a much lower level of resistance to 
phenyl arsenoxide, with 0.1 pM proving insufficient to cause lysis, and 
concentrations above lpM  bringing about rapid lysis. Of the three 
melaminophenyl arsenicals, melB was by far the most effective at lysing the 
resistant line (Figure 6.7(c)), the opposite of the situation that was found with 
the sensitive line, where melB was the least effective. At concentrations of 
100|iM, melOx caused no lysis, melCy caused very slight lysis, whereas, melB 
caused a much more marked degree of lysis compared to the other two drugs. 
Although phenyl arsenoxide was capable of lysing cells very rapidly and at much 
lower concentrations than those required for the melaminophenyl arsenicals, the 
resistant line did express a marked degree of resistance to phenyl arsenoxide
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(Figure 6.7(d)). Whereas 247 was susceptible to lysis in less than 5 minutes by 
0.1 jiM phenyl arsenoxide, greater than lOOfiM was required to have the same 
effect on 247MelCyR (Figures 6.1(d) and 6.7(d)).
Figure 6.8(a and b) illustrates a different observation concerning the 
susceptibility of trypanosomes to arsenical-induced lysis. All the results described 
above used trypanosomes from rats only 3 passages away from the original 
cloned stabilates. However, equivalent experiments were also conducted using 
247 that was syringe passaged in rats for approximately 2-3 months, involving at 
least 15 passages. This passaging resulted in the development of a 247 line that 
was less susceptible to lysis by all four arsenicals. Figure 6.8(a) shows the 
melOx-induced lysis of 247 before and after more than 15 passages. This 
reduction in the susceptibility to lysis was seen as a gradual change, with the 
degree of arsenical-induced lysis decreasing as the number of passages increased. 
As the number of times the line was passaged increased over a period of time, so 
the rate of lysis at a given concentration of arsenical drug was gradually reduced. 
This resulted in the need for increased concentrations of arsenical in order to 
bring about similar rates of lysis that were seen in the line prior to it being 
passaged. This same pattern was seen with all the arsenicals, a further example of 
which can be seen in figure 6.8(b). This shows melCy-induced lysis at a 
concentration of lpM  for 247 before and after more than 15 passages. In the 
case of phenyl arsenoxide, it was necessary to increase the concentration by 100- 
fold to bring about a similar rate of lysis in the passaged line to that observed 
with 0.1 (iM of phenyl arsenoxide in 247 before the passages.
Procyclic Trypanosomes
The unselected drug-sensitive line, 247, was assessed in the lysis assay 
with procyclic culture forms. Upon resuspension of the procyclics in CBSS, the
172
Purine Transport and Arsenical Uptake
trypanosomes remained motile when stored on ice, but as soon as they were 
brought up to room temperature, upon examination under a microscope they 
were seen to lose their motility within 5-10 minutes. Nevertheless, lysis of 247 
procyclics in CBSS was measured over one hour with frequent stirring of the 
samples to avoid the non-motile trypanosomes from settling. The trypanosomes 
remained highly motile when resuspended in SDM-79 (without adenosine). 
Figures 6.9(a-d) show no clear indication of lysis in either medium at either 26°C 
or 37°C with any of the arsenicals tested. All the arsenicals were present at high 
concentrations, capable of effecting lysis in 247 bloodstream forms. As a result 
of this finding, there was no point in examining lysis in the drug-resistant line, 
247MelCyR.
6.3.3 Adenosine Uptake
Alteration in the Rate o f Adenosine Uptake
The rate of adenosine uptake for 247 was found to be almost 10-fold 
greater than for its arsenical-resistant counterpart, 247MelCyR (Table 6.2) The 
sensitive line, 247, took up adenosine at a rate of 48pmol/108cells/sec, compared 
to 5.0pmol/108cells/sec for 247MelCyR.
Characterisation o f Adenosine Transport
Adenosine uptake in 247 bloodstream forms could be partially blocked 
by both adenine and inosine (Tables 6.3 and 6.4). Adenine in the absence of 
inosine, inhibited adenosine uptake in a concentration dependant manner, to a 
maximum inhibition of approximately 50%, which occurred at adenine 
concentrations above lOpM (Table 6.3). Similarly, inosine in the absence of 
adenine, was found to inhibit adenosine uptake up to a maximum of 
approximately 45% at and above concentrations of inosine of lOpM (Table 6.4).
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In the presence of 500pM inosine the addition of adenine brought about a further 
increase in the inhibition of adenosine uptake above the level of 45% brought 
about by inosine alone. The reciprocal experiment with excess adenine and 
increasing amounts of inosine also showed the 50% inhibition that was brought 
about by adenine alone to be increased with the addition of inosine in a 
concentration-dependant manner. In both cases, excess amounts of inosine and 
adenine together inhibited adenosine uptake by approximately 70 to 75%.
Table 6.5 shows the results of the uptake studies carried out on 
247MelCyR. Like 247, increasing amounts of adenine inhibited adenosine uptake 
in the resistant line. However, the maximum amount of inhibition reached was 
approximately 35%, a value lower than that observed in 247. At excess 
concentrations of both adenine and inosine, the adenosine uptake could be 
inhibited to a maximum level of approximately 75%, similar to the level of 
inhibition observed in the unselected line, 247.
6.4 DISCUSSION
Trypanothione has been identified as the primary intracellular target for 
arsenical drugs (Fairlamb et a l 1989). However, alterations in trypanothione 
metabolism have not been found to be a mechanism through which trypanosomes 
express arsenical-resistance. Two recent studies have provided evidence for 
arsenical-resistance being brought about through a reduction in the uptake of 
melaminophenyl arsenicals (Yarlett et al. 1991; Carter and Fairlamb 1993). One 
of these recent studies (Carter and Fairlamb 1993) compared a line of T. b. 
brucei (S427) with an arsenical-resistant cloned line (S427 cRU15) that had been 
derived from S427 by exposing the unselected line to gradually increasing sub- 
curative doses of sodium melarsen, up to a maximum of 160mg/Kg (Fairlamb et 
al. 1992b). The results of lysis and radiolabelled uptake experiments, provided
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evidence for the existence of an adenosine transporter (termed P2) that was 
responsible for the uptake of the melaminophenyl arsenicals. Based on the results 
of these studies, it was concluded that an alteration in the P2 adenosine 
transporter was responsible for the expression of resistance to the 
melaminophenyl arsenicals (Carter and Fairlamb 1993). It was the aim of the 
present study to conduct similar comparable experiments with 247 and 
247MelCyR in order to determine if the mechanism of arsenical-resistance in 
S427 cRU15 was also the mechanism of arsenical-resistance in 247MelCyR. The 
aims were therefore, to determine whether or not an adenosine transporter was 
responsible for the uptake of melaminophenyl arsenicals, and if so, whether or 
not an alteration in adenosine transport could account for the expression of 
arsenical-resistance.
Reduced intracellular accumulation of drugs has been shown to be a 
frequent mechanism through which drug-resistance is expressed. For example, a 
DFMO-resistant line of T. b. brucei showed a decrease in the incorporation of 
DFMO compared to the sensitive line (Phillips and Wang 1987). However, 
reduced drug accumulation within the trypanosome may be the result of either 
decreased drug-uptake or increased drug-efflux, as well as possible alterations in 
the metabolism of the drug. Verapamil has been shown to inhibit the function of 
P-glycoproteins, which are found on the cell membrane and have the ability to 
transport lipophilic drugs out of the cell (Gottesman and Pastan 1988). Drug- 
resistance has been shown to be reversible by verapamil in a number of cases, 
such as the reversal of some cases of chloroquine-resistance in Plasmodium 
falciparum (Martin et al. 1987) and the reversal of sodium stibogluconate- 
resistance in Leishmania donovani (Neal et al. 1989). However, verapamil was 
not able to reverse drug-resistance in African trypanosomes (Kaminsky and 
Zweygarth 1991). A number of calcium-channel antagonists, including 
verapamil, were unable to reverse melOx-resistance in isolates of T. b.
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rhodesiense (Yarlett et al. 1991), and current evidence would therefore suggest 
that resistance to melaminophenyl arsenicals is not due to increased drug-efflux. 
However, decreased drug accumulation has been shown to be involved in atoxyl- 
resistance in T. brucei (Yorke et al. 1931), and since alterations in trypanothione 
metabolism that could account for arsenical-resistance have not yet been found 
(Yarlett et al. 1991; Fairlamb et al. 1992b), it would therefore be reasonable to 
expect alterations in drug-uptake to be involved in drug-resistance.
The reduction in drug-uptake and the existence of a common transport 
mechanism has recently been offered as an explanation for the patterns of cross­
resistance between melaminophenyl arsenicals and the diamidines (Carter and 
Fairlamb 1993). The existence of cross-resistance between arsenicals and 
diamidines has been reported in a number of independent studies (Williamson 
and Rollo 1951; Frommel and Balber 1987). The results presented here also 
show a marked degree of cross-resistance between melaminophenyl arsenicals 
and the two diamidines, berenil and pentamidine. The resistance factors for 
berenil and pentamidine were 16, and greater than 63 respectively (Table 6.1). 
An explanation for these patterns of cross-resistance has recently been offered 
based on the existence of a common transport mechanism, involving a specific 
transporter, for all the melaminophenyl arsenicals and the diamidines (Fairlamb et 
al. 1992b). The two benzamidine rings in the diamidines and the melamine and 
benzene rings in the melaminophenyl arsenicals have been proposed as the 
similar structures that are recognised by the transporter, thereby accounting for 
the patterns of cross-resistance. Furthermore, the interatomic distances between 
the centres of the two rings has been found to correlate with the degree of cross­
resistance between melarsen oxide and four diamidines (Fairlamb et al. 1992b). 
As the distance between rings increased, so the degree of cross-resistance 
decreased, with only a very slight amount of cross-resistance existing between 
melarsen oxide and pentamidine, the latter having the greatest distance between
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rings compared to the other three diamidines. However, for the present study, 
this hypothesis would have predicted 247MelCyR to have a much greater degree 
of cross-resistance to berenil than pentamidine. This is clearly not the case, and 
although the existence of a common transport mechanism may indeed be the 
case, the results presented here are not in agreement with the proposal that inter­
ring distances determine the specificity of the transporter, and therefore the 
relative degrees of cross-resistance.
It has been proposed that the common transport of the melaminophenyl 
arsenicals and diamidines occurs via a specific adenosine transporter (Carter and 
Fairlamb 1993). In vitro melOx-induced lysis of trypanosomes was found to be 
blocked by adenosine, which was consistent with adenosine competing with 
melOx for uptake, thereby resulting in a lower intracellular concentration of 
melOx. These lysis experiments were carried out on a line of T. b. brucei (S427), 
using melOx and phenylarsine oxide, which is highly lipid soluble and lacks the 
melaminyl moiety of melOx. The results presented in the current study were 
from experiments carried out on 247, in an attempt to establish whether the 
proposal of an adenosine transporter being involved in the uptake of 
melaminophenyl arsenicals was a phenomenon common to other trypanosome 
lines. The lysis studies with 247 were carried out using melCy and melB as well 
as melOx and phenylarsine oxide. It was clear that the sensitive line was highly 
susceptible to melCy, and that melB was the least trypanolytic agent of the 
arsenicals. The fact that phenylarsine oxide, which can rapidly enter the 
trypanosome by diffusion, was able to bring about rapid lysis at much lower 
concentrations than melOx is consistent with the proposal that the trypanosome's 
membrane acts as a permeability barrier for the melaminophenyl arsenicals and 
that a selective uptake mechanism exists. However, if all the melaminophenyl 
arsenicals were taken up by the same route and at the same rate, it would be 
expected that melOx would be the most potent as it represents the active form of
177
Purine Transport and Arsenical Uptake
the drugs. Since melCy and not melOx was the most potent, and assuming they 
share the same target, this suggests that they are not taken up at the same rate. It 
therefore follows that either a single transporter distinguishes between different 
melaminophenyl arsenicals (and thereby providing further evidence against the 
influence of the inter-ring distances in drug recognition by the transporter) or 
that the different melaminophenyl arsenicals can be taken up by different routes.
The results of the lysis studies with 247 presented in the present study for 
melOx are consistent with the previous findings (Carter and Fairlamb 1993) that 
melOx is taken up via an adenosine transporter. Similar to the situation with 
S427, both adenosine and adenine, as well as berenil and pentamidine were able 
to block melOx-induced lysis in a dose dependant manner. Evidence has been 
presented for the existence of two adenosine transporters in the sensitive S427 
line (Carter and Fairlamb 1993). One (termed PI) was responsible for the uptake 
of adenosine and inosine but not melOx, and the other (P2) transported 
adenosine, adenine as well as melOx and melB. The results presented here for 
247 agree with the proposal that melOx uptake is blocked by adenosine and 
adenine (P2 transport) but not by inosine (PI transport). Similarly, phenylarsine 
oxide, lacking the melaminyl moiety and being highly lipid soluble, entered the 
cell by diffusion and lysis could not be blocked by adenine, adenosine or inosine, 
in agreement with the proposal that the melaminyl moiety is important in 
recognition by the transporter. Although, melCy was not used in the previously 
published study with S427, melCy behaved similar to melOx for 247 in that 
adenosine, adenine, berenil and pentamidine blocked lysis whereas inosine did 
not. MelCy, therefore, also appears to enter the cell via the P2 adenosine 
transporter. However, with S427, melB was found to competitively inhibit 
adenosine transport by the P2 transporter with a Kj of 0.28pM (Carter and 
Fairlamb 1993). In the present study, melB-induced lysis was not blocked by 
adenosine or adenine although it was by berenil and pentamidine. It would
178
Purine Transport and Arsenical Uptake
therefore appear on this evidence that melB was not taken up by an adenosine 
transporter. However, the fact that berenil and pentamidine blocked lysis to all 
three melaminophenyl arsenicals, including melB, may indicate that melOx, 
melCy, melB, berenil and pentamidine do indeed share a common transport 
system, although if this were the case, this would have to be a non-adenosine 
transporter since adenosine does not block melB-induced lysis. It is, therefore, 
impossible to explain the lysis data purely in terms of a single adenosine 
transporter that is responsible for the uptake of all melaminophenyl arsenicals 
and the diamidines. It may be that more than one route exists for drug entry into 
the trypanosome. The relatively high lipid solubility of melB may allow it to 
diffuse into the cell, bypassing the adenosine transporter, whereas melCy and 
melOx are reliant on a more specific mechanism of uptake. Alternatively, an as 
yet unidentified transporter may be responsible for melB uptake. However this 
does not take into account the fact that the diamidines can block lysis to all the 
melaminophenyl arsenicals, since if they block lysis by competing for a common 
transporter, they must compete not only for the melB transporter but also the 
melOx and melCy transporter, and consequently have two possible routes into 
the cell.
The fact that berenil and pentamidine block lysis by the melaminophenyl 
arsenicals, together with the existence of cross-resistance between the 
melaminophenyl arsenicals and diamidines seen here and elsewhere (Williamson 
and Rollo 1959; Fairlamb et al. 1992b) could be explained simply by the 
existence of similar modes of action for the two families of drugs rather than 
common uptake mechanisms. For example, assuming trypanothione is the 
primary target for arsenicals (Fairlamb et al. 1989), it may be that the primary 
targets for berenil and pentamidine may also be closely involved in maintaining 
the intracellular redox balance and detoxifying H20 2. A situation can be 
envisaged where alterations in trypanothione metabolism could bring about
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resistance to both melaminophenyl arsenicals and diamidines. Consequently, to 
give an alternative explanation for the lysis results with 247; melOx and melCy 
may enter the cell via the adenosine transporter, explaining the blocking of lysis 
by adenosine and adenine. MelB may enter either by diffusion or via an as yet 
unidentified non-adenosine transporter, explaining why adenosine and adenine 
could not block melB-induced lysis. MelOx, melCy and melB may share a 
common target with the diamidines, explaining both the existence of cross­
resistance between the diamidines and the melaminophenyl arsenicals, and also 
the reason for the diamidines blocking arsenical-induced lysis, assuming the 
diamidines are less potent at the molecular level and in some way interfere with 
the interaction of the arsenicals with their target.
Examination of the lysis data with the resistant line, 247MelCyR provides 
further evidence that an alteration in adenosine transport cannot solely be 
responsible for arsenical-resistance, particularly for melB. 247MelCyR showed a 
marked degree of resistance to melCy and melOx in the lysis assay. However, 
where melB was the least effective melaminophenyl arsenical for the lysis of 247, 
it was the most potent for 247MelCyR. lOOpM melOx was incapable of causing 
any noticeable lysis and lOOpM melCy was capable of bringing about a slow, 
partial lysis over 30 minutes, whereas lOOpM melB was noticeably a more 
effective trypanolytic agent, although some amount of melB-resistance was 
undoubtedly expressed in 247MelCyR. Significantly, there was also a very 
marked increase in resistance to phenylarsine oxide. An increase in phenylarsine 
oxide-resistance was also seen in the melarsen-resistant line of S427, although 
this was largely ignored (Fairlamb et al. 1992b). This undoubtedly indicates that 
the mechanism(s) of arsenical-resistance involves at least one alteration that is 
not involved in drug uptake. Indeed, the proposal that melB can diffuse through 
the outer membrane or enters the trypanosome by a non-adenosine transporter, 
is in agreement with the lysis data for 247MelCyR and the growth inhibition data
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(chapter 3). Therefore, the existence of at least two alterations in 247MelCyR, 
one at the adenosine transporter (inhibiting melOx and melCy uptake), and 
another at an intracellular target, would seem to be the most reasonable 
explanation for these results until more information is obtained. The distinct 
possibility that melB is not taken up by the same mechanism as melOx and 
melCy has important implications for previous and future investigations into the 
mechanism of melB-resistance that use arsenical-resistant lines that were not 
generated using melB. S427 cRU18 was selected from S427 in mice using 
increasing sub-curative drug doses of sodium melarsen up to a maximum 
tolerated dose of 160mg/Kg (Fairlamb et al. 1992b). Similarly, 247MelCyR was 
selected with melCy up to a maximum tolerated dose of 40mg/Kg. 
Consequently, neither S427 cRU18 nor 247MelCyR was selected using melB. 
Furthermore, these inconsistencies between melOx, melCy and melB bring into 
question the use of melB only, and not melCy, for the treatment of sleeping 
sickness.
One unexpected finding that arose from preliminary lysis studies was that 
the 247 line showed a gradual decrease in susceptibility to arsenical-induced lysis 
as it was passaged through rats. This was seen with all three melaminophenyl 
arsenicals as well as phenylarsine oxide. A possible explanation for this 
phenomenon is as follows: The trypanosomes were passaged in adult rats which 
were often simultaneously treated with cyclophosphamide at a dose of 50mg/Kg 
when they were infected with trypanosomes, both by i.p. injection. The toxic 
breakdown products of cyclophosphamide act on a number of different cell types 
by stopping cell division. It is thought that most cells that divide are affected by 
cyclophosphamide, including trypanosomes, although its effect on trypanosomes 
must only be slight. Nevertheless, it may be that cyclophosphamide exerts some 
sort of selective pressure on the trypanosome population in the same way as a 
sub-curative drug dose, with the subsequent development of "cyclophosphamide-
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resistant" trypanosomes. The mechanism through which the trypanosomes 
become "resistant" to cyclophosphamide may also bring about cross-resistance 
to arsenicals, although how this might occur remains unclear. The possibility that 
the actual process of passaging itself may have brought about an increase in 
arsenical-resistance can be largely discounted since the suramin-resistant lines, 
247SurR and 386SurR, did not show any increase in resistance to arsenicals and 
where themselves passaged to similar extents, but in the absence of the 
breakdown products of cyclophosphamide (chapter 2). Importantly, during the 
selections for drug-resistance, mice were infected with trypanosomes 24 hours 
after they had received cyclophosphamide, allowing sufficient time for the toxic 
breakdown products of cyclophosphamide to be removed from the circulation, 
whereas the rats were often infected and given cyclophosphamide at the same 
time.
Procyclic trypanosomes were susceptible to melCy when incubated in 
complete SDM-79 for up to one day (results not shown), and indeed melCy- 
resistant trypanosomes can be distinguished from unselected lines in procyclics in 
vitro (chapter 5). However, for periods up to one hour, procyclics had an 
extremely low susceptibility to lysis by arsenicals. Lysis studies were carried out 
on 247 resuspended in either CBSS or SDM-79 without adenosine at either 
26°C or 37°C in the presence of arsenicals at the maximum possible 
concentrations. Although CBSS is a buffered salt solution specifically designed 
for bloodstream trypanosomes (Fairlamb et al. 1992b), it was used to give a 
direct comparison with bloodstream trypanosomes. Since it contained glucose 
and no amino acids, the procyclic trypanosomes had no energy source, thus 
explaining the rapid loss in motility upon resuspension in CBSS. Active transport 
would be reduced due to this lack of energy substrate, and this may appear to 
provide a reason for the lack of susceptibility to lysis. However, even ImM 
phenylarsine oxide could not lyse the procyclics over 1 hour, thereby discounting
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the lack of active uptake as the reason for there being no lysis. Furthermore, if 
the absence of an energy substrate was important, then lysis would have been 
expected in SDM-79 without adenosine. Again, no definite signs of lysis were 
seen with any of the four arsenicals over one hour. Ionised calcium, at a 
concentration above approximately 0.3mM, has been shown to be necessary for 
lysis in vitro (Clarkson and Amole 1982), but this also could not explain the lack 
of lysis since both CBSS and SDM-79 contained sufficient calcium (0.55mM and 
1.6mM respectively). Consequently, it appears that the differences in metabolism 
between procyclics and bloodstream trypanosomes may account for the lack of 
susceptibility to lysis of the procyclics. Glycolysis and glucose catabolism is 
replaced with amino acid catabolism as the source of energy in procyclics. 
However, despite the fact that it has been shown that arsenical drugs inhibit 
pyruvate kinase (Flynn and Bowman 1974), inhibition of glycolysis is not the 
reason for cell lysis (Van Schaftingen et a l  1987). Further investigations are 
required to explain the procyclic's resistance to arsenical-induced lysis.
Despite the fact that melB does not appear to be taken up by an 
adenosine transporter, melOx-resistance and melCy-resistance may, at least in 
part, be involved with alterations in adenosine transport. Radiolabelled adenosine 
was used to characterise the adenosine transporters in 247 and 247MelCyR in 
order for a comparison to be made with previous findings. Two adenosine 
transporters were identified in S427. In this line, the PI-transporter was 
responsible for adenosine and inosine transport only, accounting for 60-70% of 
total adenosine uptake. The P2-transporter was the only other adenosine 
transporter identified, accounting for 30-40% of total adenosine uptake and 
being responsible for the uptake of adenine, melOx and melB (Carter and 
Fairlamb 1993). The situation with adenosine transport in 247 was slightly 
different. Adenine clearly inhibited adenosine uptake in a dose-dependant 
manner, which was saturable between 45-55% inhibition (Table 6.3). Similarly,
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inosine inhibited adenosine uptake by up to 40-45% (Table 6.4). However, in 
S427, inosine and adenine transport were mutually exclusive. This was clearly 
not the case with 247, since if it were, then saturable concentrations of adenine 
and inosine together should have brought about inhibition of adenosine uptake 
by between 85-100%. In fact, the maximum inhibition of adenosine uptake, 
brought about by the saturable concentrations of both inosine and adenine was 
found to be between 65 and 75% (Tables 6.3 and 6.4). This therefore indicates 
that 247 differs from S427, in that inosine and adenine transport in 247 appear to 
share a common transporter, at least in part. Since saturable concentrations of 
both inosine and adenine together inhibited adenosine uptake between 65 and 
75%, there remains approximately 30% of adenosine that was transported via a 
transporter(s) that was not blocked by either adenine or inosine. Therefore, this 
residual adenosine transport that occurred in the presence of excess inosine and 
adenine indicates a further adenosine transporter that does not transport adenine 
or inosine. Figure 6.8 illustrates one possible situation in 247 that would explain 
the results of both the transport studies and the lysis experiments. A situation 
could be envisaged in which 247 had at least four different adenosine 
transporters. In this situation P2 transport could again be responsible for melOx 
uptake, as in S427 (Carter and Fairlamb 1993). These differences in adenosine 
transport between different strains was not entirely unexpected, since a recent 
study on nucleoside transporters in Leishmania major found inosine transporters 
to be invariantly expressed in different strains, whereas adenosine transporters 
were extremely different in their inhibition profiles (Baer et al. 1992).
The two arsenical-resistant lines (S427 cRU18 and 247MelCyR) showed 
altered rates of adenosine uptake compared to the unselected line from which 
they were generated (Table 6.2; Carter and Fairlamb 1993). In the sensitive line 
of S427, the rate of total adenosine uptake was 10.7pmol/108cells/sec compared 
to 48.0pmol/108cells/sec in 247. Thus, differences in adenosine uptake existed
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between the two unselected lines. Since 247 had a higher rate of adenosine 
uptake than S427, then it may be expected to also have a higher rate of uptake of 
melOx, assuming melOx is taken up via an adenosine transporter. It would 
therefore also be reasonable to expect 247 to be more susceptible to melOx- 
induced lysis compared S427. However, the opposite was the case, with 5pM 
melOx being required to bring about a similar rate of lysis in 247 that was 
brought about by 0.5pM melOx in S427 (Fairlamb et al. 1992b). The sodium 
melarsen-resistant line of S427 cRU18 had a total rate of adenosine uptake of 
1.9pmol/108cells/sec, all of which was accounted for by the PI-transporter. The 
resistant line, 247MelCyR, also showed a decrease in total adenosine transport to 
4.8pmol/108cells/sec. However, whereas P2-transport had totally disappeared in 
S427 cRU18, it had only decreased by approximately 10% in 247MelCyR (Table 
6.5). This suggests that the decreased rate of adenosine uptake in 247MelCyR, 
which was approximately 10-fold lower than in 247, was due to alterations in 
one or more other adenosine transporters, as well as in the P2 transporter. This 
provides further evidence for the existence, in 247, of more than the two 
adenosine transporters that were identified in S427. In conclusion therefore, 
assuming melOx and melCy are indeed transported via the P2-transporter, then 
this reduction in P2 adenosine transport could account for a lower rate of uptake 
of melOx and melCy. However, even if this is the case, the lysis data certainly 
shows that altered uptake alone can not explain the patterns of drug-resistance 
seen, particularly with melB, the drug in clinical use.
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Purine Transport and Arsenical Uptake
Figure 6.1
Arsenical-Induced Lysis in 247
(a) with MelOx
(b) with MelCy
(c) with MelB
(d) with Phenyl Arsenoxide
The effects of increasing concentrations of arsenical on the lysis of 247 are 
shown, measured spectrophotometrically at a wavelength of 750nm. Control 
samples, containing only trypanosomes in solvents and buffer are shown (—).
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Purine Transport and Arsenical Uptake
Figure 6.2
The Effect of Adenosine on the Arsenical-Induced Lysis of 247
(a) with 5|iM MelOx
(b) with lpM MelCy
(c) with 25pM MelB
(d) with 0.1 |iM Phenyl Arsenoxide
The effects of increasing concentrations of adenosine on the arsenical-induced 
lysis of 247 are shown. The concentrations of adenosine are indicated in terms of 
the relative concentrations compared to the arsenical (i.e. adenosine x 1 means 
equimolar concentrations of both arsenical and adenosine).
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Figure 6.3
The Effect of Adenine on the Arsenical-Induced Lysis of 247
(a) with 5|iM MelOx
(b) with lpM  MelCy
(c) with 25pM MelB
(d) with 0.1 pM Phenyl Arsenoxide
The effects of increasing concentrations of adenine on the arsenical-induced lysis 
of 247 are shown. See legend for Figure 6.2 for explanation.
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Figure 6.4
The Effect of Inosine on the Arsenical-Induced Lysis of 247
(a) with 5|iM MelOx
(b) with l|iM  MelCy
(c) with 25|xM MelB
(d) with 0.1 |iM Phenyl Arsenoxide
The effects of increasing concentrations of inosine on the arsenical-induced lysis 
of 247 are shown. See legend for Figure 6.2 for explanation.
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Purine Transport and Arsenical Uptake
Figure 6.5
The Effect of Berenil on the Arsenical-Induced Lysis of 247
(a) with 5p,M MelOx
(b) with l(iM MelCy
(c) with 25pM MelB
(d) with 0.1 |iM Phenyl Arsenoxide
The effects of increasing concentrations of berenil on the arsenical-induced lysis 
of 247 are shown. See legend for Figure 6.2 for explanation.
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Purine Transport and Arsenical Uptake
Figure 6.6
The Effect of Pentamidine on the Arsenical-Induced Lysis of 247
(a) with 5pM MelOx
(b) with lpM MelCy
(c) with 25pM MelB
(d) with 0.1 |j,M Phenyl Arsenoxide
The effects of increasing concentrations of pentamidine on the arsenical-induced 
lysis of 247 are shown. See legend for Figure 6.2 for explanation.
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Purine Transport and Arsenical Uptake
Figure 6.7
Arsenical-Induced Lysis in 247MelCyR
(a) with MelOx
(b) with MelCy
(c) with MelB
(d) with Phenyl Arsenoxide
The effects of increasing concentrations of arsenical on the lysis of 247MelCyR 
are shown. The highest concentrations of each arsenical used were close to the 
limit in terms of their solubility in the buffer used (CBSS).
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Figure 6.8
Arsenical-Induced Lysis of 247 before and after Passages 
(a) with S|iM MelOx
VocC4
Uo
C AA<
0.3
0.2
0.1
0
3020100
Before Passages 
After Passages
Time (minutes)
(b) with lpM  MelCy
o
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3010 200
Before Passages 
After Passages
Time (minutes)
The effect of syringe-passaging on the susceptibility o f247 to arsenical-induced 
lysis is shown with (a) 5p.M melOx and (b) lfj.M melCy. The line after passages 
was syringe passaged for at least 2 months, involving 15 or more passages 
through rats. The passaged line was clearly less susceptible than the unpassaged 
line to arsenical-induced lysis.
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Purine Transport and Arsenical Uptake
Figure 6.9
The Effect of Arsenicals on Procyclic Culture Forms of 247
(a) in CBSS at 26°C
(b) in CBSS at 37°C
(c) in SDM-79 w/o Adenosine at 26°C
(d) in SDM-79 w/o Adenosine at 37°C
The effects of arsenicals on procyclic culture forms of 247 are shown. Lysis 
experiments were conducted in either CBSS or SDM-79 (without adenosine) at 
either26°C or 37°C. The highest possible concentrations of arsenical were used 
and the absorbance at 750nm was measured for 1 hour.
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Table 6.1
Cross-Resistance between MelCy and the Diamidines (Berenil and 
Pentamidine)
Drug Minimum Curative Dose (mg/Kg) Resistance Factor
247 247MeICyR
Berenil 28 32b 16
Pentamidine 1.6C >100d >63
The results of the in vivo assay for berenil and pentamidine are expressed in 
terms of the minimum curative dose required to cure all six mice in a group. The 
resistance factor is a ratio of the minimum curative dose for 247MelCyR to the 
minimum curative dose for 247.
a Doses tested were 0.5,1,2,4 and 8mg/Kg
b Doses tested were 2,4,8,16 and 32mg/Kg
c Doses tested were 0.2,0.4,0.8,1.6,3.2 and 6.4mg/Kg
d Dose tested was lOOmg/Kg
Table 6.2
Rate of Adenosine Uptake in 247 and 247MelCyR
Trypanosome Line Rate of Adenosine Uptake (pmol/108cells/sec)
247 48
247MelCyR 5.0
The rate of adenosine uptake between 2 and 7 seconds was measured using 
[3H]-adenosine. The labelled adenosine was mixed with unlabelled adenosine to 
give a final adenosine solution with a specific activity of 1.12|iCi/ml, and a total 
concentration of adenosine of 2pM.
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Table 6.3
Concentration-Dependant Inhibition of Adenosine Uptake by Adenine with 
or without 500pM Inosine in 247
[Adenine]
(pM)
Inhibition of Adenosine Uptake (%)
No Inosine With Inosine (500pM)
Exptl Expt 2 Mean Expt 1 Expt 2 Mean
0.1 11.2 11.7 11.5 13.5 72.9 43.2
1.0 33.3 ND 33.3 78.7 42.6 60.7
10.0 60.2 43.2 51.7 76.4 73.8 75.1
50.0 ND 57.3 57.3 62.2 66.9 64.6
250.0 40.8 51.6 46.2 71.4 65.9 68.7
Percentage inhibition of adenosine uptake without inosine is shown in the first 
three columns, with increasing concentrations of adenine. The putative PI 
adenosine transporter is blocked by 500pM inosine, last three columns. The 
percentage inhibition data from duplicate experiments is shown together with the 
mean values. Percentage inhibition was calculated by comparison to control 
samples containing neither adenine nor inosine.
Table 6.4
Concentration-Dependant Inhibition of Adenosine Uptake by Inosine with 
or without 250pM Adenine in 247
[Inosine]
(pM)
Inhibition of Adenosine Uptake (%)
No Adenine With Adenine (250pM)
Exptl Expt 2 Mean Expt 1 Expt 2 Mean
0.1 40.8 16.0 28.4 ND 51.0 51.0
1.0 8.2 17.8 13.0 34.4 30.6 32.5
10.0 58.5 30.3 44.4 60.1 58.8 59.5
100.0 39.7 45.5 42.6 80.5 69.1 74.8
500.0 52.9 36.4 44.7 72.8 76.3 74.6
Percentage inhibition of adenosine uptake without adenine is shown in the first 
three columns, with increasing concentrations of inosine. The putative P2 
adenosine transporter is blocked by 250p,M adenine, last three columns. See 
legend for Table 6.3.
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Table 6.5
Concentration-Dependant Inhibition of Adenosine Uptake by Adenine with 
or without 500pM Inosine in 247MelCyR
[Adenine]
(UM)
Inhibition of Adenosine Uptake (%)
No Inosine With Inosine (500pM)
0.1 1.7 22.2
1.0 29.0 ND
10.0 28.9 77.8
50.0 35.5 75.1
250.0 34.5 37.7
Percentage inhibition of adenosine uptake without inosine and with 500pM 
inosine is shown with increasing concentrations of adenine. Duplicate 
experiments were not conducted with 247MelCyR. See legend for Table 6.3.
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CHAPTER 7
GENERAL DISCUSSION
The ultimate aims of this study were to investigate the genetic and 
biochemical mechanisms controlling drug-resistance in T. brucei. This involved 
the generation and characterisation of stable cloned lines of trypanosomes in 
vivo, that expressed resistance to melCy and suramin. A suitable in vitro assay 
was developed in order to rapidly measure the levels of drug-resistance in a 
number of clones generated from a mixed transmission of melCy-resistant and 
suramin-resistant lines. Biochemical investigations were also conducted into the 
role of adenosine transporters in the uptake of the melaminophenyl arsenicals, 
indicating differences between melCy uptake and melB uptake.
This study has demonstrated the use of stable drug-resistant lines of 
Trypanosoma brucei in investigations into the biochemical and genetic basis of 
drug-resistance and their use as selectable markers in genetic exchange 
experiments. The successful use of selectable markers in genetic exchange 
studies has been demonstrated with antibiotic-resistance in two cloned lines of T. 
brucei (Gibson and Whittington 1993). However, the use of genuine 
trypanocide-resistance rather than antibiotic-resistance has the added advantage 
of allowing the simultaneous investigation into the inheritance of drug-resistance, 
and thereby providing information on the number of genes and the nature of the 
alleles controlling drug-resistance. It should also be possible to use this approach 
to study the genetic basis of other trypanocides, such as DFMO. However, this 
process of generating drug-resistant lines of trypanosomes in vivo, not only 
selected for the desired drug-resistance phenotype, but also selected for a 
monomorphic phenotype (Turner 1990). Consequently, the relatively low 
proportion of short-stumpy forms in bloodstream infections meant that fly- 
transmission of the drug-resistant lines was more difficult compared to the
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unselected stocks. It was found that a greater number of mature salivary gland 
infections were produced with the use of an infective feed containing 
bloodstream forms that were predominantly short-stumpy in morphology, rather 
than using bloodstream forms from mice with a rising parasitaemia. Another 
important point to be made concerns the screening of metacyclic populations 
from infected flies. Screening the salivary gland infections from flies after 
approximately three weeks post infection provided a more complete view the 
course of infection in the tsetse flies. However, the process of infecting mice 
directly from the tsetse flies and screening the salivary gland infections of each 
fly from day 18 post infection, two or three times each week was relatively 
expensive and time-consuming. Since the ultimate aim is to generate a whole 
series of cloned progeny resulting from genetic exchange, it may be more 
efficient to screen infected flies for mature infections only after approximately 40 
days post infection. Although the data in the present study does not support this, 
the probability of encountering products of genetic exchange is likely to be 
greatest during the latter part of infection when a mixed salivary gland infection 
has been established. In this way, the relatively time-wasting and expensive 
procedure of screening flies during the early stages of infection can be by-passed. 
Furthermore, since double drug-resistant trypanosomes appeared to bring about 
only transient, low levels of parasitaemia in double drug-treated mice, it may also 
prove fruitful to generate metacyclic clones from flies producing mixed 
infections, on the assumption that flies producing mixed infections after six 
weeks are likely to also contain the products of genetic exchange that may not be 
identified in the mouse screen. Uncloned metacyclic populations from flies 
infected in co-transmission experiments were screened in mice with drug doses 
of 5mg/Kg. However, the possibility that such levels of drug might generate new 
mutants rather than select for the pre-existing mutants cannot be overlooked. 
The dose of 5mg/Kg for melCy and suramin was initially chosen for convenience 
as it was at least double the amount of drug required to clear drug-sensitive
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infections, but was also expected to permit the selection of partially drug- 
resistant trypanosomes. In hindsight, the doses of drug used should have been 
calculated in relation to the minimum doses required to clear infections of the 
drug-resistant lines for the drugs to which these lines were sensitive. 
Furthermore, a 5-fold greater dose of drug compared to these minimum curative 
doses (chapter 2) would have been more beneficial in the screening of 
metacyclic populations in fly infected mice. Table 7.1 shows the selection doses 
that would have been used in further crosses if time had permitted. These 
changes should remove any remaining doubt from the results of the mouse 
screen, and mean that only double drug-resistant trypanosomes arising from 
genetic exchange would give rise to patent infections in double drug treated 
mice. Furthermore, the doses recommended in Table 7.1 remain sufficiently low 
to allow double drug-resistant trypanosomes that express low levels of drug- 
resistance still to survive drug treatment.
The short-term bloodstream culture described in chapter 3 provides a 
suitable system for the rapid screening of a number of cloned progeny. It was 
rapid both in terms of the time taken to set up a bloodstream culture, and in 
terms of the speed with which a result was obtained (24 hours). However, 
although the repeatability of the assays appeared to be satisfactory for both 
melCy and suramin, the fact that it was an in vitro assessment of drug-resistance 
remained a drawback. Table 7.2 compares the three different assay systems 
described in chapters 2 and 3. The most important drawbacks of using the in 
vitro assays are that growth inhibition may not be a true reflection of the 
trypanocidal nature of either melCy or suramin, and also that a 24 hour 
incubation in the presence of drug in no way reflects the complex 
pharmacokinetics that are involved when the drugs are used in vivo. These 
factors are likely to influence the final result of the in vitro assays. For this 
reason, future studies should continue to employ the in vitro assay to rapidly
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assess the levels of drug-resistance in a series of cloned progeny, but also that 
clones, that have been identified as hybrids or selfers from other known markers 
of genetic exchange, should subsequently be analysed in vivo. Although, the in 
vivo assay is time consuming and expensive, it would not be necessary to 
conduct such assays on the scale of those described in chapter 2 for each cloned 
progeny. Rather, a relatively accurate measurement could be made using only six 
mice, each receiving 105 trypanosomes, followed by a range of drug treatments 
at, for example, 1.25, 2.5, 5, 10, 20 and 40mg/Kg for melCy, and at 2.5, 5, 10, 
20, 40 and 70mg/Kg for suramin. This use of an in vivo assay may be particularly 
important for the measurement of suramin-resistance, as the four clones 
(466/61MRSR bcll-4) selected at 24mg/Kg in mice expressed relatively low 
levels in vitro (chapter 5).
The cloned trypanosome lines expressing stable resistance to melCy and 
suramin offer a number of alternatives for future co-transmission experiments. 
Further attempts at generating double drug-resistant cloned progeny could be 
attempted with 247SurR x 386MelCyR. Alternatively, the relative success of co- 
transmitting the two 247-derived lines together with a different third line could 
be further improved by the three-way co-transmission of 247MelCyR x 247SurR 
x 927/4, since the latter line transmits through flies more successfiilly than 386 
(Turner pers. comm.). Another drug-resistant line that is available for co­
transmission experiments is 247PhleoR (resistant to the antibiotic, phleomycin 
(Jeffries unpublished results)). This line has been generated in procyclic culture 
and successftdly transmitted through tsetse flies, after which, the resulting 
bloodstream infections can be distinguished from unselected lines by treating 
infected mice with daily injections (Lp.) of phleomycin at a dose of 3mg/Kg 
(results not shown). This third drug-resistant 247-derived line could be used as 
well, or instead of, 247MelCyR and 247SurR. An ambitious co-transmission 
could be envisaged with 247MelCyR x 247SurR x 247PhleoR x 927/4, in which
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the three possible different double drug-resistant phenotypes (MelCyRSurR, 
MelCyRPhleoR and SurRPhleoR) resulting from selfing could all easily be 
screened for directly in mice. These possible co-transmission experiments 
described could be conducted with the material abeady available. On the other 
band, if a new drug-resistant line were to be generated in mice, it would be 
beneficial to select a 927/4 line for resistance to melB. This would allow the 
possibihty for further crosses, such as 247SurR x 927/4MelBR and 247PhleoR x 
247SurR x 927/4MelBR, with the latter three-way co-transmission being 
particularly appealing.
A 927/4MelBR line could also be used to investigate further the role of 
adenosine transport in the uptake of melaminophenyl arsenicals. Previous studies 
on the mechanism of melB uptake have employed melOx, showing that melOx 
uptake was reduced in arsenical-resistant lines (Yarlett et al. 1991; Carter and 
Fairlamb 1993). However, the widely held assumption that melOx and melB 
have the same mode of action and the same mechanism of uptake has been 
questioned in the present study. The mode of action and uptake of melB, and the 
mechanism of melB-resistance must be investigated using melB and not melOx 
or melCy, and the use of a well characterised melB-resistant line is essential for 
fixture studies on arsenical-resistance, allowing a number of anomalies to be 
resolved. The use of a melCy-resistant line in the present study, has shown that 
conclusions drawn from studies that have used melOx-resistant lines previously 
(Yarlett et al. 1991; Carter and Fairlamb 1993) cannot necessarily be applied to 
melB. In terms of actual experimental details, the inability of adenosine and 
adenine to protect trypanosomes from melB-induced lysis should be investigated. 
The conjecture that melB is not taken up by an adenosine transporter, and has a 
different route of uptake from melCy and melOx, leads to the testable prediction 
that unselected 927/4 should be rapidly lysed by melB, but that this lysis should 
not be inhibited by adenosine or adenine. If  it were found that adenosine and
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adenine did not protect 927/4 from melB-induced lysis, then the role of an 
altered adenosine transporter in melB-resistance would certainly appear unlikely. 
The work of Carter and Fairlamb (1993) was initiated by screening numerous 
compounds (such as amino acids, sugars and nucleotides) for their effect on 
melOx-induced lysis of S427. A similar approach could be used to investigate 
melB-induced lysis and it may be far more profitable to search for compounds 
that block melB uptake rather than spend time characterising the kinetics of an 
adenosine transport system that may have no relevance to melB uptake. 
Furthermore, a melB-resistant line, such as 927/4MelBR, should show a large 
decrease in susceptibility to melB-induced lysis, unlike 247MelCyR, and also, 
most significantly, a reduction in the rate of adenosine uptake should not be 
observed in the melB-resistant line.
In conclusion, the foundations have been laid for future studies into the 
genetics and biochemistry of drug-resistance, with particular emphasis on the 
inheritance of arsenical-resistance and the mechanism of uptake of the 
melaminophenyl arsenicals. The question marks over the route of melB uptake 
and the possible differences between melB and melCy transport demand further 
investigations. Although further studies may show that melCy, melOx and melB 
do indeed share a common adenosine transport mechanism and that the results 
presented in this study cannot be applied to other lines, investigations are 
warranted with a view to the possibility that melCy might be of use in the 
treatment ofmelB-resistant cases of African sleeping sickness.
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